UCB  26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
Confidential  Page 1 of 195 A PHASE 1/2 OPEN -LABEL, MULTICENTER STUD Y TO 
ASSESS THE SAFETY, P HARMACOKINETICS, AND  
ANTITUMOR ACTIVITY O F UCB6114 ADMINISTER ED 
INTRAVENOUSLY TO PAR TICIPANTS WITH ADVAN CED 
SOLID TUMORS  
PROTOCOL ONC001  – AMENDMENT 6  
PHASE 1/2  
SHORT TITLE:  
An open -label, multicenter, first in human study in participants with advanced solid tumors 
treated with UCB6114  
Sponsor:  
UCB Biopharma SRL  
Allée de la Re cherche 60  
1070 Brussels  
BELGIUM  
Regulatory agency identifying number(s):  
Eudra CT Number:  [ADDRESS_385905] Number  [STUDY_ID_REMOVED]  
Confidential Material  
Confidential  
This document is the property of UCB and may not – in full or in part – be passed on, 
reproduced, published, or otherwise used without the express permission of UCB.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 2 of 195 PROTOCOL AMENDMENT S UMMARY OF CHANGES TA BLE 
Document History  
Document  Date  Type of amendment  
Protocol Amendment 6  26 Jun 2023  Substantial  
Protocol Amendment 5  14 Jan 2022  Substantial  
Protocol Amendment 4  17 Jun 2021  Substantial  
Protocol Amendment 3.2 ([LOCATION_006])  07 Apr 2021  Substantial  
Protocol Amendment 3.1 (US)  [ADDRESS_385906] 2019  Not applicable  
Amendment 6 ( 26 Jun 2023 ) 
Overall Rationale for the Amendment  
The overall rationale for Amendment [ADDRESS_385907] the ability to stop  either  the entire study or individual study part.  
This amendment is considered to be substantial based on the criteria  set forth in Article 10(a) of 
Directive 2001/20/EC of the European Parliament and the Council of the European Union.  
Section # and Name  [CONTACT_11029]  
6.7 Criteria for study hold or dosing 
stoppage  
11.6 Appendix 6: Rapid Ale rt 
Procedures  Clarification that either the entire study or 
an individual Study Part can be suspended . 
Clarification of the process for 
study /individual Study Part hold/potential 
restart when criteria for study /individual 
Study P art suspension are met.  To clarify the 
study /Study Part 
hold procedures  
1.3 Schedule of Activities  
9.8 Pharmacodynamics  Footnote s j and n of Table 1 -6 (Part A1, 
Cohort 3) have been updated to clarify 
when  blood sample for PK and cGremlin 
should be collected with regards to  biopsy. 
Footnotes  o and p  of Table 1 -7 (Part B) and 
Table  1.8 (Part C) has been updated to 
clarify when blood samples for ADA, 
circulating gremlin -1 and ctDNA analysis  
are to be collected . In line with this change, 
a footnote has been added for Table 9 -9 and 
Table 9 -21. Clarification  
Global  Correction of typographical errors.  Correction  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 3 of 195  
SERIOUS ADVERSE EVEN T REPORTING  
Serious adverse event reporting (24h)  
Fax Europe and Rest of the World: [PHONE_301] 21  
US and Canada: +[PHONE_299] or +[PHONE_300]  
Email  [EMAIL_6151]  
Phone  UCB Study Physician:  
UCB Celltech, [ADDRESS_385908], Slough, Berkshire, SL1 3WE, [LOCATION_006]  
24h Rapid Response Helpline:  [PHONE_6571]  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 4 of 195 TABLE OF CONTENTS  
PROTOCOL AMENDMENT S UMMARY OF CHANGES TA BLE  ................................ ...... 2 
1 PROTOCOL SUMMARY  ................................ ................................ ...............................  12 
1.1 Synopsis  ................................ ................................ ................................ .......................  12 
1.2 Schema  ................................ ................................ ................................ .........................  18 
1.3 Schedule of Activities  ................................ ................................ ................................ .. 24 
2 INTRODUCTION  ................................ ................................ ................................ ...........  42 
2.1 Study rationale  ................................ ................................ ................................ .............  42 
2.2 Back ground  ................................ ................................ ................................ ..................  42 
2.3 Benefit/risk assessment  ................................ ................................ ................................  43 
3 OBJECTIVES AND ENDPO INTS  ................................ ................................ .................  45 
4 STUDY DESIGN  ................................ ................................ ................................ .............  47 
4.1 Overall design  ................................ ................................ ................................ ..............  47 
4.1.1  Study oversight  ................................ ................................ ................................ .... 51 
Safety monitoring committee  ................................ ................................ .........................  51 
Study steering committee  ................................ ................................ ...............................  51 
4.1.2  Part A – Monotherapy dose escalation  ................................ ................................  51 
[IP_ADDRESS]  SMC  ................................ ................................ ................................ ...........  52 
[IP_ADDRESS]  Dose esc alation criteria  ................................ ................................ .............  52 
[IP_ADDRESS]  Dose de -escalation following initial dose level  ................................ .........  54 
[IP_ADDRESS]  Dose -limiting toxicity determination and maximum tolerated dose 
definition  ................................ ................................ ................................ ... 54 
[IP_ADDRESS]  Defining the recommended Phase 2 dose for monotherapy  ......................  55 
4.1.3  Part A1 – Dose optimization (alternative dosing schedules)  ...............................  55 
4.1.4  Part B – Dose escalation with TFD/TPI  ................................ ..............................  56 
[IP_ADDRESS]  Study oversight  ................................ ................................ ..........................  57 
[IP_ADDRESS]  Dose -limiting toxicity and maximum tolerated dose definition and 
determination  ................................ ................................ .............................  57 
[IP_ADDRESS]  Definition of recommended Phase 2 dose in combination with TFD/TPI  59 
4.1.5  Part C – Dose escalation with mFOLFOX6  ................................ ........................  59 
[IP_ADDRESS]  Study oversight  ................................ ................................ ..........................  60 
[IP_ADDRESS] Dose -limiting toxicity determination and maximum tolerated dose 
definition  ................................ ................................ ................................ ... 61 
[IP_ADDRESS]  Defining the recommended Phase 2 dose in  combination with 
mFOLFOX6  ................................ ................................ ..............................  62 
4.1.6  Part D – Monotherapy 1 expansion  ................................ ................................ ..... 62 
4.1.7  Part E – Monotherapy 2 expansion  ................................ ................................ ...... 63 
4.1.8  Part F – Combination 1 expansion  ................................ ................................ ....... 63 
4.1.9  Part G – Combination [ADDRESS_385909] of care regimens in Part B and Part C 66 
[IP_ADDRESS]  UCB6114 dosing  ................................ ................................ .......................  66 
[IP_ADDRESS]  Standard of Care regimen dosing  ................................ ..............................  67 
4.4 End of study definition ................................ ................................ ................................ . 68 
5 STUDY POPULATION  ................................ ................................ ................................ .. 68 
5.1 Inclusion criteria  ................................ ................................ ................................ ..........  69 
5.1.1  Part A  ................................ ................................ ................................ ...................  69 
5.1.2  Part A1  ................................ ................................ ................................ .................  70 
5.1.3  Part B ................................ ................................ ................................ ...................  71 
5.1.4  Part C ................................ ................................ ................................ ...................  73 
5.2 Exclusion cr iteria  ................................ ................................ ................................ .........  74 
5.2.1  Part A  ................................ ................................ ................................ ...................  74 
5.2.2  Part A1  ................................ ................................ ................................ .................  76 
5.2.3  Part B ................................ ................................ ................................ ...................  78 
5.2.4  Part C ................................ ................................ ................................ ...................  80 
5.3 Lifestyle restrictions ................................ ................................ ................................ ..... 82 
5.4 Screen failures  ................................ ................................ ................................ ..............  82 
6 STUDY TREATMENTS  ................................ ................................ ................................ . 83 
6.1 Treatments administered  ................................ ................................ ..............................  83 
6.1.1  Part A  ................................ ................................ ................................ ...................  83 
6.1.2  Part A1  ................................ ................................ ................................ .................  83 
6.1.3  Part B  ................................ ................................ ................................ ...................  84 
6.1.4  Part C  ................................ ................................ ................................ ...................  86 
6.2 Preparation, handling, storage, and accountability requirements  ................................  89 
6.2.1  UCB6114  ................................ ................................ ................................ .............  89 
6.2.2  TFD/TPI  ................................ ................................ ................................ ...............  89 
6.2.3  mFOLFOX6  ................................ ................................ ................................ .........  89 
6.2.4  Drug acc ountability  ................................ ................................ .............................  89 
6.3 Measures to minimize bias: Randomization and blinding  ................................ ...........  90 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 6 of 195 6.4 Treatment compliance  ................................ ................................ ................................ .. 90 
6.5 Concomitant medication(s)/treatment(s)  ................................ ................................ ..... 90 
6.5.1  Permitted concomitant treatments (medications and therapi[INVESTIGATOR_014]) during Part  A ... 90 
6.5.2  Permitted concomitant treatments (medications and therapi[INVESTIGATOR_014]) during Part  A1 . 91 
6.5.3  Permitted concomitant treatments (medications and therapi[INVESTIGATOR_014]) during Part  B .... 91 
6.5.4  Permitted concomitant treatments (medications and therapi[INVESTIGATOR_014]) during Part  C .... 92 
6.5.5  Prohibited concomitant treatments (medications and therapi[INVESTIGATOR_014]) during Part  A .. 92 
6.5.6  Prohibited concomitant treatments (medications and therapi[INVESTIGATOR_014]) during Part  A1 93 
6.5.7  Prohibited concomitant treatments (medications and therapi[INVESTIGATOR_014]) during Part  B... 93 
6.5.8  Prohibit ed concomitant treatments (medications and therapi[INVESTIGATOR_014]) during Part  C... 94 
6.5.9  Vaccines  ................................ ................................ ................................ ...............  94 
6.5.10  Rescue medication  ................................ ................................ ...............................  95 
6.6 Dose modification  ................................ ................................ ................................ ........  95 
6.6.1  Part A and Part A1  ................................ ................................ ...............................  95 
[IP_ADDRESS]  Dose escalation scheme  ................................ ................................ .............  95 
[IP_ADDRESS]  Within participant dose modification in Part A  ................................ .........  97 
[IP_ADDRESS]  Within participant dose modification in Part A1  ................................ ....... 97 
6.6.2  Part B ................................ ................................ ................................ ...................  98 
[IP_ADDRESS]  Dose esc alation scheme  ................................ ................................ .............  98 
[IP_ADDRESS]  UCB6114 dose modifications  ................................ ................................ ... 98 
[IP_ADDRESS]  TFD/TPI [CONTACT_190066]  ................................ ................................ ..... 99 
6.6.3  Part C ................................ ................................ ................................ .................  101 
[IP_ADDRESS]  Dose e scalation scheme  ................................ ................................ ...........  101 
[IP_ADDRESS]  UCB6114 dose modifications  ................................ ................................ . 101 
[IP_ADDRESS]  mFOLFOX6 dosing  ................................ ................................ .................  102 
[IP_ADDRESS] mFOLFOX6 dose modifications  ................................ .............................  102 
6.7 Criteria for study hold or dosing stoppage  ................................ ................................ . 106 
6.8 Treatment after the end of the study  ................................ ................................ ..........  106 
7 DISCONTINUATION OF S TUDY MEDICATION AND PARTICIPANT 
DISCONTINUATION/WITH DRAWAL  ................................ ................................ ...... 106 
7.1 Discontinuation of study medication  ................................ ................................ .........  106 
7.1.1  Liver Chemistry Stoppi[INVESTIGATOR_2121]  ................................ ................................ .... 107 
7.1.2  QTc Stoppi[INVESTIGATOR_2121]  ................................ ................................ ........................  107 
7.1.3  Other criteria for discontinuation of study medication  ................................ ...... 108 
7.1.4  Temporary discontinuation of study medication  ................................ ...............  109 
7.2 Participant discontinuation/withdrawal from the study  ................................ .............  [ADDRESS_385910]  ................................ ................................ ...... 118 
9.2.7  Adverse events of special monitoring  ................................ ................................  119 
9.2.8  Anticipated serious adverse events  ................................ ................................ .... 119 
9.2.9  Infusion -related reactions (hypersensitivity reactions)  ................................ ...... 119 
9.3 Safety signal detection  ................................ ................................ ...............................  120 
9.4 Treatment of overdose  ................................ ................................ ...............................  120 
9.5 Pharmacokinetics  ................................ ................................ ................................ ....... 121 
9.6 Efficacy assessments  ................................ ................................ ................................ .. 124 
9.6.1 Tumor assessments  ................................ ................................ ............................  124 
9.6.2  ECOG Performance Status  ................................ ................................ ................  125 
9.7 Genetics ................................ ................................ ................................ ......................  125 
9.8 Pharmacody namics  ................................ ................................ ................................ .... 125 
9.8.1  Blood samples for circulating gremlin -1 ................................ ...........................  126 
9.8.2  Blood samples for serum protein analysis and blood transcriptomics  ..............  128 
9.8.3  Blood samples for circulating tumor DNA analysis  ................................ ..........  129 
9.8.4  Blood samples for serum bone turnover markers  ................................ ..............  130 
9.8.5  Urine samples for urinary bone turnover markers  ................................ .............  131 
9.8.6  Blood samples for genetic analysis  ................................ ................................ .... 132 
9.8.7  Tumor biopsy for PD assessments and predictive biomarker assessments  ....... 132 
Biopsy procedure in Part A1  ................................ ................................ ........................  133 
9.8.8  Historical tumor samples  ................................ ................................ ...................  134 
9.9 Biomarkers  ................................ ................................ ................................ .................  134 
9.10  Immunogenicity  ................................ ................................ ................................ .........  134 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 8 of 195 10 STATISTICAL CONSIDER ATIONS  ................................ ................................ ...........  136 
10.1  Definition of analysis sets  ................................ ................................ ..........................  136 
10.2  General statistical considerations  ................................ ................................ ...............  137 
10.3  Planned safety and other analyses ................................ ................................ ..............  137 
10.3.1  Safety analyses  ................................ ................................ ................................ ... 137 
10.3.2  Analysis of Baseline and Demographic Variables  ................................ ............  140 
10.3.3  Other analyses  ................................ ................................ ................................ .... 140 
10.3.3 .1 Analysis of PK endpoints  ................................ ................................ ........  140 
[IP_ADDRESS]  Analysis of genetic endpoints  ................................ ................................ .. 141 
[IP_ADDRESS]  Analysis of PD endpoints  ................................ ................................ ........  142 
[IP_ADDRESS]  Analysis of biomarker endpoints  ................................ .............................  142 
[IP_ADDRESS]  Analysis of immunologic endpoints  ................................ ........................  142 
10.4  Planned efficacy/outcome analyses  ................................ ................................ ...........  142 
10.4.1  Analysis of antitumor activity/outcome endpoint  ................................ ..............  142 
[IP_ADDRESS]  Antitumor activity endpoint definitions  ................................ ..................  142 
[IP_ADDRESS]  Analysis of the antitumor activity endpoints  ................................ ...........  143 
10.5  Handling of protocol deviations ................................ ................................ .................  144 
10.6  Handling of dropouts or missing data  ................................ ................................ ........  144 
10.7  Planned interim analysis and data monitoring  ................................ ...........................  144 
10.8  Determination of sample size  ................................ ................................ .....................  145 
10.8.1  Dose escalation modules  ................................ ................................ ....................  145 
10.8.2  Expansion modules  ................................ ................................ ............................  145 
11 SUPPORTING DOCUMENTA TION AND OPERATIONAL  CONSIDERATIONS . 146 
11.1  Appendix 1: Regulatory, ethical, and study oversight considerations  .......................  146 
11.1.1  Regulatory and ethical considerations  ................................ ...............................  146 
11.1.2  Financial disclosure  ................................ ................................ ...........................  147 
11.1.3  Informed consent process  ................................ ................................ ..................  147 
11.1.4  Data protection  ................................ ................................ ................................ ... 147 
11.1.5  Committees structure  ................................ ................................ .........................  148 
11.1.6  Data quality assurance  ................................ ................................ .......................  148 
[IP_ADDRESS]  Electronic Case Report Form completion  ................................ ...............  148 
11.1.7  Source documents  ................................ ................................ ..............................  149 
11.1.8 Study and site closure  ................................ ................................ ........................  149 
11.1.9  Publication policy  ................................ ................................ ..............................  150 
11.2  Appendix 2: Clinical laboratory tests  ................................ ................................ ........  151 
11.3  Appendix 3: Adverse events – Definitions and procedures for recording, evaluating, 
follow -up, and reporting  ................................ ................................ ............................  154 
11.4  Appendix 4: Contraceptive Guidance and Collection of Pregnancy Information  ..... 159 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 9 of 195 11.5  Appendix 5: Genetics  ................................ ................................ ................................ . 163 
11.6  Appendix 6: Rapid Alert Procedures  ................................ ................................ .........  164 
11.7  Appendix 7: Country -specific Requirements ................................ .............................  166 
11.8  Appendix 8: ECOG Performance Status Scale  ................................ ..........................  166 
11.9  Appendix 9: RECIST v1.1 guidelines  ................................ ................................ ....... 166 
11.9.1  Measurability of tumor at Baseline  ................................ ................................ .... 166 
11.9.2  Objective response status at each evaluation  ................................ .....................  168 
11.10  Appendix 10: Abbreviations and Trademarks  ................................ ...........................  172 
11.11  Appendix 11: Protocol amendment history  ................................ ...............................  175 
Amendment 5 (14 Jan 2022)  ................................ ................................ ..............................  175 
Amendment 4 (17 June 2021)  ................................ ................................ ............................  176 
Amendment 3 (07 Jan 2021)  ................................ ................................ ..............................  182 
Amendment 2 ([ADDRESS_385911] 2020)  ................................ ................................ .............................  183 
Amendment 1 (11 Jun 2020)  ................................ ................................ .............................  [ADDRESS_385912] OF TABLES  
Table  1-1: Objectives and endpoints for the dose escalation module (Part A) and the 
dose optimization module (Part A1)  ................................ ................................  13 
Table  1-2: Objectives and endpoints for the dose escalation modules in Part B and 
Part C  ................................ ................................ ................................ ...............  14 
Table  1-3: Objectives and endpoints for the expansion modules in Parts D, E, F, and 
G ................................ ................................ ................................ .......................  15 
Table  1-4: Schedule of Activities for Part  A (monotherapy dose escalation)  ...................  24 
Table  1-5: Schedule of Activities for Part  A1 – Cohorts 1, 2, 4  ................................ ....... 29 
Table  1-6: Schedule of Activities for Part  A1 – Cohort 3  ................................ .................  32 
Table  1-7: Schedule of Activities for Part  B ................................ ................................ ..... 35 
Table  1-8: Schedule of Activities for Part  C ................................ ................................ ..... 39 
Table  3-1: Objectives and endpoints for the dose escalation module (Part A) and the 
dose optimization module (Part A1)  ................................ ................................  45 
Table  3-2: Objectives and endpoints for the dose escalation modules in Part B and 
Part C  ................................ ................................ ................................ ...............  46 
Table  3-3: Objectives and endpoints for the expansion modules in Parts D, E, F, and 
G ................................ ................................ ................................ .......................  47 
Table  4-1: Study modules for dose escalation and expansion  ................................ ...........  48 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 10 of 195 Table  4-2: Part B dose escalation/de -escalation schema for mTPI [INVESTIGATOR_313458] ......................  59 
Table  4-3: Part C dose escalation/de -escalation schema for mTPI [INVESTIGATOR_313458] ......................  62 
Table  4-4: TFD/TPI [INVESTIGATOR_313459]  ................................ ................................ ............  67 
Table  4-5: mFOLFOX6 dosing  ................................ ................................ .........................  68 
Table  5-1: Study population  ................................ ................................ ..............................  68 
Table  6-1: Treatments administered in Part  A ................................ ................................ .. 83 
Table  6-2: Treatments administered in Part  A1 ................................ ................................  84 
Table  6-3: Study treatments in Part  B ................................ ................................ ...............  84 
Table  6-4: Treatments administered in Part  C ................................ ................................ ... 87 
Table  6-5: Dose escalation steps and justification (Part A)  ................................ ..............  95 
Table  6-6: Planned dose optimization scheme for Part  A1 ................................ ...............  97 
Table  6-7: Dose escalation steps and justification (Part B)  ................................ ...............  98 
Table  6-8: TFD/TPI [INVESTIGATOR_313460]  ................................ ................................ ................................ ...........  99 
Table  6-9: TFD/TPI [INVESTIGATOR_313461] -
hematological toxicities  ................................ ................................ ...................  99 
Table  6-10: TFD/TPI [INVESTIGATOR_313462]  .............................  100 
Table  6-11: Dose escalation steps and justification (Part C)  ................................ .............  101 
Table  6-12: mFOLFOX6 dosing  ................................ ................................ .......................  102 
Table  6-13: Dose modification for oxaliplatin -related neurological toxicity  ....................  103 
Table  6-14: Dose modification for hematological toxicity  ................................ ...............  103 
Table  6-15: Dose modification for non -hematological, non -neurological toxicity  ...........  104 
Table  7-1: Bundle Branch Block discontinuation criteria  ................................ ...............  108 
Table  9-1: Total blood volume collected during Cycle 1 of Part A  ................................  112 
Table  9-2: Total blood volume collected during Cycle 1 of Part A1  ..............................  113 
Table  9-3: Total blood  volume collected during Cycle 1 of Parts B and C  ....................  114 
Table  9-4: Blood collection time points for PK analysis for Part A  ...............................  122 
Table  9-5: Blood collection time points for PK analysis for Part A1  .............................  123 
Table  9-6: Blood collection time points for PK analysis for Part B and Part C  ..............  124 
Table  9-7: Sample time points for serum gremlin -1 analysis in Part A  ..........................  127 
Table  9-8: Sample time poi nts for serum gremlin -1 analysis in Part A1  ........................  127 
Table  9-9: Sample time points for serum gremlin -1 analysis in Part B and Part  C ........  128 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 11 of 195 Table  9-10: Sample time points for serum protein analysis and blood transcriptomics 
in Part A  ................................ ................................ ................................ .........  128 
Table  9-11: Sample time points for serum protein analysis and blood transcriptomics 
in Part A1  ................................ ................................ ................................ ....... 129 
Table  9-12: Sample time points for ctDNA analysis in Part A  ................................ .........  129 
Table  9-13: Sample time points for ctDNA analysis in Part A1  ................................ ....... 130 
Table  9-14: Sample time points for ctDNA analysis in Part B and Part C  .......................  130 
Table  9-15: Blood samples for serum bone turnover markers in Part A  ...........................  131 
Table  9-16: Blood samples for serum bone turnover markers in Parts B and C  ...............  131 
Table  9-17: Urine samples for urinary bone turnover markers in Part A  ..........................  132 
Table  9-18: Urine samples for urinary bone turnover markers in Parts B and C  ..............  132 
Table  9-19: Blood sample time points for ADA analysis in Part A  ................................ .. 135 
Table  9-20: Blood sample time points for ADA analysis in Part A1  ................................  135 
Table  9-21: Blood sample time points for ADA analysis in Part B and Part  C ................  136 
Table  10-1: Pharmacokinetic parameters  ................................ ................................ ..........  [ADDRESS_385913] OF FIGURES  
Figure  1-1: ONC001 study design  ................................ ................................ ......................  19 
Figure  1-2: ONC001 Part  A cohorts  ................................ ................................ ...................  20 
Figure  1-3: ONC001 Part  A1 ................................ ................................ ..............................  21 
Figure 1-4: ONC001 Part  B ................................ ................................ ................................  22 
Figure  1-5: ONC001 Part  C ................................ ................................ ................................  23 
Figure  4-1: Dose escalation decision making: no DLT observed in sentinel participant  ... 53 
Figure  4-2: Dose escalation decision making: DLT observed in sentinel participant  ........  54 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 12 of 195 1 PROTOCOL SUMMARY  
1.1 Synopsis  
Protocol title: A Phase 1/2 open -label, multicenter study to assess the safety, pharmacokinetics 
(PK), and antitumor activity of UCB6114 administered intravenously (iv) to participants with 
advanced solid tumors.  
Short Title: An open -label, multic enter, first in human (FIH) study in participants with 
advanced solid tumors treated with UCB6114.  
Rationale: Gremlin -1, secreted by [CONTACT_313553], binds to bone morphogenetic proteins 
(BMPs) and antagonizes signaling, thereby [CONTACT_313554], renewal, and a more 
mesenchymal phenotype. By [CONTACT_313555] -1 BMP antagonism, UCB6114 is expected to 
restore BMP signaling, limit tumor cell expansion, and favor a more epi[INVESTIGATOR_313463]. 
Gremlin -1 messenger ribonucleic acid (mRNA) has been  shown to be expressed in >60% of 
colorectal, pancreatic, and esophageal cancer cases and approximately 50% of bladder, breast, 
and lung cancer cases (Sneddon  et al, 2006). It has also been shown to be a key driver in 
hereditary mixed polyposis syndrome (H MPS) (Jaeger  et al, 2012), a rare and severe 
premalignant condition characterized by [CONTACT_313556]. Despi[INVESTIGATOR_313464], there is still a large unmet 
need in the therapy of c ancer types mentioned above. For example, in colorectal cancer (CRC), 
nearly 25% will present with metastatic disease and 40% to 50% of those initially diagnosed 
with early -stage disease will eventually develop metastatic disease (Moriarity  et al, 2016).  
UCB6114 is a fully human immunoglobulin G4 (IgG4) monoclonal antibody (mAb), optimized 
for neutralizing activity against the human gremlin -1 protein, for the treatment of advanced solid 
tumors. Based on the mechanism of action of UCB6114 and previously gene rated nonclinical 
data, it is believed that UCB6114 could potentially represent an advance in the treatment of 
advanced solid tumors. This supports the testing of the objectives of this FIH study, which are to 
evaluate the safety, PK, and antitumor activit y of iv UCB6114 and identify the recommended 
Phase 2 dose (RP2D) for UCB6114 when administered as monotherapy or in combination with 
standard of care (SOC) in participants with advanced solid tumors.  
Objectives and endpoints  
Study objectives and endpoints for the dose escalation and expansion modules are presented in 
Table  1-1 (Part A and Part A1), Table  1-2 (Part B and Part C), and Table  1-3 (Parts D, E, F, and 
G), respectively. The overarching objective of this study is to determine the RP2D for 
monotherapy (RP2D -M) and for combination therapy. This will be determined using the totality 
of data generated based on the objectives in Table  1-1 (Part A and Part A1), Table  1-2 (Part B 
and Part C), and Table  1-3 (Parts D, E, F, and G) . 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 13 of 195 Table  1-1: Objectives and endpoints for the dose escalation module (Part A) 
and the dose o ptimization module (Part A1)  
Objectives  Endpoints  
Primary  
To characterize the safety profile of UCB6114 as 
monotherapy  Incidence of TEAEs  
Severity of TEAEs  
Incidence of DLTs  
Secondary  
To characterize the PK of UCB6114 administered 
as monotherapy  UCB6114 concentration by [CONTACT_313557]/exploratory  
To document any antitumor activity observed with 
UCB6114 according to relevant RECIST criteria  Antitumor activity as indicated by:  
• ORR  
• DCR  
• DOR  
• PFS 
• OS 
To explore PD biomarkers  of UCB6114  • Change in transcriptional and protein marker 
levels in blood and tumor tissue by [CONTACT_313558]  
• Change in ctDNA levels in blood by [CONTACT_313559], emergence, and impact 
of ADA  ADA (an ti-UCB6114 antibody) titer and sample 
status by [CONTACT_313560]=antidrug antibody; ctDNA=  circulating tumor DNA ; DCR=disease control rate; DOR=duration of antitumor 
response; DLT=dose -limiting toxicity; ORR=objective response rate; OS=overall sur vival; 
PD=pharmacodynamic(s); PFS=progression -free survival; PK=pharmacokinetic(s); RECIST=Response 
Evaluation Criteria in Solid Tumors; TEAE=treatment -emergent adverse event  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 14 of 195 Table  1-2: Objectives and endpoints for the dose escalation modules in Part B 
and Part C  
Objectives  Endpoints  
Primary  
To characterize the safety profile of UCB6114 
administered in combination with selected SOC 
regimens  Incidence  of TEAEs  
Severity of TEAEs  
Incidence of DLTs  
Secondary  
To characterize the PK of UCB6114 administered 
in combination with selected SOC regimens  UCB6114 concentration by [CONTACT_313561]/exploratory  
To document any antitumor activity observed with 
UCB6114 administered in combination with 
selected SOC regimens according to relevant 
RECIST criteria  Antitumor activity as indicated by:  
• ORR  
• DCR  
• DOR  
• PFS 
• OS 
To explore PD biomarkers of UCB6114 
administered in combination with selected SOC 
regimens  • Change in protein marker levels in blood by 
[CONTACT_313562]  
• Change in ctDNA levels in blood by [CONTACT_313563]6114 
administered in combination with selected SOC 
regimens  ADA (anti -UCB6114 antibody) titer and sample 
status by [CONTACT_313560]=antidrug antibody; ctDNA=  circulating tumor DNA ; DCR=disease control rate; DLT=dose -limiting toxicity; 
DOR=duration of antitumor respons e; ORR=objective response rate; OS=overall survival; 
PD=pharmacodynamic(s); PFS=progression -free survival; PK=pharmacokinetic(s); RECIST=Response Evaluation 
Criteria in Solid Tumors; SOC=standard of care; TEAE=treatment -emergent adverse event  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 15 of 195 Table  1-3: Objectives and endpoints for the expansion modules in Parts D, E, F, 
and G  
Objectives  Endpoints  
Primary  
To assess preliminary antitumor activity of 
UCB6114 when administered as monotherapy 
(Part  D and Part  E) or in combination with selected 
SOC regimens (Part  F and Part  G) according to 
relevant RECIST criteria  Antitumor activity as indicated by [CONTACT_313564] 6114 as 
monotherapy or in combination with selected SOC 
regimens  • Incidence of TEAEs  
• Severity of  TEAEs  
To document any antitumor activity observed with 
UCB6114 when administered as monotherapy or in 
combination with selected SOC regimens  Antitumor activity  as indicated by:  
• DCR  
• DOR  
• PFS 
• OS 
Tertiary/exploratory  
To explore PD biomarkers of UCB6114 
administered as monotherapy or in combination 
with selected SOC regimens  Change in transcriptional and protein marker levels 
in blood and tumor tissue by [CONTACT_313565]6114 administered 
as monotherapy or in combination with selected 
SOC regimens  UCB6114 concentration by [CONTACT_313566]6114 
administered as monotherapy or in  combination 
with selected SOC regimens  ADA (anti -UCB6114 antibody) titer and sample 
status by [CONTACT_313560]=antidrug antibody; DCR=disease control rate; DOR=duration of antitumor response; ORR=objective response 
rate; OS=overall survival; PD=p harmacodynamic(s); PFS=progression -free survival; PK=pharmacokinetic(s); 
RECIST=Response Evaluation Criteria in Solid Tumors; SOC=standard of care; TEAE=treatment -emergent 
adverse event  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 16 of 195 Overall design  
ONC001 is a multicenter, nonrandomized, open -label, Phase 1/2 study evaluating the safety, PK, 
efficacy (as assessed by [CONTACT_313567]), pharmacodynamics (PD), biomarkers, and 
immunogenicity (as assessed by [CONTACT_313568][ADA] participant classification) of iv 
UCB6114 as monotherapy (Parts A, A1, D, and E) or in combination with selected SOC 
regimens (Parts B, C, F, and G) in participants with advanced solid tumors. The RP2D -M or 
RP2D of iv UCB6114 for each combination therapy under evaluation will also be determined.  
The study has a modular design in cluding up to 3 dose escalation modules (Parts A, B, and C), 
1 dose optimization module (Part  A1), and up to 4 expansion modules (Parts D, E, F, and G) 
(see Table  4-1). Depending on emerging data, not all modules may open.  
After completion of Part  A, specific characteristics of modules subsequent to Part  A will be 
described in planned protocol amendments. The updated characteristics will include, but not b e 
limited to, tumor type selection, participant inclusion/exclusion criteria, route and frequency of 
study medication administration, and selection of the SOC treatment regimen.  
Part A consists of a Screening Period, Treatment Period (consisting of 28 -day cycles), a Safety 
Follow -Up (SFU) Visit, and a Final Visit, as shown in Table  1-4 and Figure  1-2. During the 
Treatment Period, UCB6114 is administered by [CONTACT_313569] 1 and 15 of each cycle, until 
the occurrence of progressive disease, unacceptable toxicity, or withdrawal of consent. The full 
Schedu le of Activities is provided in Table  1-4. 
Part A1 may commence after the fifth cohort in Part A (2000mg, every 2 weeks [Q2W]) has 
been determined to be  (ie, DLT incidence <33%, see Section  [IP_ADDRESS] ). Based on emerging 
data from Part A, this module will evaluate different frequencies of dosing (eg,  every 3 weeks 
[Q3W], every 4 weeks [Q4W]) and different durations of infusion ( Figure  1-3). Four different 
dosing schedules (cohorts) have been defined:   
• Cohort 1: 2000mg Q2W (60 -minute infusion), 28 -day treatment cycle  
• Cohort 2: 2000mg Q2W (30 -minute infusion), 28 -day treatment cycle  
• Cohort 3: 3000mg Q3W (90 -minute infusion), 21 -day treatment cycle  
• Cohort 4: 4000mg Q4W (120 -minute infusion), 28 -day treat ment cycle  
In Part A1, as all cohorts will receive a new dose formulation, Cohort 1 will repeat the dosing 
schedule of Part A Cohort 5.  
Part A1 consists of a Screening Period, Treatment Period (consisting of 28 -day cycles for 
Cohorts 1, 2, and 4, and of 2 1-day cycles for Cohort 3), a SFU Visit and a Final Visit. During the 
Treatment Period, UCB6114 is administered as iv infusion as per defined dosing schedules until 
the occurrence of progressive disease, unacceptable toxicity, or withdrawal from the study.  The 
full Schedule of Activities is provided in Table  1-5 and Table  1-6. 
Part B consists of a Screening Period, Treatment Period (consisting of 28 -day cycles), a SFU 
Visit, and a Final Visit, as shown in Table  1-7 and Figure  1-4 During the Treatment Period, 
UCB6114 will be administered in combination with trifluridine/tipi[INVESTIGATOR_14965] (TFD/TPI; TAS -102; 
Lonsurf®). UCB6114 will be administered as an iv infusion every 2 weeks (Q2W), while 
TFD/TPI [INVESTIGATOR_313465] (bid) within 1 hour of completion of morning 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 17 of 195 and evening meals on Days 1 to 5 and Days 8 to 12 (28 -day cycle). For the convenience of the 
participants, TFD/TPI [INVESTIGATOR_313466] w for the 12 -hour interval between 
TFD/TPI [INVESTIGATOR_313467]. For administration at home on Cycle [ADDRESS_385914] be confirmed within 3 days prior to Day 1 dosing as per the Schedule of Assessments.  
Trifluridine/tipi[INVESTIGATOR_313468]. The starting 
dose of UCB6114 in Part  B will depend on the dose level evaluated in Cohort 3 of Part  A 
(anticipated to be 500mg Q2W iv) and the emerging safety profile of UCB6114 monotherapy, 
including any ove rlappi[INVESTIGATOR_313469]/TPI. The full Schedule of Activities is provided in 
Table  1-7. 
Part C consists of a Screening Period, Treatment Period (consis ting of 28 -day cycles), a SFU 
Visit, and a Final Visit, as shown in Table  1-8 and Figure  1-5. During the Treatment Period, 
UCB6114 will be administered as an iv infusion Q2W followed by [CONTACT_313570], leucovorin, 
and 5 -fluorouracil (FOLFOX) Q2W on a 28 -day cycle. Modified FOLFOX 6 (mFOLFOX6) will 
be admin istered at the recommended standard of care dose: oxaliplatin 85mg/m2 iv infusion on 
Day 1, leucovorin 400mg/m2 iv infusion on Day 1, 5 -fluorouracil 400mg/m2 iv bolus on Day 1, 
followed by 5 -fluorouracil 1200mg/m2/day continuous infusion on Days 1 and 2 (2 400mg/m2 
over 46 hours). The starting dose of UCB6114 in Part  C will depend on the dose level evaluated 
in Cohort 3 of Part  A (anticipated to be 500mg Q2W iv), and the emerging safety profile of 
UCB6114 monotherapy, including any overlappi[INVESTIGATOR_313470]6 regimen. The 
full Schedule of Activities is provided in Table  1-8. 
If any participant withdraws early, the site will attempt to contact [CONTACT_313571].  
The end of the study is defined as the date of the Final Visit /last contact [CONTACT_313572].  
Number of participants  
Overall, approximately [ADDRESS_385915] 3 years.  
The planned number of study participants for each study part is provided below.  
Part A – Dose escalation (monotherapy)  
Up to [ADDRESS_385916] udy treatment.  
Part A1 – Dose optimization (monotherapy)  
Up to 32 eligible participants will be assigned to study treatment.  
Part B – Dose escalation (combination therapy)  
Up to 27 eligible participants will be assigned to each combination therapy regimen to be 
explored . 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 18 of 195 Part C – Dose escalation (combination therapy)  
Up to 27 eligible participants will be assigned to each combination therapy regimen to be 
explored . 
Part D and Part  E – Monotherapy expansion  
Up to 15 eligible participants each will be assigned to study treatment in Part  D and Part  E. 
Up to 15 additional participants each may be enrolled in Part  D and Part  E (ie, a total sample size 
of up to 30  participants in each expansion cohort, depending on emerging data).  
Part F and Part  G – Combin ation therapy expansion  
Up to 15 eligible participants each will be assigned to study treatment in Part  F and Part  G. 
Up to 15 additional participants each may be enrolled in Part  F and Part  G (ie, a total sample size 
of up to 30  participants in each expan sion cohort, depending on emerging data).  
Treatment groups and duration  
Participants will continue treatment with study medication until disease progression, 
unmanageable toxicity, criteria for discontinuation are met, or withdrawal of consent.  
Where possi ble, participants will attend an SFU Visit approximately 30 days after 
discontinuation of study treatment and a Final Visit approximately 3 months after 
discontinuation of study treatment. The Final Visit may be undertaken by [CONTACT_648], where 
applicable.  
1.2 Schem a 
A schematic of the study design is shown in Figure  1-1 and a detailed description of Part  A is 
shown in  Figure  1-2. A detailed schematic of Part  A1 is shown in Figure  1-3. A detailed 
schematic of Part  B is shown in Figure  1-4. A detailed schematic of Part  C is shown in 
Figure  1-5. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendm ent 6 UCB6114  ONC001  
  
Confidential  Page 19 of 195 Figure  1-1: ONC001 study design  
 
FIH=first in human; FOLFOX=oxaliplatin, leucovorin, and 5 -fluorouracil regi men; PAC3=Part A Cohort 3; PD=pharmacodynamics; PK=pharmacokinetics; 
RP2D -F=Recommended phase 2 dose in combination with FOLFOX; RP2D -M=Recommended phase 2 dose for monotherapy based on acceptable safety and 
tolerability profile and PK, may also include av ailable PD data; RP2D -T=Recommended phase 2 dose in combination with TFD/TPI; TBD=to be determined; 
TFD/TPI=trifluridine/tipi[INVESTIGATOR_313471].
UCB   26 Jun 2023  
Clinical Study Protocol Amendm ent 6 UCB6114  ONC001  
  
Confidential  Page 20 of 195 Figure  1-2: ONC001 Part  A cohorts  
 
d=days; iv=intravenous; PK=pharmacokinetic(s); Q2W=every 2 weeks; SMC=Safety Monitoring Committee  
Note: The SMC may add up to 2 additional cohorts based on emerging data, not to exceed 2000mg iv Q2W.  
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendm ent 6 UCB6114  ONC001  
  
Confidential  Page 21 of 195 Figure  1-3: ONC001 Part  A1 
 
D=day; iv=intravenous; Q2W=every 2 weeks; Q3W=every 3 weeks; Q4W=every 4 weeks  
Pre-treatment 
period Cycle 1 * Subsequent Cycles * Safety 
Follow -up
Up to 28 days
Baseline
AssessmentsCohort 1: n=1+7
UCB6114 iv 2000mg, 60 -minute infusion
D1 +  D15
Up to 30 days
Cohort 3: n=1+7
UCB6114 iv 3000mg, 90 -minute infusion
D1 
Sentinel 
assessment 
period
48 hoursCohort 4: n=1+7
UCB6114 iv 4000mg, , 120 -minute infusion
D1 Sentinel 
assessment 
period 
48 hoursCohort 2: n=1+7
UCB6114 iv 2000mg 30 -minute infusion
D1 + D15 Cohort 1:
UCB6114 iv 2000mg 
Q2W in 28 Day Cycles
Cohort 2:
UCB6114 iv 2000mg 
Q2W in 28 Day Cycles
Cohort 3:
UCB6114 iv 3000mg
Q3W in 21 Day Cycles
Cohort 4:
UCB6114 iv 4000mg
Q4W in 28 Day Cycles
* Cohorts 1, 2, and 4: 28 -day treatment cycles; Cohort 3: 21 -day treatment cycles Sentinel 
assessment 
period 
48 hoursTreatment Period
Sentinel 
assessment 
period 
48 hours
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendm ent 6 UCB6114  ONC001  
  
Confidential  Page 22 of 195 Figure  1-4: ONC001 Part  B 
 
bid=twice daily; D=Day; DLT=dose -limiting toxicity; iv=intravenous; mTPI= modified toxicity probability interval; po=oral; TFD/TPI=trifluridine/tipi[INVESTIGATOR_14965]  
*Dose must not exceed 80mg/dose  
Notes: Dose levels may have more than 1 cohort.  
Escalation to the next  dose level or de -escalation to the previous dose level will be guided by [CONTACT_203326] [CONTACT_59637].  
 
Dose level 1Dose level 2Dose level 3
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendm ent 6 UCB6114  ONC001  
  
Confidential  Page 23 of 195 Figure  1-5: ONC001 Part  C 
 
D=Day; DLT=dose -limiting toxicity; mFOLFOX6=leu covorin 400mg/m2 on Day 1, 5 -fluorouracil 400mg/m2 on Day 1 + 1200mg/m2/day on Day 1 and Day 2, 
and oxaliplatin 85mg/m2 on Day 1; iv=intravenous; Q2W=every 2 weeks; mTPI= modified toxicity probability interval  
Notes: Dose levels may have more than 1 cohort.  
Escalation to the next dose level or de -escalation to the previous dose level will be guided by [CONTACT_203326] [CONTACT_59637].  
 
Dose level 1Dose level 2Dose level 3
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
  
Confidential  Page 24 of 195 1.3 Schedule of Activities  
The Schedule of Activities for Part  A (monotherapy dose es calation) is provided in Table  1-4.  
Table  1-4: Schedule of Activities for Part  A (monotherapy dose escalation)  
Assessments  Screeninga Treatmenta SFU Visita Final 
Visita 
 -28 
to -
1 -14 
to -1 Cycle 1  
(28 days)  Cycle 2  
(28 days)  Cycle 3 onwardsc 
(28 days)  Within 
[ADDRESS_385917] 
dosef Cycle day  1d 2/3 8 15d/16 22 1d 8 15d 22e 1d 15d 22 
Infor med consent g X                
Eligibility assessment  X X Xee              
Demographic data and 
height  X                
Medical/surgical/cancer 
history/  
concomitant disease 
and current medical 
status.  X  X              
ECGh  X X  X Xz X X  X  X X  X  
Pregnancy test, if 
applicablei  X X   Xz  X  X  X X  X X 
Study medication 
(UCB6114) 
administrationj   X   Xz  X  X  X X    
Physical examination 
and weightgg  Xk X  X X X X  X  X X  X  
Vital signs (BP, HR, 
RR, and temperature) l  X X X X X X X X X  X X  X  
ECOG performance 
status   X X  X Xz X X  X  X X  X  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
  
Confidential  Page 25 of 195 Table  1-4: Schedule of Activities for Part  A (monotherapy dose escalation)  
Assessments  Screeninga Treatmenta SFU Visita Final 
Visita 
 -28 
to -
1 -14 
to -1 Cycle 1  
(28 days)  Cycle 2  
(28 days)  Cycle 3 onwardsc 
(28 days)  Within 
[ADDRESS_385918] 
dosef Cycle day  1d 2/3 8 15d/16 22 1d 8 15d 22e 1d 15d 22 
Urinalysism  Xk Xk   Xz  X  X  X X  X  
Urinalysis for urinary 
markers of bone 
turnovern   X   Xz   X    X   X  
Hematology   Xk Xk  X Xz X X X X X X X  X  
Blood chemistry   Xk Xk  X Xz X X X X X X X  X  
Coagulation   Xk Xk   Xz  X    X   X  
Blood collection for 
serum markers of bone 
turnover n   X    Xz  X    X   X  
Blood collection for 
immunogenicity 
(ADA)p,q,r   Xr   Xz X X    X   X  
Blood  collection for 
circulating gremlin -1 
analysisn, r,dd    X Xs  Xz  X    X   X  
Blood collection for 
serum 
protein/proteomic 
analysisn   X   Xz  X    X   X  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
  
Confidential  Page 26 of 195 Table  1-4: Schedule of Activities for Part  A (monotherapy dose escalation)  
Assessments  Screeninga Treatmenta SFU Visita Final 
Visita 
 -28 
to -
1 -14 
to -1 Cycle 1  
(28 days)  Cycle 2  
(28 days)  Cycle 3 onwardsc 
(28 days)  Within 
[ADDRESS_385919] 
dosef Cycle day  1d 2/3 8 15d/16 22 1d 8 15d 22e 1d 15d 22 
Blood collection for 
transcriptomic analysisn   X   Xz  X    X   X  
Blood collection for 
genetic analysis    X              
Blood collection for 
ctDNA analysis    X   Xz  X    Xaa   X  
Echocardiogram   X      X    Xbb   X  
Tumor assessmentscc Xt          Xu   Xv Xcc  
Tumor biopsy for PD 
analysisw X      X          
Historical tumor sample 
(from prior to entry into 
study) if availablex X                
Concomitant 
medication  X X Recorded throughout  X  
Adverse events 
(including DLT in 
Cycle 1)  X X Recorded throughout  Xy  
Survival censusff               X  X 
AE=adverse event; ALP=alkaline phosphatase; ALT=alanine transaminase; ANC=absolute neutrophil count; AST=aspartate transaminase; 
COVID -19=SARS -CoV2 (COVID -19) pandemic; CR=complete  response; CT=computed tomography; ctDNA=circulating tumor DNA; 
ECG=electrocardiogram; ECOG=Eastern Coopera tive Oncology Group; h=hours; hCG=human chorionic gonadotropin; iv=intravenous; 
LDH=lactate  dehydrogenase; MRI=magnetic resonance imaging; PD=pharmacodynamic(s); PK=pharmacokinetic(s); PR=partial  response; PSA=prostate 
specific antigen; RBC=red blood cell;  SFU=Safety Follow -Up; SMC=Safety Monitoring Committee; WBC=white blood cell  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
  
Confidential  Page 27 of 195 a Allowed visit window: ± 2 days (unless specified otherwise). Note: Day [ADDRESS_385920] dose.  
b Deleted.  
c From Cycle 3 and Cycle 4 onwards, visits on Day 22 may be omitte d at the discretion of the investigator and based on toxicity seen at Cycle 1 and 2, unless 
these visits were required for tumor assessments, or participant assessment.  
d The following safety assessments will be performed predose: physical examination, vit al signs, hematology, blood chemistry, coagulation, urinalysis, 
pregnancy testing, ECOG performance status, echocardiograms, and ECG. All other safety assessments will be performed postdose .  
e The visit on Day [ADDRESS_385921] at any point from Day 21 to  Day 28 of Cycle 2; tumor assessments should take place within this window at the 
investigator’s discretion.  
f When participants are unable to attend the SFU or Final Visit, it will not be considered a protocol deviation.  
g Informed consent must be given b efore any study -specific Screening procedures are performed.  
h ECGs are to be performed in triplicate with the participant in a supi[INVESTIGATOR_55848] a minimum of [ADDRESS_385922]. When ECG coin cides with PK (and PD), the 
ECG should be performed first. On Days 1  and 15 of Cycle 1, triplicate ECGs should be performed 3 times: the first predose; the second at the end of the 
infusion; and the third [ADDRESS_385923] be performed prior to dosing on dosing days. Addi tional pregnancy tests should also be 
performed during the study if indicated.  
j UCB6114 is administered as an iv infusion on Days 1 and 15 of each cycle, until the occurrence of progressive disease, unacce ptable toxicity, or withdrawal of 
consent.  
k Physi cal examination, weight, and laboratory tests (hematology, blood chemistry, coagulation, and urinalysis), may be repeated wit hin 72h prior to Cycle 1 Day 
1 for any borderline assessments identified at Days -14 to -3. Laboratory tests (hematology, blood che mistry, coagulation, and urinalysis) do not have to be 
repeated on Day 1 predose if performed within 72h of starting dosing. Laboratory tests (hematology, blood chemistry, coagulat ion, and urinalysis) may be 
obtained 24h prior to the scheduled visit and ma y be obtained at local laboratories.  
l Vital signs on treatment days will be assessed at multiple time points in a semi -supi[INVESTIGATOR_55848] [ADDRESS_385924]: predose, 10min (±5min) and 30min 
(±10min) after the start of the infusion, at the end of the in fusion (+15min); and at 1h (+15min) after the end of the infusion. In addition, on Cycle 1 Day 1 vital 
signs will also be assessed at 2 hours (+1h) and 8 hours (+2h) after the end of the infusion, to correspond with PK time poin ts; vital signs will be asse ssed prior 
to collection of PK samples.  
m Urinalysis parameters include specific gravity, pH, glucose, protein, ketones, blood, bilirubin, urobilinogen, nitrite, leuko cyte esterase by [CONTACT_5230]. If there are 
abnormalities in urine dipstick blood or protein results, microscopic analysis should be performed (including crystals).  
n Samples will only be collected up to and including Cycle 4.  
q At visits where U CB6114 is administered, ADA samples will be collected predose as described in Section  9.10. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_385925] –enhanced spi[INVESTIGATOR_313472], abdomen, pelvis, and any other areas of known or suspected 
disease, must be obtai ned within [ADDRESS_385926] and MRI scans (with gadolinium chelate contrasts) of the abdomen and pelvis may be used instead  of CT scans of the abdomen and pelvis. 
A CT or MRI scan that is dated prior to consent (up to 42 days prior to starting study medication) for this study may be used  as the Screening assessment, 
where this has been performed as per standard care or at the end of a prior research study. The same method of assessment is to be used per participant for the 
duration of study participation.  
u Further tumor assessments are to be performed between Days 21 and 28 of every even cycle (±2 days).  
v Tumor assessments ar e to be completed on even cycles.  
w If there are accessible tumor lesions, optional biopsies may be performed at Screening and at Cycle 1 Day 22. The  allowed time -window for collection of the 
Cycle 1 Day 22 sample is from Cycle 1 Day 22 up to Cycle 2 Day 22. 
x If an historical tumor biopsy specimen obtained prior to the participant’s entry into the study (eg, at the time of diagnosis ) is available, samples of this tissue 
will be requested for PD analysis.  
y Follow -up of AEs: AEs will be recorded up to [ADDRESS_385927] dose of study medication. After that time, any unresolved drug -related AEs should be 
followed until resolution or stabilization of the AE to obtain the date of resolution/stabilization (this follow -up can be via routine clinic visits or correspondence 
with a treating physician or other healthcare professional).  
z Assessed on Day [ADDRESS_385928] dose.  
gg A complete physical e xamination is to be performed at Screening and on Cycle 1 Day 1 predose. Physical examinations will be symptom -directed and 
performed prior to administration of UCB6114 on all other visits.  
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
  
Confidential  Page 29 of 195 The Schedule of Activities for Part  A1 (monotherapy dose optimiz ation) is provided in Table  1-5 (Cohorts 1, 2 and 4) and Table  1-6 
(Cohort  3).  
Table  1-5: Schedule of Activities for Part  A1 – Cohorts 1, 2, 4  
Assessments  Screening  Treatme nt SFU Visit  Final Visit  
 -28 
to -1 -14 
to -1 Cycle 1  
(28 days)  Cycle 2  
(28 days)  Cycle 3 
onwards  
(28 days)  Within 
[ADDRESS_385929] 
dose  
Cycle day  1 15 1 15 1 15   
Informed consenta X          
Eligibility assessmentb X X X        
Demographic data and height  X          
Medical/surgical/cancer history/  
concomitant disease and current medical status.  X  X        
ECGc X  X  X  X  X  
Pregnancy test, if applicabled X  X  X  X  X X 
UCB6114 - Cohort 1 (Q2W)    X X X X X X   
UCB6114 – Cohort 2 (Q2W)    X X X X X X   
UCB6114 – Cohort 4 (Q4W)    X  X  X    
Physical examination and weighte X  X X X X X X f X  
Vital signs (BP, HR, RR, and temperature)g X  X X X X  X X f X  
ECOG performance status  X  X  X  X  X  
Urinalysish X  X X X X X X f X  
Hematologyi X  X X  X X  X X f X  
Chemistryi X  X X X X X X f X  
Coagulationi X  X  X  X  X  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
  
Confidential  Page 30 of 195 Table  1-5: Schedule of Activities for Part  A1 – Cohorts 1, 2, 4  
Assessments  Screening  Treatme nt SFU Visit  Final Visit  
 -28 
to -1 -14 
to -1 Cycle 1  
(28 days)  Cycle 2  
(28 days)  Cycle 3 
onwards  
(28 days)  Within 
[ADDRESS_385930] 
dose  
Cycle day  1 15 1 15 1 15   
Echocardiogramj X      X  X  
Immunogenicity (ADA)l   X  X  X  X  
Tumor assessmentm X  Every  8 weeks from Day 1  X  
Concomitant medication  X  Recorded throughout  X  
Adverse Events (including DLT in Cycle 1)n X  Recorded throughout  X  
Survival census          X X 
Biomarker analyses            
Blood collection for circulating gremlin -1 
analysiso   X X X  X  X  
Blood collection for serum protein/proteomic 
analysisp  X  X X  X  X  
Blood collection for transcriptomic analysisp  X  X X  X  X  
Blood collection for genetic analysis   X         
Blood collection for ctDNA analysis   X  X X  X  X  
Tumor biopsy for PD analysisq X   X       
Historical tumor sample (from prior to entry 
into study) if availabler X          
ADA=anti -drug antibodies; AE=adverse event; BP= blood pressure; CT=computed tomography; ctDNA=circulating tumor DNA; h=hours; DLT=Dose  limiting 
toxicity; ECG=electrocardiogram; ECOG=Eastern Cooperative Oncology Group; HR=heart rate; min=minutes; MRI=magnet ic resonance imaging; 
PD=pharmacodynamic(s); PK=pharmacokinetic(s); Q2W=every 2 weeks; Q4W=every 4 weeks; RR= respi[INVESTIGATOR_697]; SFU=Safety Follow U p;  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
  
Confidential  Page 31 of 195 Note: The allowed visit window is ± 2 days (unless specified otherwise). All assessments are to be perfor med prior to dosing with UCB6114 (unless specified 
otherwise)  
a Informed consent must be given before any study -specific Screening procedures are performed.  
b Eligibility must be confirmed prior to proceeding to tumor biopsy and on Cycle 1 Day 1 prior to dosing with UCB6114. 
c ECGs are to be performed at screening; during Cycle 1 prior to dosing, at the end of the infusion, and 2h after the end of in fusion; during each subsequent cycle 
prior to dosing with UCB6114 on Day 1. Electrocardiograms are to be per formed in triplicate with the participant in a supi[INVESTIGATOR_55848] a minimum of 5min 
rest. When ECG coincides with PK (and PD), the ECG should be performed first.  
d Serum pregnancy test must be performed at screening. Serum or urine pregnancy test must b e performed prior to dosing on Day [ADDRESS_385931]: prior to dosing, 10min (±5min) and 30min 
(±10min) after the start of the infusion, at the end of the infusion (+15min) and 2h after the end of the infusion (+15min). In addition, on Cycle 1 Day 1, vit al 
signs will also be assessed at 5h (+2h) after the end of the infusion. Vital signs will be assessed prior to collection of PK  samples.  
h If there are abnormalities in urine dipstick, a microscopic analysis should be performed (including crystals). Urinalysis does not have to be repeated on Cycle 1 
Day 1 predose if performed within 72h of starting dosing.  
i Laboratory tests (hematology, blood chemistry, and coagulation) do not have to be repeated on Day 1 predose if performed with in 72h of starting d osing. They 
may be obtained 24h prior to the scheduled visit and may be obtained at local laboratories.  
j During the treatment period, echocardiograms are to be completed at the beginning of Cycle 3 (± 7 days), as clinically indica ted afterwards, and at th e SFU 
Visit.  
l Immunogenicity (ADA) samples will be collected on Cycle [ADDRESS_385932] cycle  thereafter (i.e. cycle 6, 9 
etc.) and at the SFU Visit.  
m Tumor assessments including spi[INVESTIGATOR_313472], abdomen, and any other area of known or suspected disease, mu st be obtained at Screening. 
A CT or MRI scan that is dated prior to consen t (up to 42 days prior to starting IMP) for this study may be used as the Screening assessment, where this has 
been performed as per standard of care or at the end of a prior study. The same method of assessment is to be used per partic ipant for the durati on of study 
participation. Tumor assessments are to be performed every 8 weeks from Day 1 (± 7 days). Tumor assessment at SFU is not requ ired if the participant has 
withdrawn due to progressive disease or if the previous tumor assessment was within 42 days  of SFU visit.  
n Follow -up of AEs: AEs will be recorded up to [ADDRESS_385933] dose of study medication. After that time, any unresolved drug -related AEs should be 
followed until resolution or stabilization of the AE to obtain the date of resolution/ stabilization (this follow -up can be via routine clinic visits or correspondence 
with a treating physician or other healthcare professional).  
o Blood samples for circulating gremlin -1 analysis will be collected at Cycle 1 Day 1, pre -dose (within 30 min pri or to dosing), end of infusion (+15min), and 4h 
(+1h) post -infusion as well as at Day 15 at predose (within 30min prior to dosing) or on day of visit if a non -dosing day. At all subsequent cycles, blood 
samples will be collected at Day 1 predose (within 30 min prior to dosing) and at the SFU Visit; for Cycle 3 only, an additional 4h (+1h) postdose sample 
should be taken on Day 1. An additional sample should also be collected on the day of on -treatment biopsy (only if taking place on a day where no PK samples  
are scheduled).  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_385934] Cycle 1 
Day 15 (ie, between Cycle 1  Day 15 and Cycle 2 Day 1). If on -treatment biopsy occurs a non -dosing day, an additional PK and an additional cGremlin -1 
samples should be collected on the day of biopsy.  
r If an historical tumor biopsy specimen obtained prior to the participant’s entry i nto the study (eg, at the time of diagnosis) is available, samples of this tissue 
will be requested for PD analysis at the time of consent.  
 
Table  1-6: Schedule of Activit ies for Part  A1 – Cohort 3  
Assessments  Screening  Treatment  SFU Visit  Final Visit  
 -28 
to -1 -14 
to -1 Cycle 1  
(21 days)  Cycle 2  
(21 days)  Cycle [ADDRESS_385935]  
(21 days)  Within [ADDRESS_385936] 
dose   
Cycle day  1 15 1 15 1 15   
Informed consenta X          
Eligibility assessmentb X X X        
Demographic data and height  X          
Medical/surgical/cancer history/  
concomitant disease and current medical status.  X  X        
ECGc X  X  X  X  X  
Pregnancy test, if applicabled X  X  X  X  X X 
UCB6114 - Schedule 3 (Q3W)    X  X  X    
Physical examination and weighte X  X  X  X  X  
Vital signs (BP, HR, RR, and temperature)f X  X  X  X  X  
ECOG performance status  X  X  X  X  X  
Urinalysisg X  X  X  X  X  
Hematologyh X  X  X  X  X  
Chemistryh X  X  X  X  X  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
  
Confidential  Page 33 of 195 Table  1-6: Schedule of Activit ies for Part  A1 – Cohort 3  
Assessments  Screening  Treatment  SFU Visit  Final Visit  
 -28 
to -1 -14 
to -1 Cycle 1  
(21 days)  Cycle 2  
(21 days)  Cycle [ADDRESS_385937]  
(21 days)  Within [ADDRESS_385938] 
dose   
Cycle day  1 15 1 15 1 15   
Coagulationh X  X  X  X  X  
Echocardiogrami X      X  X  
Immunogenicity (ADA)    X  X  Xk  X  
Tumor assessmentl X  Every 8 weeks from Day 1  X  
Concomitant medication  X  Recorded throughout  X  
Adverse Events (including DLT in Cycle 1)m X  Recorded throughout  X  
Survival census          X X 
Biomarker studies            
Blood, collection for circulating gremlin -1 
analysisn   X X X  X  X  
Blood collection for serum protein/proteomic 
analysiso  X   X  X  X  
Blood collection for transcriptomic analysiso  X   X  X  X  
Blood collection for genetic analysis   X         
Blood collection for ctDNA analysis   X   X  X  X  
Tumor biopsy for PD analysisp X    X      
Historical tumor sample (from prior to entry 
into study) if availableq X          
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
  
Confidential  Page 34 of 195 ADA=anti -drug antibodies; AE=adverse event; BP= blood pressure; CT=computed tomography; ctDNA=circulating tumor DNA; h=hours; DLT=Dose  limiting 
toxicity; ECG=electrocardiogram; ECOG=Eastern Cooperative Oncology Group; HR=heart rate; min=minutes; MRI=magnet ic resonance imaging; 
PD=pharmacodynamic(s); PK=pharmacokinetic(s); Q3W=every 3 weeks; RR= respi[INVESTIGATOR_697]; SFU=Safety Follow Up;  
Note: The allowed visit window is ± 2 days (unless specified otherwise). All assessments are to be performed prior to dosing  with UCB6114 (unless specified 
otherwise)  
a Informed consent must be given before any study -specific Screening procedures are performed.  
b Eligibility must be confirmed prior to proceeding to tumor biopsy and on Cycle 1 Day 1 prior to dosing with UCB6114.  
c ECGs are to be performed at screening; during Cycle 1 prior to dosing, at the end of the infusion, and 2h after the end of in fusion; during each subsequent cycle 
prior to dosing with UCB6114 on Day 1. Electrocardiograms are to be performed in triplicate  with the participant in a supi[INVESTIGATOR_55848] a minimum of 5min 
rest. When ECG coincides with PK (and PD), the ECG should be performed first.  
d Serum pregnancy test must be performed at screening. Serum or urine pregnancy test must be performed prior to  dosing on Day [ADDRESS_385939]: prior to dosing, 10min (±5min) and 30min 
(±10min) after the start of the infusion, at the end of the infusion (+15min) and 2h after the end of the infusion (+15min). In  addition, on Cycle 1 Day 1, vital 
signs will also be assessed at 5h (+2h) after the end of the infusion. Vital signs will be asses sed prior to collection of PK samples.  
g If there are abnormalities in urine dipstick, a microscopic analysis should be performed (including crystals). Urinalysis doe s not have to be repeated on Cycle 1 
Day 1 predose if performed within 72h of starting do sing.  
h Laboratory tests (hematology, blood chemistry, and coagulation) do not have to be repeated on Day 1 predose if performed with in 72h of starting dosing. They 
may be obtained 24h prior to the scheduled visit and may be obtained at local laboratories.  
i During the treatment period, echocardiograms are to be completed at the beginning of Cycle 3 (± 7 days), as clinically indicated afterwards, and a the SFU 
Visit.  
k Immunogenic ity (ADA) samples will be collected on Cycle [ADDRESS_385940] cycle thereafter  (i.e. cycle 6, 9 
etc.) as well as at the SFU Visit.  
l Tumor assessments including spi[INVESTIGATOR_313472], abdomen, and  any other area of known or suspected disease, must be obtained at Screening. 
A CT or MRI scan that is dated prior to consent (up to 42 days prior to starting IMP) for this study may be used as the Scree ning assessment, where this has 
been performed as per  standard of care or at the end of a prior study. The same method of assessment is to be used per participant for the duration  of study 
participation. Tumor assessments are to be performed every 8 weeks from Day 1 (± 7 days). Tumor assessment at SFU is not  required if the participant has 
withdrawn due to progressive disease or if the previous tumor assessment was within 42 days of SFU Visit.  
m Follow -up of AEs: AEs will be recorded up to [ADDRESS_385941] dose of study medication. After that time, any unresolved drug -related AEs should be 
followed until resolution or stabilization of the AE to obtain the date of resolution/stabilization (this follow -up can be via routine clinic visits or correspondence 
with a treating physician or other healthcare profe ssional).  
n Blood samples for circulating gremlin -1 analysis will be collected at Cycle 1 Day 1 at predose (within 30min prior to dosing), end of infusion (+15min), and 4h 
(+1h) post -infusion . An additional sample should be collected on Day [ADDRESS_385942] -infusio n on day of visit. . In all subsequent cycles blood samples will be collected 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
  
Confidential  Page 35 of 195 at Day 1 predose (within 30min prior to dosing) and at the SFU Visit; for Cycle 3 only an additional 4h (+1h) sample should b e taken on Day 1. An additional 
sample should also be collected on the day of the on -treatment biopsy (only if taking place on a day where no PK samples are scheduled).  
o To be confirmed based on Part A Cohort [ADDRESS_385943] Cycle 2 
Day 1 (ie, between Cycle 2 Day 1 and Cycle 2 Day 15). If on -treatment biopsy occurs a non -dosing day, an additional PK and an additional cGremlin -1 
samples should be collected on the day  of biopsy.  
q If an historical tumor biopsy specimen obtained prior to the participant’s entry into the study (eg, at the time of diagnosis ) is available, samples of this tissue 
will be requested for PD analysis at the time of consent.  
 
The Schedule of Act ivities for Part  B is provided in Table  1-7. 
Table  1-7: Schedule of Activities for Part  B 
Procedure  Screening  Treatment  SFU Visit  Final Visit  
-28 
to -1 -3 
to -1 Cycle 1 & Cycle 2  
(28 days)  Cycle 3 onwards 
(28 days)  Within 
30 days after 
final dose  3 months 
after final 
dose  Cycle day  1 8 15 22 1 15 
Informed consenta X          
Eligibility assessmentb X X Xg        
Demographic data and height  X          
Medical/surgical/cancer history/concomitant 
disease and current medical status  X  Xg        
ECGc  X X X  X  X  X  
Pregnancy test, if applicabled X X X    X  X X 
TFD/TPI [INVESTIGATOR_313473]  X X        
TFD/TPI [INVESTIGATOR_313474]/TPI [INVESTIGATOR_313475] 1 to 5 and Days 8 to 12 of each cycle    
UCB6114 administration    UCB6114 is administered as an iv infusion  
on Days 1 and 15 of each cycle    
Physical examination and weightf X X X Xg X Xg X X X  
Vital signs (BP, HR, RR, and temperature)h X X X Xg X Xg X X X  
ECOG performance statush X X X Xg X Xg X X X  
Urinalysisi X X X  X X X  X  
Urinalysis for urinary markers of bone turnover    X  X  X  X  
Hematologyk X X X X X X X X X  
Blood chemistryl X X X X X X X X X  
Coagulationm X X X  Xg  X  X  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
  
Confidential  Page 36 of 195 Table  1-7: Schedule of Activities for Part  B 
Procedure  Screening  Treatment  SFU Visit  Final Visit  
-28 
to -1 -3 
to -1 Cycle 1 & Cycle 2  
(28 days)  Cycle 3 onwards 
(28 days)  Within 
30 days after 
final dose  3 months 
after final 
dose  Cycle day  1 8 15 22 1 15 
Blood collection for serum markers of bone 
turnover    X  X  X  X  
Blood collection for immunogenicity (ADA)    X    Xp  X  
Blood collection for circulating gremlin -[ADDRESS_385944] X  Recorded throughout  X  
Survival census          X X 
ADA=antidrug antibody; AE=adverse event; ALP=alkaline phosphatase; BP=blood pressure; CT=computed tomography; ctDNA=circulati ng tumor DNA; 
DLT=dose -limiting toxicity; ECG=electrocardiogram; ECOG=Eastern Cooperative Oncology Group; h=hour(s); HR=heart rate;  iv=intravenous; 
min=minute(s); MRI=magnetic resonance imaging; PD=pharmacodynamic(s); PK=pharmacokinetic(s); RR=respi[INVESTIGATOR_697]; TFD/TPI=  trifluridine/tipi[INVESTIGATOR_14965]; 
SFU=Safety Follow -Up 
Note: The allowed visit window is ±2 days (unless specified otherwise).  All assessments are to be performed prior to dosing with IMP (unless specified 
otherwise).  
a Informed consent must be given before any study -specific Screening procedures are performed.  
b Eligibility must be confirmed within [ADDRESS_385945] to be repeated on Day 1 predose if performed within 3 days prior to starting any IM P. On Days 1 and 15 of Cycle 
1 only, ECGs will also be performed at multiple timepoints in relation to d osing with UCB6114 (pre -infusion, end of infusion, and at [ADDRESS_385946] infusion). 
When ECG coincides with blood collection for PK (and PD), the ECG should be performed first.  
d Serum pregnancy test must be performed in Screening and does not have to be re peated on Day [ADDRESS_385947] can be performed on all other visits.  
e TFD/TPI [INVESTIGATOR_313476] (see footnote b).  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
  
Confidential  Page 37 of 195 Table  1-7: Schedule of Activities for Part  B 
Procedure  Screening  Treatment  SFU Visit  Final Visit  
-28 
to -1 -3 
to -1 Cycle 1 & Cycle 2  
(28 days)  Cycle 3 onwards 
(28 days)  Within 
[ADDRESS_385948]: 
predose, 10 min (±5min) and 30min (±10min) after the start of the infusion, at the end of the infusion (+15min); and at 1h (+15min) after  the end of the 
infusion. In addition, on Cycle 1 Day 1 vital signs will be assessed at 2h (+1h) and 5h (+1h) after the end of the infusion.  
i Urinalysis is to be performed in Screening and does not have to be repeated on Day 1 predose if performed within 3 days prior  to starting any IMP. If there 
are abnormalities in urine dipstick, a microscopic analysis should be performed (includi ng crystals).  
j Deleted  
k Hematology is to be performed in Screening and does not have to be repeated on Day [ADDRESS_385949] to be repeated on Day 1 if performed within 3 days prior to  dosing with any IMP. At all 
other visits blood, the chemistry sample may be obtained 24h prior to the scheduled visit . In the case of liver function abnormalities considered potential 
Hy’s law cases, the liver -specific ALP must be separated from the total in participants with bone metastases and used to assess the liver function inst ead of 
the total ALP. 
m Coagulation is  to be performed in Screening and does not have to be repeated on Day 1 pre -dose if performed within 3 days prior to starting any IMP. At all 
o No sample required if done p reviously .  
p To be completed in Cycle 3 and thereafter in even cycles only (i.e., Cycle 4, 6)  
q Sample for circulating gremlin -1 will be collected at the same time as PK samples (ie, 30 minutes prior to dosing with UCB6114).  
r Tumor assessments including spi[INVESTIGATOR_313472], abdomen, pelvis, and any other areas of known or suspected di sease, must be obtained at 
Screening. A CT or MRI scan that is dated prior to consent (up to 42 days prior to starting IMP) for thi s study may be used as the Screening assessment, 
where this has been performed as per standard care or at the end of a prior research study. The same method of assessment is to be used per participant for 
the duration of study participation. Tumor assessme nts are to be performed every 8 weeks from Day 1 (±7 days). Tumor assessment at SFU is not required if 
the participant has withdrawn due to progressive disease or if the previous tumor assessment was within 42 days of SFU visit.  
s If an historical tumor bi opsy specimen obtained prior to the participant’s entry into the study (eg, at the time of diagnosis) is available, samples o f this tissue 
will be requested for PD analysis.  
t Including DLT in Cycle 1. Follow -up of AEs: AEs will be recorded up to 30 days a fter the final dose of IMP. After that time, any unresolved drug -related 
AEs should be followed until resolution or stabilization of the AE to obtain the date of resolution/stabilization (this follo w-up can be via routine clinic visits 
or correspondence wi th a treating physician or other healthcare professional).  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
  
Confidential  Page 38 of 195 Table  1-7: Schedule of Activities for Part  B 
Procedure  Screening  Treatment  SFU Visit  Final Visit  
-28 
to -1 -3 
to -1 Cycle 1 & Cycle 2  
(28 days)  Cycle 3 onwards 
(28 days)  Within 
30 days after 
final dose  3 months 
after final 
dose  Cycle day  1 8 15 22 1 15 
u During the treatment period, echocardiograms are to be completed at the beginning of Cycle 3 (±7  days), as clinically indicated afterwards, and at the SFU 
Visit.  
 
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
  
Confidential  Page 39 of 195 The Schedule of Activities for Part  C is provided in Table  1-8. The Schedule of Activities for modules subsequent to Parts  A, B, and C 
will be defined in  a planned protocol amendment.  
Table  1-8: Schedule of Activities for Part  C 
Procedure  Screening  Treatment  SFU Visit  Final Visit  
-28 
to -1 -14 
to -1 Cycle 1 & Cycle 2  
(28 days)  Cycle 3 
onwards  
(28 days)  Within 
30 days after 
final dose  3 months 
after final 
dose  
Cycle day  1 8 15 22 1 15 
Informed consenta X          
Eligibility assessmentb X X Xg        
Demographic data and height  X          
Medical/surgical/cancer history/concomitant 
disease and current medical status  X  Xg        
ECGc   X X  X  X X X  
Pregnancy test, if applicable   Xd X    X  X X 
UCB6114 administration    UCB6114 is administered as an iv infusion on Days 1 
and 15 of each cycle    
mFOLFOX6 administration    mFOLFOX6 is administered iv starting on Days  1 and 
15 of each cyclee   
Physical examination and weightf  X X Xg X Xg X X X  
Vital signs (BP, HR, RR, and temperature)h  X X Xg X Xg X X X  
ECOG performance status   X X Xg X Xg X X X  
Urinalysisi  X X  X X X  X  
Urinalysis for urinary markers of bone turnover    X  X  X  X  
Blood collection for serum markers of bone 
turnover    X  X  X  X  
Hematologyk  X X X X X X X X  
Blood chemistryl  X X X X X X X X  
Coagulationm  X X  Xg  X  X  
Blood collection for immunogenicity (ADA)    X    Xp  X  
Blood collection for circulating gremlin -1 
analysis X Xo Xo, q  Xq  Xp,q  X  
Blood collection for genetic analysis  X Xo         
Blood  collection for ctDNA analysis  X Xo Xo  X  X  X  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
  
Confidential  Page 40 of 195 Table  1-8: Schedule of Activities for Part  C 
Procedure  Screening  Treatment  SFU Visit  Final Visit  
-28 
to -1 -14 
to -1 Cycle 1 & Cycle 2  
(28 days)  Cycle 3 
onwards  
(28 days)  Within 
30 days after 
final dose  3 months 
after final 
dose  
Cycle day  1 8 15 22 1 15 
Echocardiogram  X      Xu  X  
Tumor assessmentsr X  Every 8 weeks from Day 1  X  
Historical tumor sample if availables X          
Concomitant medication  X X Recorded throughout  X  
Adverse events t X X Recorded throughout  X  
Survival census          X X 
ADA=antidrug antibody; AE=adverse event; BP=blood pressure; CT=computed tomography; ctDNA=circulating tumor DNA; DLT=dose -limiting toxicity; 
ECG=electrocardiogram; ECOG=Eastern Cooperative Oncology Group; HR=heart rate; iv=intravenous; mFOLFOX6=leucovorin 400mg/m2 on Day 1, 5 -
fluorouracil 400mg/m2 on Day 1 + 1200mg/m2/day on Day 1 and Day 2, and oxaliplatin 85mg/m2 on Day 1; MRI=magnetic resonance imaging; 
PD=pharmacodynamic(s); PK=pharmacokinetic(s); RR=respi[INVESTIGATOR_697]; SFU=Safety Follow -Up 
Note: The allowed visit window is ±2 days (unless specified otherwise). All assessments are to be performed prior to dosing with UCB611 4 (unless specified 
otherwise).  
a Informed consent must be given before any study -specific Screening procedures are performed.  
b Eligibility must be confirmed on Cycle [ADDRESS_385950]. On 
Days  1 and 15 of Cycle 1 o nly, ECGs will also be performed at the end of infusion and at 2 hours after the infusion of UCB6114. When ECG coincides with  
blood collection for PK (and PD), the ECG should be performed first.  
d Serum pregnancy tests must be performed at Screening. Seru m or urine pregnancy test must be performed on dosing days prior to dosing with any IMP. 
Tests should also be performed during the study if indicated.  
e The infusions will begin on Day [ADDRESS_385951]: prior to dosing with UCB6114, 10min 
(±5min) and 30min (±10min) after the start of the infusion, at the end of t he infusion (+15min), and at 1h (+15min) after the end of the infusion of 
UCB6114. In addition, on Cycle 1 Day 1 vital signs will be assessed at 2 hours (+1h) and 5 hours (+1h) after the end of the i nfusion of UCB6114.  
i If there are abnormalities in urine  dipstick, a microscopic analysis should be performed (including crystals). Urinalysis does not have to be repeated on 
Cycle  [ADDRESS_385952] to be repeated on Day 1 predose if performed within 72h of starting dosing. At all other visits, the  hematology sample may be 
obtained 24h prior to the scheduled visit.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
  
Confidential  Page 41 of 195 Table  1-8: Schedule of Activities for Part  C 
Procedure  Screening  Treatment  SFU Visit  Final Visit  
-28 
to -1 -14 
to -1 Cycle 1 & Cycle 2  
(28 days)  Cycle 3 
onwards  
(28 days)  Within 
[ADDRESS_385953] to be repeated on Day 1 predose if performed within 72h of starting dosing. At all other visits, the blood chemistry samp le 
may be obtained 24h prior to the scheduled visit. In the case of liver function abnormalities considered potential Hy’s law case s, the liver -specific ALP must 
be separated from the total in participants with bone metastases and used to assess the liver function instead of the total A LP. 
m Coagulation does not have to be repeated on Day 1 predose if performed within 72h of starting dosing. At all other visits, the coagulation sample may be 
obtained 24h prior to the scheduled visit.  
o No sample required if done previously .  
p To be completed in Cycle 3 and thereafter in even cycles only (i.e., Cycle 4, 6)  
q Sample for circulating gremlin -1 will be collected at the same time as PK samples (ie, 30 minutes prior to dosing with UCB6114).  
r Tumor assessments including spi[INVESTIGATOR_313472], abdomen, pelvis, and any other areas of known or suspected di sease, must  be obtained at 
Screening. A CT or MRI scan that is dated prior to consent (up to 42 days prior to starting IMP) for this study may be used a s the Screening assessment, 
where this has been performed as per standard care or at the end of a prior research st udy. The same method of assessment is to be used per participant for 
the duration of study participation. Tumor assessments are to be performed every 8 weeks from Day 1 (±7 days). Tumor assessme nt at SFU is not required if 
the participant has withdrawn due  to progressive disease or if the previous tumor assessment was within 42 days of the SFU visit.  
s If an historical tumor biopsy specimen obtained prior to the participant’s entry into the study (eg, at the time of diagnosis ) is available, samples of this tissue 
will be requested for PD analysis.  
t Including DLT in Cycle 1. Follow -up of AEs: AEs will be recorded up to 30 days after the final dose of IMP. After that time, any unresolved drug -related 
AEs should be followed until resolution or stabilization of  the AE to obtain the date of resolution/stabilization (this follow -up can be via routine clinic visits 
or correspondence with a treating physician or other healthcare professional).  
u During the treatment period, echocardiograms are to be completed at the  beginning of Cycle 3 (±7  days), as clinically indicated afterwards, and at the SFU 
Visit.  
 
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_385954] the human 
gremlin -1 protein and is currently under development for advanced solid tumors. Gremlin -1, 
secreted by [CONTACT_313553], binds to BMP and antagonizes signaling, thereb y allowing tumor 
cell expansion, renewal, and a more mesenchymal phenotype. By [CONTACT_313555] -1 BMP 
antagonism, UCB6114 is expected to restore BMP signaling, limit tumor cell expansion, and 
favor a more epi[INVESTIGATOR_313463]. Gremlin -1 has been shown  to be expressed in multiple solid 
tumor types, with mRNA expression being observed in >60% of colorectal, pancreatic, and 
esophageal cases. Despi[INVESTIGATOR_313464], there is still a 
large unmet need in the therapy of cancer types mentioned above. Expression data in human 
tumor models, together with nonclinical evidence, suggests a therapeutic potential of UCB6114 
and supports its proposed initial clinical investigation in participants with advanced solid tumors.  
The p rimary objectives of this study are to characterize the safety profile (dose escalation 
modules of this study), to assess preliminary antitumor activity (expansion modules of this 
study), and to determine the RP2D  of iv UCB6114 as monotherapy and in combin ation with 
selected SOC regimens. In addition, the PK, PD, PD biomarker profiles, and ADA of iv 
UCB6114 will be assessed.  
The scientific rationale for the study design is presented in Section  4.2. 
2.2 Background  
Gremlin -1 has an essential role in skeletal development and homeostasis, and in kidney 
development (Khokha  et al, 2003). The protein is highly conserved between species. Gremlin -1 
has several cellul ar signaling mechanisms (Brazil et al, 2015). The most well -described role for 
gremlin -[ADDRESS_385955] regulating the activity of BMPs 2, 4, and 7, members of 
the transforming growth factor -β superfamily (Mulloy and Rider, 2015). Gremlin -1 has also been 
reported to bind to the vascular endothelial growth factor receptor 2, however the functional 
relevance is currently unclear. Further described roles for gremlin -1 include binding to slit 
guidance ligand  1 and 2 (Slit1 and Slit2) and facil itating their binding to the roundabout receptor 
which leads to inhibition of monocyte chemotaxis, as well as associating to fibrillin microfibers 
and activating Slug expression, leading to epi[INVESTIGATOR_018] –mesenchymal transition and mesothelioma 
cell survival ( Mulloy  et al, 2015).  
Gremlin -1 mRNA has been shown to be expressed in >60% of colorectal, pancreatic, and 
esophageal cancer cases and in approximately 50% of bladder, breast, and lung cancer cases 
(Sneddon et al, 2006). It has also been shown to be a key d river in HMPS (Jaeger  et al, 2012), a 
rare and severe premalignant condition characterized by [CONTACT_313573]. It was demonstrated in this condition that there is a [ADDRESS_385956] on polyp development, allowing prolonged 
survival of animals through reduced tumor burden. In a highly aggressive model of CRC with 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 43 of 195 established disease,  the combination of Ab7326 mIgG1 antibody together with cytotoxic 
chemotherapy was efficacious, whereas either individual agent alone was not.  
The nonclinical safety program for UCB6114 comprised two 13 -week Good Laboratory Practice 
(GLP) compliant repeate d iv dose toxicity studies at dose levels of 30mg/kg and 150mg/kg, one 
in cynomolgus monkeys and the other in rats. No adverse effects, related to the mechanism of 
action (MoA) of UCB6114, were observed in any of the toxicology, safety pharmacology, and 
immunotoxicology parameters examined in cynomolgus monkeys or in male rats. In female rats, 
histopathological changes were noted in the ovaries, mammary gland, adrenal gland, and 
pi[INVESTIGATOR_2117]. No histopathological changes were noted in the cynomolgus monkey (fe males and 
males) and male rats. The endocrine changes in the female rats are considered related to the 
MoA of UCB6114 through BMPs effects in ovarian function and this pattern of changes occurs 
commonly in rats, particularly in aging Sprague Dawley rats. T he potential effects on ovarian 
function in the rat led to an anovulatory state (lack of corpora lutea and cystic follicles) with a 
series of downstream rat -specific effects in the uterus, vagina, and mammary gland. Rodents are 
known to be specifically sen sitive to hormonal changes and related impact on the 
hypothalamic -pi[INVESTIGATOR_2117] -adrenal (HPA) -mammary axis. The findings noted at the end of the main 
phase were either not observed or  noted at comparable incidence to the control group at the end 
of the recover y period (Day 183).  
For more detailed information regarding the nonclinical program, see the current Investigator’s 
Brochure (IB).  
2.3 Benefit/risk assessment  
This is the first study of UCB6114 in humans. Nonclinical studies demonstrate that UCB6114 
binds to gremlin -1, inhibits its pharmacological activity, and has antitumor activity in several in 
vivo mouse cancer models. Gremlin -[ADDRESS_385957] e tumor types. Taken 
together these data indicate that UCB6114 could play a role in treating a range of solid tumors.  
No adverse effects, related to the MoA of UCB6114, were observed in any of the toxicology, 
safety pharmacology, and immunotoxicology param eters examined in cynomolgus monkeys or 
in male rats. In female rats, histopathological changes were noted in the ovaries, mammary 
gland, adrenal gland, and pi[INVESTIGATOR_2117]. No histopathological changes were noted in the cynomolgus 
monkey (females and males) and  male rats. The endocrine changes in the female rats were 
considered related to the MoA of UCB6114 through BMPs effects in ovarian function and this 
pattern of changes occurs commonly in rats, particularly in aging Sprague Dawley rats. The 
potential effect s on ovarian function in the rat led to an anovulatory state (lack of corpora lutea 
and cystic follicles) with a series of downstream rat -specific effects in the uterus, vagina, and 
mammary gland. Rodents are known to be specifically sensitive to hormonal changes and related 
impact on the HPA -mammary axis. The findings noted at the end of the main phase were either 
not observed or noted at comparable incidence to the control group at the end of the recovery 
period (Day 183). These drug -related changes are c onsidered pharmacologically -related and 
shown to be reversible, and do not preclude further development of this molecule in the oncology 
indication.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 44 of 195 The FIH start dose (Part A, UCB6114 monotherapy) is anticipated to have a >100 -fold safety 
margin based on the outcome of the 13 -week GLP toxicity study in rats (the most sensitive 
species).  
In Part A, a number of safeguards are in place to minimize risk to study participants which 
reflect the state of knowledge of the study medication. There are detailed selec tion criteria and 
the study is designed using a sequential dose -escalation strategy (modified rolling -6), with at 
least [ADDRESS_385958] be en determined based upon the currently available 
data, including the safety profile, pharmacokinetic (PK) data, pharmacodynamic (PD) biomarker 
data, and available anti -tumor activity. A number of safety measures are in place to minimize the 
risk to study p articipants. Each of the 4 cohorts incorporates a sentinel participant. The 
enrollment of a sentinel participant has been included as an additional risk mitigation measure to 
monitor potential infusion reactions and other potential acute adverse events as UCB6114 will be 
administered with a new dose formulation (all cohorts), with a shorter infusion time (Cohort 2), 
or higher initial dose (Cohorts 3 and 4) than previously administered in Part A of the study. Each 
sentinel participant will be assessed for at  least [ADDRESS_385959] treatment 
administration before further participants within the same cohort can be enrolled.  
Parts B and C will use the modified toxicity probability interval (mTPI) design to guide dose 
escalation. The mTPI [INVESTIGATOR_313477] (ie, 0 of 3, 
1 of 3, 2 of 3, and 3 of 5) with a model -based inference on the toxicity probability intervals. The 
number of observed dose -limiting toxicities (DLTs) within a dose level will be used to calcu late 
the probability that the current dose level under consideration is within the underdosing, 
equivalent dosing, or overdosing range relative to the prespecified target toxicity considered 
acceptable for the disease setting.  
The target toxicity specified  within this protocol (25%) results in a more conservative set of 
escalation rules as compared with an algorithmic approach in that a single DLT observed in the 
first cohort of 3 will result in a recommendation to treat the next cohort of participants at t he 
same dose level rather than a recommendation to dose escalate. Consequently, the mTPI [INVESTIGATOR_313478] (MTD) and generally yields 
higher probabilities in identifying the true MTD.  
Dose escalation be tween cohorts in Part A, Part B, and Part C will follow clearly defined criteria 
including a review by a Safety Monitoring Committee (SMC), with a dose de -escalation, if 
appropriate. In consultation with the SMC, a Study Steering Committee (SSC) will recom mend 
to the Sponsor the dose and dosing regimen to be taken forward for the combination therapy dose 
escalation modules (Part B and C). The dosing schedules in Part A1 have been designed to 
achieve similar exposures at steady -state to those deemed sufficie ntly safe by [CONTACT_313574] A. 
There are also clearly defined criteria for stoppi[INVESTIGATOR_313479].  
Targeted therapi[INVESTIGATOR_313480], increasing 
survival rates in combination with cytotoxic chemotherapy. Despi[INVESTIGATOR_313481], the 
paucity of approved agents for progressive disease constitutes an important medical need that 
needs to be addressed.  
There is the potential for UCB6114 to be a beneficial treatment for patients with advanc ed solid 
tumors both in the context of this study and the wider clinical development program. Therefore, 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 45 of 195 taking into account the above considerations, the benefit/risk is considered favorable for the 
clinical study ONC001.  
More detailed information about t he preclinical pharmacology activity, potential benefits, and 
potential adverse events (AEs) of UCB6114 may be found in the current IB.  
3 OBJECTIVES AND ENDPO INTS  
Study objectives and endpoints for the dose escalation and expansion modules are presented in 
Table  3-1 (Part A and Part A1), Table  3-2 (Part B an d Part C), and Table  3-3 (Parts D, E, F, and 
G), respectively. The overarching objective of this study is to determine the RP2D for 
monotherapy (RP2D -M) and for combination therapy. This will be determined using the totality 
of data generated based on the objectives in and Table  3-1 (Part A and Part A1), Table  3-2 (Part 
B and Part C), and Table  3-3 (Parts  D, E, F, and G) . 
Table  3-1: Objectives and endpoints for the dose escalation module (Part A) 
and the dose optimization module (Part A1)  
Objectives  Endpoints  
Primary  
To characterize the safety profile of UCB6114 as 
monotherapy  Incidence of TEAEs  
Severity of TEAEs  
Incidence of DLTs  
Secondary  
To characterize the PK of UCB6114 administered 
as monotherapy  UCB6114 concentration by [CONTACT_313557]/exploratory  
To document any antitumor activity observed with 
UCB6114 according to relevant RECIST criteria  Antitumor activity as indicated by:  
• ORR  
• DCR  
• DOR  
• PFS 
• OS 
To explore PD biomarkers of UCB6114  • Change in transcriptional and protein marker 
levels in blood and tumor tissue by [CONTACT_313558]  
• Change in ctDNA levels in blood by [CONTACT_313559], emergence, and impact 
of ADA  ADA (anti -UCB6114 antibody) titer and sample 
status by [CONTACT_313575]=antidrug antibody; ctDNA=  circulating tumor DNA ; DCR=disease control rate; DOR=duration of antitumor 
response; DLT=dose -limiting toxicity; ORR=objective response rate; OS=overall survival; 
PD=pharmacodynamic(s); PFS=progression -free surviv al; PK=pharmacokinetic(s); RECIST=Response 
Evaluation Criteria in Solid Tumors; TEAE=treatment -emergent adverse event  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 46 of 195 Table  3-2: Objectives and endpoin ts for the dose escalation modules in Part B 
and Part C  
Objectives  Endpoints  
Primary  
To characterize the safety profile of UCB6114 
administered in combination with selected SOC 
regimens  Incidence of TEAEs  
Severity of TEAEs  
Incidence of DLTs  
Secondary  
To characterize the PK of UCB6114 administered 
in combination with selected SOC regimens  UCB6114 concentration by [CONTACT_313561]/exploratory  
To document any antitumor activity observed with 
UCB6114 administered in combinati on with 
selected SOC regimens according to relevant 
RECIST criteria  Antitumor activity as indicated by:  
• ORR  
• DCR  
• DOR  
• PFS 
• OS 
To explore PD biomarkers of UCB6114 
administered in combination with selected SOC 
regimens  • Change in protein marker levels in blood  by 
[CONTACT_313562]  
• Change in ctDNA levels in blood by [CONTACT_313563]6114 
administered in combination with selected SOC 
regimens  ADA (anti -UCB6114 antibody) titer and sample 
status by [CONTACT_313560]=antidrug antibody; ctDNA=  circulating tumor DNA ; DCR=disease control rate; DLT=dose -limiting toxicity; 
DOR=duration of antitumor response; ORR=objective response rate; OS=overall survival; 
PD=pharmacodynamic(s); PFS=progre ssion -free survival; PK=pharmacokinetic(s); RECIST=Response Evaluation 
Criteria in Solid Tumors; SOC=standard of care; TEAE=treatment -emergent adverse event  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 47 of 195 Table  3-3: Objectives and endpoints for the expansion modules in Parts D, E, F, 
and G  
Objectives  Endpoints  
Primary  
To assess preliminary antitumor activity of 
UCB6114 when administered as monotherapy 
(Part  D and Part  E) or in combination with selected  
SOC regimens (Part  F and Part  G) according to 
relevant RECIST criteria  Antitumor activity as indicated by [CONTACT_313564]6114 as 
monotherapy or in combination with selected SOC 
regimens  • Incidence of TEAEs  
• Severity  of TEAEs  
To document any antitumor activity observed with 
UCB6114 when administered as monotherapy or in 
combination with selected SOC regimens  Antitumor activity as indicated by:  
• DCR  
• DOR  
• PFS 
• OS 
Tertiary/exploratory  
To explore PD biomarkers of UCB6114 
administered as monotherapy or in combination 
with selected SOC regimens  Change in transcriptional and protein marker levels 
in blood and tumor tissue by [CONTACT_313565]6114 administered 
as monotherapy or in combination with selected 
SOC regimens  UCB6114 concentration by [CONTACT_313566]6114 
administered as monotherapy or in combination 
with selected SOC regimens  ADA (anti -UCB6114 antibody) titer and sample 
status by [CONTACT_313560]=antidrug antibody; DCR=disease control rate; DOR=duration of antitumor response; ORR=objective response 
rate; OS=overall survival; PD=pharmacodynamic(s); PFS=progression -free survival; PK=pharmacokinetic(s); 
RECIST=Response Eva luation Criteria in Solid Tumors; SOC=standard of care; TEAE=treatment -emergent 
adverse event  
4 STUDY DESIGN  
4.1 Overall design  
ONC001 is a multicenter, nonrandomized, open -label, Phase 1/2 study evaluating the safety, PK, 
and antitumor activity of iv UCB6114 in  participants with advanced solid tumors.  
The study has a modular design including up to 3 dose escalation modules ( Parts A, B, and C), 
1 dose optimization module (Part  A1), and up to 4 expansion modules (Parts D, E, F, and G) (see 
Section  1.2). Depending on emerging data, not all modules may open.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 48 of 195 After completion of Part  A, Part A1, Part B, and Part C, specific characteristics of modules 
subsequent to Part  A, Part A1, Part B, and  Part C will be described in planned protocol 
amendments. The updated characteristics will include, but not be limited to, tumor type 
selection, participant’s inclusion/exclusion criteria, route and frequency of study medication  
administration, and selecti on of the SOC treatment regimen.  
There are 8 different study modules for dose escalation and expansion, which are shown in 
Table  4-1. 
Table  4-1: Study modules for dose escalation and expansion  
Module  Module description  
Part A Dose -escalation to identify the RP2D -M, based on emerging safety, PK, PD, and antitumor 
effec t data. Participants will receive UCB6114 Q2W via iv infusion. The starting dose will 
be escalated (or de -escalated) stepwise in successive cohorts of 3 to 6 evaluable participants 
(modified rolling -6 design) (see Section  4.1.2 ), until the RP2D -M is determined. Up to 
42 participants may be enrolled.  
Part A1 Dose -optimization to evaluate alternative dosing schedules for UCB6114 administered as 
monotherapy in participant with unresectable locally advanced or metastatic colorectal 
adenocarcinoma, gastric adenocarcinoma, adenocarcinoma of the gastroesophageal junction, 
or pancreatic cancer. Based on emerging data from Part  A, this module will evalu ate a new 
dose formulation, different frequencies of dosing (eg, Q3W, QW4), and different time of 
infusion. Up to 32 participants may be enrolled.  
Part B Dose -escalation with TFD/TPI [INVESTIGATOR_313482], gastric adenocarcinoma, or adenocarcinoma of the 
gastroesophageal junction to identify the RP2D -T. 
The starting dose of UCB6114 in Part  B will depend on the dose level evaluated in Cohort 3 
of Part  A (anticipated to be 500mg Q2W iv) and  the emerging safety profile of UCB6114 
monotherapy, including any overlappi[INVESTIGATOR_313469]/TPI . It is expected that 2 or 3 
dose levels of UCB6114 will be explored. The starting dose will be escalated stepwise in 
successive cohorts of 2 to 4 evaluable  participants (mTPI [CONTACT_8345]), until the RP2D -T is 
determined. Up to 27 participants may be enrolled.  
Part C Dose -escalation with mFOLFOX6 in participants with unresectable locally advanced or 
metastatic colorectal adenocarcinoma, gastric adenocarcinoma, an d adenocarcinoma of the 
gastroesophageal junction to identify the RP2D -F. 
The starting dose of UCB6114 in Part  C will depend on the dose level evaluated in Cohort 3 
of Part  A (anticipated to be 500mg Q2W iv), and the emerging safety profile of UCB6114 
mono therapy, including any overlappi[INVESTIGATOR_313470]6 regimen . The 
starting dose and dose escalation scheme may differ from that evaluated in Part  B. It is 
expected that 2 or 3 dose levels of UCB6114 will be explored. The starting dose will be 
escalated stepwise in successive cohorts of 2 to 4 evaluable participants (mTPI [CONTACT_8345]), until 
the RP2D -F is determined. Up to 27 participants may be enrolled.  
Part D Expansion module to explore the safety and antitumor activity of UCB6114 as monotherapy 
with the RP2D -M dosing regimen. It is planned to evaluate 15 participants with a selected 
recurrent/metastatic tumor type 1 (to be decided based on emerging internal and external 
data). Up to 15 additional participants may be enrolled depending on the observed  antitumor 
activity (total sample size of up to 30 participants).  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 49 of 195 Table  4-1: Study modules for dose escalation and expansion  
Module  Module description  
Part E Expansion module to explore the safety and antitumor activity of UCB6114 as monotherapy 
with the RP2D -M dosing regimen in an alternative selected tumor type (tumor  type 2). It is 
planned to evaluate 15 participants with a selected recurrent/metastatic tumor type 2 (to be 
decided based on emerging internal and external data). Up to 15 additional participants may 
be enrolled depending on the observed antitumor activity (total sample siz e of up to 30 
participants).  
Part F Expansion module to explore the safety and antitumor activity of UCB6114 in combination 
with the SOC regimen tested in Part  B (RP2D -T). It is planned to evaluate UCB6114 plus 
SOC in 15 participants with a selected recur rent/metastatic tumor type. Up to 15  additional 
participants may be enrolled depending on the observed antitumor activity (total sample size 
of up to 30 participants).  
Part G Expansion module to explore the safety and antitumor activity of UCB6114 in comb ination 
with the SOC regimen tested in Part  C (RP2D -F). It is planned to evaluate 15  participants 
with a selected recurrent/metastatic tumor type. Up to 15 additional participants may be 
enrolled depending on the observed antitumor activity (total sample s ize of up to 30 
participants ). 
iv=intravenous(ly); mFOLFOX6=leucovorin 400mg/m2 on Day 1, 5 -fluorouracil 400mg/m2 on Day 1 + 
1200mg/m2/day on Day 1 and Day 2, and oxaliplatin 85mg/m2 on Day 1; mTPI= modified toxicity probability 
interval; QW=once weekly; Q2W=every 2 weeks; Q3W=every 3 weeks; PD=pharmacodynamics; 
PK=pharmacokinetics; RP2D -F=recommended Phase 2 dose of UCB6114 when used in combination with 
FOLFOX; RP2D -M=recommended Phase 2 dose for monotherapy; RP2D -T=recommended Phase 2 dose of 
UCB6114 whe n used in combination with TFD/TPI; sc=subcutaneous; SOC=standard of care; 
TFD/TPI=trifluridine/tipi[INVESTIGATOR_313483] A, each cohort will include 3 to 6  participants. Dose escalation (or de -escalation) will be 
guided by [CONTACT_313576] . At each dose level, PD samples will be 
collected to evaluate the PK/PD relationship.  
In Part  A, eligible participants will receive UCB6114 as an iv infusion every 2 weeks (Q2W) as 
monotherapy. UCB6114 will be administered as a flat dose (ie, not adjuste d for weight or body 
surface area [BSA]) unless emerging data indicate that weight - or BSA -based dosing would be 
more appropriate. Doses of UCB6114, ranging from 100mg to 2000mg (corresponding to 
approximately 1 to 30mg/kg) ( Table  6-5) may be explored. Five dose levels are planned; 
however, an additional 2 dose levels may be added based on emerging data. Dose escalation 
steps are currently planned at a max imum of 2.5 -fold; however, may be adjusted based on 
observed PK in the preceding cohort(s) and will not exceed 5 -fold. Up to 42 participants may be 
enrolled.  
The planned duration of treatment is 2 cycles. Participants may, however, remain on study for 
additional cycles if they are receiving therapeutic benefit (stable disease [SD], partial response 
[PR], or complete response [CR]) or until they fulfill one of the criteria for study discontinuation.  
Upon discontinuation of treatment, participants will be ref erred to appropriate follow -up care per 
the investigator’s judgment.  
Part A will include participants with tumor types associated with expression of GREM1  mRNA. 
These tumor types include bladder urothelial carcinoma, breast invasive carcinoma, colorectal 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 50 of 195 adenocarcinoma, esophageal carcinoma, head and neck squamous cell carcinoma, lung 
adenocarcinoma, lung squamous cell carcinoma, pancreatic adenocarcinoma, prostate 
adenocarcinoma, and stomach adenocarcinoma based on GREM1  expression data from Sneddon 
et al,  2006 and the  Cancer Genome Atlas (The Cancer Genome Atlas, 2019).  
From Part  A, a RP2D for UCB6114 monotherapy (RP2D -M) will be selected based upon the 
totality of information, including the safety profile, PK profile, and available antitumor activity 
and PD data. The start of any modules subsequent to Part A (monotherapy dose escalation) will 
be reliant on module -specific criteria and the approval of planned protocol amendments.  
Part A1 will be initiated after Cohort 5 of Part A (2000mg Q2W) has been deter mined to be  
(ie, DLT incidence <33%, see Section  [IP_ADDRESS] ). Eligible participants with unresectable locally 
advanced or metastatic colorectal aden ocarcinoma, gastric adenocarcinoma, adenocarcinoma of 
the gastroesophageal junction, or pancreatic cancer will receive iv infusion of UCB6114 as 
monotherapy. Four alternative dosing schedules (cohorts) have been planned and will explore 
shorter infusion ti me, and less frequent administration ( Table  6-6). Each cohort will enroll [ADDRESS_385960] udy. For all dose levels, participants 
will be treated in cohorts of 2 to 4 (target of 3), each dose level will have a minimum of 3 and a 
maximum of 9 participants  (Section  [IP_ADDRESS].2  [Part B] and Section  [IP_ADDRESS].2  [Part C]).  
In Part  B, eligible participants with unresectable locally advanced or metast atic colorectal 
adenocarcinoma, gastric adenocarcinoma, or adenocarcinoma of the gastroesophageal junction 
will receive UCB6114 as an iv infusion in combination with orally administered TFD/TPI. The 
initial dose and schedule of UCB6114 will depend on the d ose level evaluated in Cohort 3 of 
Part A (anticipated to be 500mg Q2W iv), the emerging safety profile of UCB6114 
monotherapy, and any predicted overlappi[INVESTIGATOR_313484]/TPI. Up to 3 dose levels 
(anticipated to be 500mg, 1000mg, and 2000mg administ ered Q2W iv) are planned 
(Section  4.3.3 ). Up to 27  participants are planned. Dose escalation decisions in this module will 
be guided by a model -based estimation of the probability of DLT in Cycle 1.  
In Part  C, eligible participants with unresectable locally advanced or metastatic colorectal 
adenocarcinoma, gastric adenocarcinoma, or adenocarcinoma of the gastroesophageal junction 
will receive UCB6114 as  an iv infusion in combination with mFOLFOX6 chemotherapy. The 
initial dose and schedule of UCB6114 will depend on the dose level evaluated in Cohort 3 of 
Part A (anticipated to be 500mg Q2W iv), the emerging safety profile of UCB6114 
monotherapy, and any predicted overlappi[INVESTIGATOR_313485]6. Up to 3 dose levels 
(anticipated to be 500mg, 1000mg, and 2000mg administered Q2W iv) are planned 
(Section  4.3.3 ). Up to 27  participants are planned. Dose escalation decisions in this module will 
be guided by a model -based estimation of the probability of DLT in cycle 1.  
In the expansion modules, the RP2D from the respective escalation modules (Part  A through 
Part C) will be tested either as monotherapy in selected tumor types (Part  D and Part  E) or in 
combination with SOC (Part  F and Part  G). Participants recruited to the se modules must have at 
least 1 measurable tumor lesion according to relevant Response Evaluation Criteria in Solid 
Tumors  (RECIST).  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_385961] been monitored for a minimum of 28 days (ie, 
1 cycle). However, all available safety d ata (both within the cohort and from preceding cohorts) 
will be taken into consideration when dose escalation decisions are made.  
In the expansion modules, response will be assessed after completion of 2 cycles of treatment 
(ie, 4 doses on Q2W dosing regim en) and at regular intervals thereafter.  
4.1.1  Study oversight  
Study safety oversight will be performed via an SMC as well as regular safety conference calls in 
Part A , and by [CONTACT_313577],  as well as regular safety conference calls, once modules 
subsequen t to Part A commence . 
Safety monitoring committee  
A SMC will be established for Part A and will comprise key Sponsor personnel and Investigators 
from participating sites. Once modules subsequent to Part A commence, the members of the 
SMC will include Inve stigators who are actively enrolling study participants into the study.  
Responsibilities of the SMC include:  
• Review of safety data for study participants including review and provision of adjudication 
of individual DLTs, when applicable.  
• Review of availab le PK and PD biomarker data.  
• Make dose escalation recommendations, dosing schedule recommendations, 
recommendations to continue the study as planned or with protocol adjustments, if needed.  
• Determination of the MTD, if applicable.  
Study steering committee  
An SSC will be implemented prior to the start of modules subsequent to Part A. The SSC 
members will include the coordinating Investigator, supporting co -Investigators, and clinical 
experts not involved in the study. The medical, scientific, and clinical s tudy expertise of the SSC 
will assist the Sponsor in identifying and resolving study related issues, such as study design, 
study implementation and conduct, and data analysis and reporting. In consultation with the 
SMC, the SSC will recommend to the Sponso r the dose and dosing regimen to be taken forward 
for Part B and Part C.  
4.1.2  Part A – Monotherapy dose escalation  
In Part  A of the study, [ADDRESS_385962] 
24 hours following second treatment adm inistration before further participants within the dose 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 52 of 195 cohort can be enrolled. In the absence of a DLT observation in the sentinel participant after 16 
days, the remaining 5 participants may be enrolled concurrently ( Figure  4-1). Should the sentinel 
participant experience a DLT, then participants 2 and 3 will be enrolled and observed for 16 days 
(Figure  4-2). Escalation can be performed when 3/3, 4/4, 5/5, 5/6, or 6/[ADDRESS_385963] dose (assuming UCB6114 is dosed Q2W). If dosing is less frequent (due to missed 
or delayed doses or due to a planned change in schedule), at least 3 participants should be treated 
and observed for a minimum of 28 days (ie, 1 cycle), before dose escal ation is considered. The 
second participant in any new cohort should also not be dosed until the first participant has 
received at least 2 doses and been observed for a minimum of 16 days (ie, 24 hours following the 
second treatment administration). All pa rticipants will remain in the hospi[INVESTIGATOR_313486]’s 
standard monitoring facility for continuous monitoring for the first [ADDRESS_385964] 
dose; at subsequent doses, the participant may remain at the hospi[INVESTIGATOR_313486]’s standard 
monitori ng facility at the investigator’s discretion.  
[IP_ADDRESS]  SMC  
Once the last participant in a given cohort has completed the required 28 -day DLT Observation 
Period, an SMC meeting will be convened to review all safety data, available PK data, and any 
available PD data.  The SMC will decide whether to halt dose escalation, further expand the 
cohort to gain additional safety data, or determine the next dose level to be tested.  Details are 
described in an SMC Charter.  
[IP_ADDRESS]  Dose escalation criteria  
Dose -limiting toxicities observ ed in the full [ADDRESS_385965] or whether cohort expansion or dose 
de-escalation should occur. However, all available safety data (both within the cohort and from 
preceding cohorts) will be taken into consideration when making such decisions.  
Dose -limiting toxicities may not be encountered in this study. There is no intention to continue 
dose escalation until an MTD can be established. The decision -making guidelines for dose 
escalation are shown in Figure  4-1 (no DLT was observed in the sentinel participant) and 
Figure  4-2 (a DLT was observed in the sentinel participa nt). The SMC will make dose escalation 
decisions based upon review of safety data and available PK data after all participants in a cohort 
complete at least the first treatment cycle (28 days) or have discontinued.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 53 of 195 Figure  4-1: Dose escalation decision making: no DLT observed in sentinel 
participant  
 
DLT=dose -limiting toxicity; MTD=maximum tolerated dose  
Note: Figure 2 is shown in Figure  4-2. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 54 of 195 Figure  4-2: Dose escalation decision making: DLT observed in sentinel 
participant  
 
DLT=dose -limiting toxicity; MTD=maximum tolerated dose  
[IP_ADDRESS]  Dose de -escalation following initial dose level  
The SMC will determine if a dose de -escalation may be warran ted, for example, if DLTs are 
observed in ≥2 participants in Cohort 1.  
[IP_ADDRESS]  Dose -limiting toxicity determination and maximum tolerated dose 
definition  
Dose -limiting toxicity is defined as an AE that is at least possibly related to the study medication 
that occu rs during Cycle 1 and fulfills any one of the following criteria:  
1. Grade 3 or 4 nonhematological toxicity according to the National Cancer Institute (NCI) 
Common Terminology Criteria for AEs (CTCAE Version 5.0) except for alopecia (of any 
severity or durati on), or nausea, vomiting, or diarrhea that reverses to Grade ≤2 within 
24 hours with appropriate medical therapy.  
2. Grade 3 or 4 biochemical abnormality that persists despi[INVESTIGATOR_313487] n ontransient (does not return to baseline 
within 24 hours, with or without appropriate supplementation).  
3. Any Grade ≥3 hematological toxicity of >5 days duration or febrile neutropenia (absolute 
neutrophil count [ANC]<1000/mm3 with a single temperature of >38.3°C or sustained 
temperature ≥38°C for more than one hour), infection (documented clinically or 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 55 of 195 microbiologically) with Grade 3 or 4 neutropenia, thrombocytopenia with bleeding or 
requiring platelet transfusion, or Grade 4 thrombocytopenia.  
4. Prolonged Grade 2 diarrhea (>7 days) despi[INVESTIGATOR_313488], or multiple 
Grade 1or 2 toxicities (eg, Grade 1 or 2 diarrhea, vomiting, rash, and fatigue) may also be 
considered dose -limiting if considered so by [CONTACT_8647].  
Investigators, in consultation with the study physician or medically qualified designee , can 
declare a DLT if a participant is experiencing toxicity and treatment cannot be continued without 
exposing the participant to excessive risk.  
The MTD is c onsidered to be the dose level immediately below that which results in a 
DLT  incidence of 33% or higher.  
[IP_ADDRESS]  Defining the recommended Phase [ADDRESS_385966] completed a minimum of 
28 days o f treatment (ie, 1 Cycle) or have discontinued prematurely ( Table  1-4). All safety, PK, 
available PD biomarker, ADA, and antitumor activity data will be u sed to select the RP2D -M. 
The RP2D -M will not exceed the MTD (if an MTD is established). Pharmacodynamic effects 
consistent with the mechanism of action of UCB6114 and/or clinical evidence of antitumor 
activity may also help determine the RP2D -M. 
4.1.3  Part A1 – Dose optimization (alternative dosing schedules)  
Part A1 is a multicenter, non -randomized, open -label, dose optimization module of Study 
ONC001 to evaluate alternative dosing schedules and infusion times for UCB6114 administered 
as monotherapy in patients  with unresectable locally advanced or metastatic colorectal cancer, 
gastric cancer, cancer of the gastro -esophageal junction, or pancreatic cancer.  
Part A1 may commence after the fifth cohort in Part  A (Cohort 5) is considered sufficiently  
by [CONTACT_313578] C (DLT rate less than 33%). The planned dose optimization scheme for Part  A1 will 
assess the safety and tolerability of the drug new formulation and will explore shortening of the 
infusion time and less frequent dosing as follows:  
• Cohort 1: 2000mg Q2W (60 -minute iv infusion), 28 -day treatment cycle  
• Cohort 2: 2000mg Q2W (30 -minute iv infusion), 28 -day treatment cycle  
• Cohort 3: 3000mg Q3W (90 -minute iv infusion), 21 -day treatment cycle  
• Cohort 4: 4000mg Q4W (120 -minute iv infusion), 28 -day treatment cycle  
Details of each planned cohort are provided in Table  6-6. 
Up to 32 participants will be allocated 1:1:1:[ADDRESS_385967] cycle and the SMC will convene before further 
participants within the cohort can be enrolled.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 56 of 195 The SMC will also convene after 25%, 50% and 100% of study participants in Part A1 have 
complet ed the required 28 -day observation period. If deemed necessary, an additional SMC 
meeting can convene after 75% of the participants have completed the required observation 
period. If 1 DLT, or more, (refer to Section  [IP_ADDRESS]  for the definition of DLTs) are reported for a 
cohort then, an ad -hoc SMC will convene to determine if the dosing schedule and study can 
continue as planned.  
If 3 or more participan ts experience DLT(s) in a given cohort, no further participants will be 
enrolled in the cohort and the dosing schedule will be considered to be unacceptably toxic.  
After consultation, the SMC will provide recommendations which could include to expand 
enrollment in a particular cohort to gain additional safety data, continue this Part with 
modifications or temporary suspension of enrollment in a particular cohort. Details are described 
in a SMC Charter.  
The planned duration of treatment is 2 cycles. Partici pants may, however, remain in the study for 
additional cycles if they are receiving therapeutic benefit (SD, PR, or CR) or until they fulfill one 
of the criteria for treatment discontinuation. Participants will continue treatment until disease 
progression,  unmanageable toxicity, or withdrawal from the study. Upon discontinuation from 
treatment, participant will be referred to appropriate follow -up care per the Investigator’s 
judgment.  
4.1.4  Part B – Dose escalation with TFD/TPI  
[CONTACT_9524] B is a single arm open -label m ultiple ascending dose -escalation module of ONC001 
evaluating UCB6114 in combination with TFD/TPI [INVESTIGATOR_313489] 2 dose of 
UCB6114 when used in combination with TFD/TPI (RP2D -T). Up to 27 participants with 
unresectable locally advanced o r metastatic colorectal adenocarcinoma, gastric adenocarcinoma, 
or adenocarcinoma of the gastroesophageal junction will be enrolled.  
Part B of ONC001 is planned to be initiated after Cohort 3 of Part  A has completed the 28 -day 
DLT assessment period and onc e the SMC has provided a recommendation to dose escalate to 
the next protocol -defined level in Part  A of the study.  
During the Treatment Period, UCB6114 will be administered in combination with TFD/TPI. 
UCB6114 will be administered as an iv infusion every  2 weeks (Q2W), while TFD/TPI [INVESTIGATOR_313490] (bid) within 1 hour of completion of morning and evening meals 
at home on Days 1 to 5 and Days 8 to 12 (28 -day cycle). For the convenience of the participants, 
TFD/TPI [INVESTIGATOR_313491] d at home to allow for the 12 -hour interval between TFD/TPI [INVESTIGATOR_313492]. For administration at home on Cycle [ADDRESS_385968] be 
confirmed within 3 days prior to Day 1 dosing as per the Schedule of Assessments.  
Trifluridine/tipi[INVESTIGATOR_313493]. The starting 
dose of UCB6114 in Part  B will depend on the dose level evaluated in Cohort 3 of Part  A 
(anticipated to be 500mg Q2W iv) and the emerging safety profile of UCB6114 monotherapy, 
including any overlappi[INVESTIGATOR_313469]/TPI.  
Part B will be undertaken using the mTPI [INVESTIGATOR_12183]. A target DLT rate of 25% with an equivalence 
interval (20% to 30%) will be used to estimate the MTD during dose escalation. For all dose 
levels, enrolled part icipants will be treated in cohorts of 2 to 4 participants (target of 3), who can 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_385969] TFD/TPI [CONTACT_228674]. However, additional dose levels may be added based on 
emerging data and recommendations of the SMC. Dose escalation steps are currently planned at 
a maximum of 2 -fold. Escalating dos e levels in Part  B will not exceed a dose level tested and 
considered safe by [CONTACT_313579] (Part  A). 
The decision to dose escalate, have no change in dose, or dose de -escalate in the next cohort will 
occur once all partic ipants in the preceding cohort have been monitored for a minimum of 28 
days (ie, 1 cycle). All available safety data (both within the cohort and from preceding cohorts 
and other parts of the study) will be taken into consideration when dose escalation deci sions are 
made. The dose justification is given below in Section  4.3.3 . 
The planned duration of treatment is 2 cycles. Participants may, however, remai n in the study for 
additional cycles if they are receiving therapeutic benefit (SD, PR, or CR) or until they fulfill one 
of the criteria for study discontinuation (Section  7.2). Participants will continue treatment until 
disease progression, unmanageable toxicity, or withdrawal of consent. Upon discontinuation of 
treatment, participants will be referred to appropriate follow -up care per the investigator’s 
judgment.  
From Part  B, a RP2D -T for UCB6114 in combination with TFD/TPI [INVESTIGATOR_313494], including the safety profile, PK data, PD biomarker data, and 
available antitumor activity.  
[IP_ADDRESS]  Study oversight  
The SMC will convene after the last participant in a given cohort has completed the required 
28-day DLT Observation Period. The SMC will decide whether to halt dose escalation, further 
expand the dose level to gain additional safety data, or determine the ne xt dose level to be tested.  
Safety conference calls with investigators and key Sponsor personnel will be held regularly.  
[IP_ADDRESS]  Dose -limiting toxicity and maximum tolerated dose definition and 
determination  
[IP_ADDRESS].1  Definition of DLT  
Dose -limiting toxicity is defined as one of the following toxicities (according to the NCI CTCAE 
Version 5.0) occurring during the DLT assessment window (Days 1 to 28 of Cycle 1) that is at 
least possibly related to UCB6114:  
• Grade ≥4 neutropenia (ANC <500/μL) lasting ≥7 days  
− In the event of C TCAE Grade [ADDRESS_385970] be performed on the 
seventh day after the onset of the event to determine if a DLT has occurred  
• Grade ≥3 neutropenia complicated by [CONTACT_411] (≥38° C) or infection  
• Grade 3 thrombocytopenia with bleeding or requir ing platelet transfusion or Grade 4 
thrombocytopenia  
• Any Grade ≥3 non -hematological event with the following exceptions:  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 58 of 195 − Grade 3 nausea, vomiting, diarrhea, or fatigue that resolves to Grade ≤2 within 24 hours 
of implementing optimal supportive care  
− Grade 3 laboratory abnormality that is asymptomatic and also deemed by [CONTACT_313580], in consultation with the medical monitor, can declare a DLT if a participant is 
experiencing toxicity and treatment cannot be continued without exposing the participant to 
excessive risk.  
[IP_ADDRESS].2  Determination of maximum -tolerated dose  
For every dose levels, participants will be treated in cohorts of 2 to 4 (target of 3), each dose 
level will have a minimum of 3 and a maximum of 9 partic ipants.  
The target rate of DLTs is 25% (equivalence interval 20% to 30%). The target rate will define 
the MTD of the combination regimen (UCB6114 given in combination with TFD/TPI).  
The mTPI [INVESTIGATOR_128574] a statistical probability algorithm, calculate d using data from all 
participants treated in prior and current cohorts at the same dose level, to determine whether 
future cohorts should be dose escalated, have no change in dose, or be dose de -escalated. The 
dose escalation will stop if any of the follo wing criteria is met:  
• The maximum sample size has been reached (27 participants total)  
• At least [ADDRESS_385971] been accumulated on a dose that is predicted to be the MTD  
• All doses explored appear to be overly toxic and the MTD cannot be determined  
• The escalation would exceed a dose level tested and considered safe by [CONTACT_313581] (Part  A) 
The mTPI [INVESTIGATOR_134921] a Bayesian decision framework to inform dose -escalation and dose 
de-escalation decisions. These rules are conceptually similar to those  used by [CONTACT_941] 3+[ADDRESS_385972] table ( Table  4-2). 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 59 of 195 Table  4-2: Part B dose escalation/de -escalation schema for mTPI [INVESTIGATOR_313495]  
[ADDRESS_385973] 
D=de -escalate to next lower dose; DLT=dose -limiting toxicity; DR=the current dose is unacceptably toxic; 
E=escalate to next higher dose; mTPI= modified toxicity probability interval; S=stay at current dose  
a Target toxicity=0.25  
Table  4-2 has the following interpretation (using 3 and 6 treated participants as examples):  
With 3 participants treated at current dose level:  
• 0 DLTs = escalate  
• 1 DLT = remain at the current dose  
• 2 DLTs = de -escalate  
• 3 DLTs = de -escalate and consider current dose as unacceptably toxic  
With 6 participants treated at current dose level:  
• 0 DLTs = escalate  
• 1 to 2 DLTs = remain at the current dose  
• 3 DLTs = de -escalate  
• >3 DLTs = de -escalate and consider cu rrent dose as unacceptably toxic  
[IP_ADDRESS]  Definition of recommended Phase 2 dose in combination with 
TFD/TPI  
[INVESTIGATOR_313496]2D -T will be defined after all participants evaluable for DLT assessment in Part  B have 
completed a minimum of 28 days of treatment (ie, 1 cycle). The  RP2D -T will not exceed the 
RP2D -M or the MTD (if an MTD is established). The definition of the RP2D -T will take into 
account the safety profile, PK, PD biomarkers, and any antitumor effect data.  
4.1.5  Part C – Dose escalation with mFOLFOX6  
Part C is a single ar m, open -label, multiple ascending dose -escalation module of ONC001 
evaluating UCB6114 in combination with a mFOLFOX6 to identify the recommended Phase 2 
dose of UCB6114 when used in combination with mFOLFOX6 (RP2D -F). Up to 27 participants 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 60 of 195 with unresectabl e locally advanced or metastatic colorectal adenocarcinoma, gastric 
adenocarcinoma, and adenocarcinoma of the gastroesophageal junction will be enrolled.  
Part C of ONC001 is planned to be initiated after Cohort 3 of Part  A has completed the 28 -day 
DLT asse ssment period and once the SMC has provided a recommendation to dose escalate to 
the next protocol -defined level in Part  A of the study. Eligible participants will receive UCB6114 
as an iv infusion Q2W in combination with iv mFOLFOX6 (Q2W) on a [ADDRESS_385974] of care dose: oxaliplatin 
85mg/m2 iv infusion on Day 1, leucovorin 400mg/m2 iv infusion on Day 1, 5 -fluorouracil 
400mg/m2 iv bolus on Day 1, followed by 5 -fluorouracil 1200mg/m2/day con tinuous infusion on 
Day 1 and Day 2 (2400mg/m2 over 46 hours). The starting dose of UCB6114 in Part  C will 
depend on the dose level evaluated in Cohort 3 of Part  A (anticipated to be 500mg Q2W iv), and 
the emerging safety profile of UCB6114 monotherapy, in cluding any overlappi[INVESTIGATOR_313497]6 regimen.  
Part C will be undertaken using the mTPI [INVESTIGATOR_12183]. A target DLT rate of 25% with an equivalence 
interval (20% to 30%) will be used to estimate MTD during dose escalation. For all dose levels, 
enroll ed participants will be treated in cohorts of 2 to 4 participants (target of 3), who can be 
treated in parallel. Each dose level may have more than one cohort and will have a minimum of 
3 evaluable participants.  
It is expected that up to 3 dose levels of U CB6114 will be explored in combination with the 
selected mFOLFOX6 dosing regimen. However, additional dose levels may be added based on 
emerging data and recommendations of the SMC. Dose escalation steps are currently planned at 
a maximum of 2 -fold. Escala ting dose levels in Part  C will not exceed a dose level tested and 
considered safe by [CONTACT_313579] (Part  A). 
The decision to dose escalate, have no change in dose, or dose de -escalate in the next cohort will 
occur once al l participants in the preceding cohort have been monitored for a minimum of 
28 days (ie, 1 cycle). All available safety data (both within the cohort and from preceding cohorts 
and other parts of the study) will be taken into consideration when dose escalat ion decisions are 
made. The dose justification is given below in Section  4.3.3 . 
The planned duration of treatment is 2 cycles. Participants may, howeve r, remain in the study for 
additional cycles if they are receiving a therapeutic benefit (SD, PR, or CR) or until they fulfill 
one of the criteria for study discontinuation (Section  4.3.3 ). Participants will continue treatment 
until disease progression, unmanageable toxicity, or withdrawal of consent. Upon 
discontinuation from treatment, participants will be referred to appropriate follow -up care per the 
investigator’s judgment.  
From Part  C, a RP2D -F for UCB6114 in combination with mFOLFOX6 will be determined 
based upon the totality of information, including the safety profile, PK data, PD biomarker data, 
and available antitumor activity.  
[IP_ADDRESS]  Study oversight  
The SMC will convene after the last  participant in a given cohort has completed the required 
28-day DLT Observation Period. The SMC will decide whether to halt dose escalation, further 
expand the dose level to gain additional safety data, or determine the next dose level to be tested.  
Safet y conference calls with investigators and key Sponsor personnel will be held regularly.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 61 of 195 [IP_ADDRESS]  Dose -limiting toxicity determination and maximum tolerated dose 
definition  
[IP_ADDRESS].1  Definition of DLT  
Dose -limiting toxicity is defined as one of the following toxicities (accor ding to the NCI CTCAE 
Version 5.0) occurring during the DLT assessment window (Days 1 to 28 of Cycle 1) that is at 
least possibly related to UCB6114:  
• Grade ≥4 neutropenia (ANC <500/μL) lasting ≥7 days  
− In the event of CTCAE Grade [ADDRESS_385975] be performed on the 
seventh day after the onset of the event to determine if a DLT has occurred  
• Grade ≥3 neutropenia complicated by [CONTACT_411] (≥38° C) or infection  
• Grade 3 thrombocytopenia with bleeding or requiring platelet transfusion or Grade 4 
thrombocytopenia  
• Any Grade ≥3 non -hematological event with the following exceptions:  
− Grade 3 nausea, vomiting, diarrhea, or fatigue that resolves to Grade ≤2 within 24 hours 
of implementing optimal supportive care  
− Grade 3 laboratory abnormality that is asymp tomatic and also deemed by [CONTACT_313580], in consultation with the medical monitor, can declare a DLT if a participant is 
experiencing toxicity and treatment cannot be continued without exposing the partici pant to 
excessive risk.  
[IP_ADDRESS].2  Determination of maximum -tolerated dose  
For every dose levels, participants will be treated in cohorts of 2 to 4 (target of 3), each dose 
level will have a minimum of 3 and a maximum of 9 participants.  
The target rate of DLTs is 25%  (equivalence interval 20% to 30%). The target rate will define 
the MTD of the combination regimen (UCB6114 given in combination with mFOLFOX6).  
The mTPI [INVESTIGATOR_128574] a statistical probability algorithm, calculated using data from all 
participants tr eated in prior and current cohorts at the same dose level, to determine whether 
future cohorts should be dose escalated, have no change in dose, or be dose de -escalated. The 
dose escalation will stop if any of the following criteria are met:  
• The maximum sa mple size has been reached (27 participants total)  
• At least [ADDRESS_385976] been accumulated on a dose that is predicted to be the MTD  
• All doses explored appear to be overly toxic and the MTD cannot be determined  
• The escalation would exceed a dose leve l tested and considered safe by [CONTACT_313581] (Part  A) 
The mTPI [INVESTIGATOR_134921] a Bayesian decision framework to inform dose -escalation and de -
escalation decisions. These rules are conceptually similar to those used by [CONTACT_941] 3+[ADDRESS_385977] table ( Table  4-3). 
Table  4-3: Part C dose escalation/de -escalation schema for mTPI [INVESTIGATOR_313495]  
[ADDRESS_385978] 
D=de -escalate to next lower dose; DLT=dose -limiting toxicity; DR=the current dose is unacceptably toxic; 
E=escalate to next higher dose; mTPI= modified toxicity probability interval; S=stay at current dose  
a Target toxicity=0.25  
Table  4-3 has the following interpretation (using 3 and 6 treated participants as examples):  
With 3 participants treated at current dose level:  
• 0 DLTs = escalate  
• 1 DLT = remain at the same dose  
• 2 DLTs = de -escalate  
• 3 DLTs = de -escalate and consider current dose as intolerable  
With 6 participants treated at current dose level:  
• 0 DLTs = escalate  
• 1 to 2 DLTs = remain at  the same dose  
• 3 DLTs = de -escalate  
• >3 DLTs = de -escalate and consider current dose as intolerable  
[IP_ADDRESS]  Defining the recommended Phase [ADDRESS_385979] 
completed a minimum of 28 days of treatment (ie, 1 cycle). The RP2D -F will not exceed the 
RP2D -M or the MTD (if an MTD is established). The definition of the RP2D -F will take into 
account the safety profile, PK, PD biomarkers, and any antitumor effect  data.  
4.1.6  Part D – Monotherapy 1 expansion  
Part D can be initiated as soon as the RP2D -M is determined in Part  A, or commencement may 
be delayed until evaluation of other schedules or routes of administration in Part  A1. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 63 of 195 4.1.7  Part E – Monotherapy 2 expansion  
Part E can be initiated as soon as the RP2D -M is determined in Part  A, or commencement may 
be delayed until evaluation of other schedules or routes of administration in Part  A1. 
4.1.8  Part F – Combination 1 expansion  
Part F can be initiated as soon as the RP2D -T is determined in Part  B. 
4.1.9  Part G – Combination [ADDRESS_385980] -Part A 
The tumor types to be explored in the modules following Part  A will be selected  based upon the 
following:  
• Data collected through Part  A 
• Evolving preclinical and translational data  
• Literature data on the role of gremlin -1 in specific tumors  
• Feasibility of enrollment  
The protocol may be amended to replace the tumor types based on emerg ing data.  
4.[ADDRESS_385981] dose escalation module of the study is an open -label, nonrandomized modified rolling -6 
design (an algorithm -based extension of the 3+[ADDRESS_385982] practice in Phase 1 
oncology studies) in participants with advanced solid tumors, where UCB6114 will be 
administered as monotherapy.  
Two additional dose escalation modules will explore combination regimens (Part B and Part C). 
These will use the mTPI [INVESTIGATOR_313498] (Ji and Wang, 2013). This design has a 
low risk of exposing participants to doses above the MTD and yields high probabilities for 
identifying the correct MTD.  
The planned monotherapy expansio n modules and combination expansion modules will allow 
the simultaneous evaluation of multiple tumor types and standard of care regimens, replacing 
separate Phase [ADDRESS_385983] followed after identification of the RP2D. Combining 
dose escalatio n and the expansion modules under one protocol will allow multiple hypotheses to 
be addressed (ie, different tumor types, doses) and potentially expedite development and 
approval of UCB6114.  
4.2.[ADDRESS_385984] ion 2.1.  
The tumor types for Part A were selected based on the reported prevalence of detectable 
expression and/or expression level of GREM1  mRNA and include bladder urothelial carcinoma, 
breast inva sive carcinoma, colorectal adenocarcinoma, esophageal carcinoma, head and neck 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 64 of 195 squamous cell carcinoma, lung adenocarcinoma, lung squamous cell carcinoma, pancreatic 
adenocarcinoma, prostate adenocarcinoma, and stomach adenocarcinoma.  
4.2.2  Rationale for Part A1  
GREM1  mRNA expression has been reported in more than half of tissue samples from colorectal 
and pancreatic cancer (Sneddon et al, 2006). Upregulated gremlin -1 expression has been linked 
to a more advanced tumor stage and poor clinical prognosis in gastric  cancer (Sun et al, 2020). In 
CRC, high levels of GREM1  expression were associated with a shorter disease -free survival 
when compared with low levels of GREM1  expression (Davis et al, 2015; Dutton et al, 2019).  
Part A1 will be conducted in participants wit h colorectal -, gastric -, gastroesophageal junction or, 
pancreatic cancer and will evaluate alternative dosing schedules and duration of infusion to allow 
for future combination regimens with UCB6114 and a range of other treatments. Part A1 will use 
modific ations to the 5th dose -level in Part A (2000mg Q2W) should this be determined to be  
(i.e. DLT incidence <33%, see Section  [IP_ADDRESS] ). 
4.2.3  Rationale for Part B and Part  C 
UCB nonclinical data showed that, in the ApcMin;Vil1 -Grem -1 model of CRC in late stage, 
disease established mice, the combination of 5 -fluorouracil and the murinized version of 
UCB6114, Ab7326 mIgG1, significantly prolonged mouse lifespan . This supports the evaluation 
of UCB6114 in selected gastrointestinal cancer types in combination with a fluoropyrimidine -
based chemotherapy.  
Trifluridine/tipi[INVESTIGATOR_313499], the patients’ comorbidities, and personal preferences. As no overlappi[INVESTIGATOR_313500], in Part  B the dose escalation of UCB6114 will start in combination with therapeutic 
doses of the TFD/TPI [CONTACT_11553], with the expectation that participants will be nefit from the 
standard of care chemotherapy.  
The mFOLFOX6 chemotherapy regimen, consisting of leucovorin, 5 -fluorouracil, and 
oxaliplatin, has been evaluated in CRC for more than 15 years and is commonly used in a variety 
of gastrointestinal cancers, incl uding CRC and gastric - and gastroesophageal junction 
adenocarcinoma. The mFOLFOX6 chemotherapy regimen is used in different lines of treatment 
which depends on the tumor type, the patients’ comorbidities, and personal preferences. As no 
overlappi[INVESTIGATOR_313501] y is expected, in Part  C the dose escalation of UCB6114 will start in 
combination with therapeutic doses of the mFOLFOX6 chemotherapy, with the expectation that 
participants will benefit from the standard of care chemotherapy.  
4.2.4  Dosing strategy  
The monotherapy dose escalation module (Part  A) will systematically evaluate the safety, 
tolerability, and PK of UCB6114 at increasing dose levels.  
The planned dose escalation steps are given in Table  6-5. In the event that exposure is 
substantially lower than anticipated, dose escalations will still not exceed a 5 -fold increase. 
Doses will be administered every 2 weeks by [CONTACT_313582].  
In Part A, the SMC will decide on the dose escalation steps (see Section  [IP_ADDRESS] ). Based upon the 
emerging data, the SMC may decide to add up to 2 additional dose levels and/o r schedules. 
Doses above 2000mg iv Q2W will be subject to a substantial amendment.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 65 of 195 The combination dose escalation modules (Part  B and Part  C) will start with the Part  A Cohort  3 
dose of UCB6114. Depending on the eventual determination of the RP2D -M from Part A, this 
starting dose could represent 25% to 100% of the RP2D -M. Doses of UCB6114 in the 
combination dose escalation modules will not exceed the MTD if an MTD is determined. 
Combination agents will be given at the approved doses and schedules.  
The RP2 D-M will be used in the monotherapy expansion modules (Part  D and Part  E) and the 
RP2D in combination therapy will be used for the combination expansion modules (Part  F and 
Part G). 
4.3 Justification for dose  
4.3.1  Starting dose in Part A  
The rationale to start at U CB6114 100mg administered iv Q2W in Part A is based on the 
following:  
• The maintenance of a predicted suppression of gremlin -1 associated with antitumor activity 
(prolonged survival; predicted 95% suppression across the dosing interval) observed in 
nonclini cal pharmacology models assuming a low level of  gremlin -1 ( ) in human 
and a slow gremlin -1 turnover  rate ) based on a PK/PD model scaled to human 
developed using single ascending dose data from cynomolgus monkeys.  
• The low risk of UCB611 4’s mechanism of action (antagonism of gremlin -1) and the  class of 
molecule (fully human IgG4P), in combination with the lack of relevant adverse findings 
from the nonclinical 13 -week GLP toxicity  studies.  
When Ab7326 mIgG1 (murinized version of UCB6114) w as dosed iv at 30mg/kg twice weekly 
(BIW) in the ApcMin/Vil1-Grem1 model, or 30mg/kg once weekly (QW) in the Vil1-Grem1 
model, a significantly increased survival over vehicle control was observed. Lower doses had 
reduced antitumor activity or had no effect, whereas higher doses did not appear to further 
increase survival. The human exposures at this dose level are anticipated to be lower than the 
exposures achieved at the efficacious doses identified in the nonclinical pharmacology models. 
These model s are known to highly over -express gremlin -[ADDRESS_385985] much higher 
levels of gremlin -1 protein present than in patients with advanced solid tumors; therefore, the 
human exposures required for antitumor activity are anticipated to be lower. The medi an average 
concentration at steady state (C av,ss) anticipated following 100mg iv Q2W is 20.4µg/mL, which 
corresponds to a concentration 10 -fold greater than the cellular IC 50 for the ID-1 reporter assay 
(an in vitro assay measuring the functional inhibitio n of BMP signaling by [CONTACT_313583] -1). The FIH 
starting dose is anticipated to have a >100 -fold safety margin based on the outcome of the 13 -
week GLP toxicity studies in cynomolgus monkeys and rats. Further details regarding dose 
modification are provided in Se ction  6.6. 
4.3.2  Doses in Part A1  
Part A1 will be initiated after Cohort 5 of Part A, with dosing schedules that aim to maintain a 
similar exposure at stea dy state (average UCB6114 concentration at steady -state; C av,ss; see 
Table  6-5) to the Part A Cohort [ADDRESS_385986] of care regimens in Part B 
and Part C  
[IP_ADDRESS]  UCB6114 dosing  
In both Part  B and Part  C, UCB6114 will  be administered by [CONTACT_313569] 1 and 15 of 
each cycle. The starting dose of UCB6114 will depend on the dose level evaluated in Cohort 3 of 
Part A (anticipated to be 500mg Q2W iv), the emerging safety profile of UCB6114 monotherapy 
which may overla p with expected toxicities associated with TFD/TPI (Part  B) or mFOLFOX6 
(Part  C). The rationale for the UCB6114 starting dose in combination with TFD/TPI (Part  B) or 
mFOLFOX6 (Part  C) is based on:  
• Nonclinical safety studies of UCB6114, which demonstrated n o toxicities (with the possible 
exception of reproductive findings in female rats) that would overlap with those commonly 
seen with cytotoxic chemotherapy.  
• A review of dosing targeted and cytotoxic drug combinations between 2010 and 2013 which 
showed that  for combinations involving an antibody as the targeted agent, 69 out of 121 
studies (57%; 37 out of 68 drug combinations) could give both agents at 100% of the 
recommended dose (Nikanjam et al, 2016).  
• A nonclinical study of Ab7326 mIgG1 in the ApcMin;Vil1 -Grem -[ADDRESS_385987] monotherapy dose that showed qualitative improvement in survival was 
15mg/kg  BIW subcutaneously (sc) (for 6 weeks followed by 15mg/kg QW sc thereafter) 
when dosing from an age of 21  days. A clinical dose of UCB 6114 of 1000mg Q2W iv is 
expected to provide similar exposure in humans as the 15mg/kg BIW dose achieved in mice. 
The combination UCB6114 start dose of 500mg Q2W iv is expected to provide an exposure 
approximately 50% of this.  
• A nonclinical study of Ab7326  mIgG1 in the ApcMin;Vil1 -Grem -1 mouse model, in which 
30mg/kg BIW sc (for 6 weeks followed by 30mg/kg QW thereafter) given in combination 
with 5 -fluorouracil increased survival relative to either monotherapy when dosing from an 
age of 35 days (which is cl ose to the point where untreated mice are sacrificed on humane 
grounds). The combination UCB6114 start dose of 500mg Q2W iv is expected to provide an 
exposure approximately 25% of this.  
Considering the above points, a start dose of UCB6114 of 500mg Q2W iv in combination with 
TFD/TPI (Part  B) or FOLOFX (Part  C) is expected to have an adequate safety profile and is 
expected to provide approximately 25% of the exposure that was associated with increased 
survival in combination with 5 -fluorouracil in the mouse model .  
As no significant difference in survival was observed between doses of 30 and 60mg/kg BIW sc 
of Ab7326 mIgG1 in the ApcMin;Vil1 -Grem -1 mouse model, doses of UCB6114 higher than 
2000mg Q2W iv in humans are not likely warranted as monotherapy or in c ombination. 
Therefore, evaluation of 3 UCB6114 dose -levels escalated in combination with TFD/TPI 
(Part  B) or mFOLFOX6 (Part  C), anticipated to be 500mg, 1000mg, and 2000mg administered 
Q2W iv, is proposed.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 67 of 195 [IP_ADDRESS]  Standard of Care regimen dosing  
There are no plann ed escalations of the standard of care regimen doses. Dose modifications 
based on toxicity are described in Section  6.6.  
[IP_ADDRESS].1  Part B  
In Part  B, TFD/TPI w ill be given orally bid on Days 1 to 5 and Days 8 to 12 of each 28 -day 
treatment cycle. The starting dose of TFD/TPI [INVESTIGATOR_313502] 35mg/m2/dose administered orally bid 
on Days  1 to 5 and Days 8 to 12 of each 28 -day cycle. The dosage is calculated according to 
body surface area (BSA) ( Table  4-4). The dosage must not exceed 80mg/dose (based on the 
trifluridine component).  
Table  4-4: TFD/TPI [INVESTIGATOR_313503] (m2) Dose (mg)  Tablets per dose  Total daily 
dose (mg)  15mg/6.14mg  20mg/8.19mg  
35 mg/m2 < 1.07  35 1 1 70 
1.07 to 1.22 40 0 2 80 
1.23 to 1.37  45 3 0 90 
1.38 to 1.52  50 2 1 100 
1.53 to 1.68  55 1 2 110 
1.69 to 1.83  60 0 3 120 
1.84 to 1.98  65 3 1 130 
1.99 to 2.14  70 2 2 140 
2.15 to 2.29  75 1 3 150 
≥2.30  80 0 4 160 
BSA=body surface area  
The tablets must be swallowed whole with a glass of water within 1 hour of completion of the 
morning and evening meals. Study participants will be instructed to swallow the required number 
of tablets at approximately the same times on each day. Study participants will be i nstructed to 
wash their hands before and after taking the drug. The TFD/TPI [INVESTIGATOR_313504], up to 
3 days prior to Day 1 ( Table  1-7). The sites can, however, choose to do all assessments on Day  1, 
prior to dosing of any study medication.  
Participants must not retake doses of TFD/TPI [INVESTIGATOR_313505]. If tablets are handled by [CONTACT_313584], this person must wear gloves.  
[IP_ADDRESS].[ADDRESS_385988] of oxaliplatin 85mg/m2 iv infusion 
on Day 1, leucovorin 400mg/m2 iv infusion on Day 1, 5 -fluorouracil 400mg/m2 iv bolus on Day 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 68 of 195 1, followed by 5 -fluorouracil 1200mg/m2/day continuous infusion on Day 1 and 2 (2400mg/m2 
over 46 hours).  
The recommended administration of mFOLFOX6 is shown in Table  4-5.  
Table  4-5: mFOLFOX6 dosing  
Drug  Dose  Administration  
Oxaliplatina 85mg/m2 iv in 250 to 500mL glucose 5% over 2 hours  
Leucovorina 400mg/m2 iv in 250mL glucose 5% over 2 hours  
5-Fluorouracil  400mg/m2 iv bolus  
5-Fluorouracil  2400mg/m2 iv over 46 hours via an infusor  
mFOLFOX6=leucovorin 400mg/m2 on Day 1, 5 -fluorouracil 400mg/m2 on Day 1 + 1200mg/m2/day on Day 1 
and Day 2, and oxaliplatin 85mg/m2 on Day 1; iv=intravenous(ly)  
a Oxaliplatin and leucovorin may be infused over the same two -hour period by [CONTACT_2329] a Y -site connector placed 
immediately before the infusion site.  
Within the study, mFOLFOX6 is administered every [ADDRESS_385989] participant in the study.  
5 STUDY POPULATION  
Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as 
protocol waivers or exemptions, is not permitted.  
The study population is defined separately for each study module and is presented in Table  5-1. 
Table  5-1: Study population  
Study module  Population  
Part A: Monotherapy dose 
escalation  Participants with recurrent or metastatic advanced solid tumors resistant or 
refractory to standard treatment from a variety of tumors types associated 
with gremlin -1 mRNA expression (ie, bladder urothelial carcinoma, breast 
invasive carcinoma, colorectal adenocarcinoma, esophageal carcinoma, 
head and neck squamous cell carcinoma, lung adenocarcinoma, lung 
squamous cell carcinoma, pancreatic adenocarcinoma, prostate 
adenocarcinoma and stomach adenocarcinoma)  
Part A1: Monotherapy  dose 
optimization  Participants with unresectable locally advanced or metastatic colorectal 
adenocarcinoma, gastric adenocarcinoma, adenocarcinoma of the 
gastroesophageal junction, or pancreatic cancer  
Part B: Combination dose 
escalation with TFD/TPI  [INVESTIGATOR_313506], gastric adenocarcinoma, or adenocarcinoma of the 
gastroesophageal junction  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 69 of 195 Study module  Population  
Part C: Combination dose 
escalation with 
mFOLFOX6  Participants with unresectable locally advanc ed or metastatic colorectal 
adenocarcinoma, gastric adenocarcinoma, or adenocarcinoma of the 
gastroesophageal junction  
Part D: Monotherapy 
expansion  Participants with recurrent or metastatic advanced solid tumor type 
selected  
Part E: Monotherapy 
expans ion  Participants with recurrent or metastatic advanced solid tumor type 
selected  
Part F: Combination 
therapy expansion  Participants with recurrent or metastatic advanced solid tumor type 
selected  
Part G: Combination 
therapy expansion  Participants with recurrent or metastatic advanced solid tumor type 
selected  
mFOLFOX6=leucovorin 400mg/m2 on Day 1, 5 -fluorouracil 400mg/m2 on Day 1 + 1200mg/m2/day on Day 1 and 
Day 2, and oxaliplatin 85mg/m2 on Day 1; mRNA=messenger ribonucleic acid; TFD/TPI=trifluridine/tipi[INVESTIGATOR_14965]  
5.1 Inclusion criteria  
5.1.1  Part A  
Participants are eligible to be included in Part A of the study only if all of the following criteria 
apply:  
Age 
1. Participant must be at least 18 years o f age inclusive, at the time of signing the informed 
consent.  
Type of participant and disease characteristics  
2a. Participant has a histologically and/or cytologically confirmed diagnosis of one of the 
following advanced solid tumor types: colorectal adeno carcinoma, esophageal carcinoma, 
head and neck squamous cell carcinoma, lung adenocarcinoma, lung squamous cell  
carcinoma, pancreatic  adeno carcinoma, prostate  adenocarcinoma, stomach  adenocarcinoma, 
bladder urothelial  carcinoma, or breast invasive  carcinom a. 
3b. Participant has advanced disease (ie, unresectable locally recurrent or metastatic) and had 
access to approved therapi[INVESTIGATOR_014].  
4. Participant has measurable or non -measurable disease as defined by [CONTACT_313585] 
(Appendix 9, Section  11.9). 
5. Participant has a performance status of ≤1 on the Eastern Cooperative Oncology Group 
(ECOG) scale (Appendix 8, Section  11.8). 
6. Participant has discontinued all previous therapi[INVESTIGATOR_72911] (with exception of treatments 
defined in Section  6.5.1 ), including chemotherapy, radiotherapy, cancer -related hormonal 
therapy, or other investigational therapy for a minimum of 28 days or 5 half -lives (whichever 
is shorter) (6 weeks for mitomycin -C or nitrosoureas) prior to study enrollment and 
recovered from the acute effects of therapy.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 70 of 195 7. Participant has an estimated life expectancy of ≥12 weeks.  
8. Participant has adequate bone marrow function, including the following:  
a. Absolute neutrophil count ≥1 .5x109/L. 
b. Platelet count ≥100x109/L. 
c. Hemoglobin ≥9.0g/dL (or 5.5mmol/L).  
Participants with hemoglobin ≥8g/dL but <9g/dL may receive erythrocyte transfusions to 
achieve a hemoglobin level ≥9.0 g/dL. Initial treatment must not begin until 2 days after 
the er ythrocyte transfusion and after the confirmation of hemoglobin ≥9.0g/dL.  
Contraception  
9. A male participant must agree to use contraception as detailed in Appendix 4 (Section  11.4) 
of this protocol during the treatment period and for at least [ADDRESS_385990] dose of 
study treatment and refrain from donating sperm during this period.  
10. A female participant is eligible to participate if she is not pregnant (see Appendix 4 
[Section  11.4]), not breastfeeding, and at least one of the following conditions appl ies: 
a. Not a woman of childbearing potential as defined Appendix 4 (Section  11.4). 
OR 
b. A woman of childbearing potential who agrees to follow the contraceptive guidance in 
Appendix 4 (Section  11.4) during the treatment period and for at least  [ADDRESS_385991] dose of study treatment.  
Informed consent  
11. Participant  is capable of giving signed informed consent  which includes compliance with the 
requirements and restrictions listed in the Informed Consent Form (ICF) and in this protocol . 
5.1.2  Part A1  
Participants are eligible to be included in Part A1  of the study only if all of the following criteria 
apply:  
Age 
1. Participant must be at least 18 years of age inclusive, at the time of signing the informed 
consent.  
Type of participant and disease characteristics  
2. Participant has histologically and/or cytologically confirmed diagnosis of one of the 
following advanced solid tumor types: colorectal adenocarcinoma, gastric adenocarcinoma, 
adenocarcinoma of the gastroesophageal junction, or pancreatic cancer.  
3. Participant has advanced disease (ie, unresectable locally recurrent or metastatic).  
4. Participant must have re ceived and is refractory or intolerant to standard therapy appropriate 
for the tumor type.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_385992] 
(Appendix 9, Section  11.9). 
6. Participant has a performance status of ≤1 on the Eastern Cooperative Oncology Group 
(ECOG) scale (Appendix 8, Section  11.8). 
7. Participant must have tumor lesion(s) or metastases amenable to biopsy, excluding bone 
metastases, as confirmed by a radiologist, if appropriate, and as deemed safe by [CONTACT_3786].  
8. Participant must consent to  the mandatory pretreatment and on -treatment tumor biopsies.  
9. Participant has discontinued all previous therapi[INVESTIGATOR_72911] (with exception of treatments 
defined in Section  6.5.2 ), including chemotherapy, radiotherapy, cancer -related hormonal 
therapy, or other investigational therapy for a minimum of 28 days or 5 half -lives (whichever 
is shorter) (6 weeks for mitomycin -C or nitrosoureas) prior to sta rt of study medication and 
recovered from the acute effects of therapy.  
10. Any clinically significant treatment -related toxicity from prior therapy must have resolved to 
Grade ≤1 prior to study entry, with the exception of alopecia.  
11. Participant has an  estimated life expectancy of ≥[ADDRESS_385993] agree to use contraception as detailed in Appendix 4 (Section  11.4) 
of this protocol during the treatment period and for at least [ADDRESS_385994] dose of 
study treatment and refrain from donating sperm during this period.  
13. A female participant is eligible to participate if she is not pregnant (see Appendix 4 
[Section  11.4]), not breastfeeding, and at least one of the following conditions applies:  
a. Not a woman of childbearing potential as defined in Appendix 4 (Section  11.4). 
OR 
b. A woman of childbearing potential who agrees to follow the contraceptive guidance in 
Appendix 4 (Section  11.4) during the treatment period and for at least [ADDRESS_385995] dose of study treatment.  
Informed consent  
14. Participant is capable of g iving signed informed consent which includes compliance with the 
requirements and restrictions listed in the Informed Consent Form (ICF) and in this protocol.  
5.1.3  Part B 
Participants are eligible to be included in Part B of the study only if all of the followi ng criteria 
apply:  
Age 
1. Participant must be at least 18 years of age inclusive, at the time of signing the ICF.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 72 of 195 Type of participant and disease characteristics  
2. Participant has a histologically and/or cytologically confirmed diagnosis of one of the 
following advanced solid tumor types: colorectal adenocarcinoma, gastric adenocarcinoma, 
or adenocarcinoma of the gastroesophageal junction.  
3a. Participant has advanced disease (ie, unresectable locally advanced or metastatic).  
4a. Participants must have re ceived, or be intolerant to, or deemed not suitable for, at least [ADDRESS_385996] of care anti -cancer treatments 
(where such treatments are available as standard of care):  
a. Participants with colorectal cancer:  fluoropyrimidine -, oxaliplatin -, and irinotecan -based 
chemotherapy, an anti -vascular endothelial growth factor biological therapy, and, if RAS 
wild-type, an anti -epi[INVESTIGATOR_3506] (EGFR) therapy, or if microsatellite 
instability high/defici ent mismatch repair (MSI -H/dMMR) immunotherapy (eg, 
nivolumab, pembrolizumab and ipi[INVESTIGATOR_125]).  
b. Participants with gastric or gastroesophageal junction adenocarcinoma: fluoropyrimidine, 
a platinum, either a taxane  or irinotecan, ramucirumab, and, if appropri ate, human 
EGFR  2/neu -targeted therapy.  
5. Participant has measurable or nonmeasurable disease as defined by [CONTACT_313585].  
6. Participant has a performance status of ≤1 on the ECOG scale.  
7. Participant has discontinued all previous therapi[INVESTIGATOR_72911] (with exception of treatments 
defined in Section  6.5.3  ), including chemotherapy, radiotherapy, cancer -related hormonal 
therapy, or other inves tigational therapy for a minimum of 28 days or 5 half -lives (whichever 
is shorter) (6 weeks for mitomycin -C or nitrosoureas) prior to start of study medication and 
recovered from the acute effects of therapy.  
Any clinically significant treatment -related to xicity from prior therapy must have resolved to 
Grade ≤1 prior to study entry, with the exception of alopecia.  
8. Participant has an estimated life expectancy of ≥[ADDRESS_385997] one of the following conditions applies:  
a. Not a woman of childbearing potential as defined in Appendix 4 (Section  11.4). 
OR 
b. A woman of childbearing potential who agrees to follow the contraceptive guidance in 
Appendix 4 (Section  11.4) during the  Treatment Period and for at least  6 months after the 
final dose of study treatment.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 73 of 195 Informed consent  
10. Participant  is capable of giving signed informed consent  which includes compliance with the 
requirements and restrictions listed in the ICF and in thi s protocol . 
5.1.4  Part C 
Participants are eligible to be included in Part C of the study only if all of the following criteria 
apply:  
Age 
1. Participant must be at least 18 years of age inclusive, at the time of signing the ICF.  
Type of participant and disease c haracteristics  
2. Participant has a histologically and/or cytologically confirmed diagnosis of one of the 
following advanced solid tumor types: colorectal adenocarcinoma, gastric adenocarcinoma, or 
adenocarcinoma of the gastroesophageal junction.  
3a. Parti cipant has advanced disease (ie, unresectable locally advanced or metastatic) not 
amenable to curative treatment.  
4. Participants must have received, or be intolerant to, or deemed not suitable for at least [ADDRESS_385998].  
6. Participant has a performance status of ≤1 on the ECOG scale.  
7. Participant has discontinued all previous therapi[INVESTIGATOR_72911] (with exception of treatments 
defined in Section  Section  6.5.4  ), including chemotherapy, radiotherapy, cancer -related 
hormonal therapy, or  other investigational therapy for a minimum of 28 days or 5 half -lives 
(whichever is shorter) (6 weeks for mitomycin -C or nitrosoureas) prior to start of study 
medication.  
Any clinically significant treatment -related toxicity from prior therapy must have resolved to 
Grade ≤1 prior to study entry, with the exception of alopecia.  
8. Participant has an estimated life expectancy of ≥[ADDRESS_385999] one of the following conditions applies:  
a. Not a woman of childbearing potential as defined in Appendix 4 (Section  11.4). 
OR 
b. A woman of c hildbearing potential who agrees to follow the contraceptive guidance in 
Appendix 4 (Section  11.4) during the Treatment Period and for at least  6 mon ths after the 
final dose of study treatment.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 74 of 195 Informed consent  
10. Participant  is capable of giving signed informed consent  which includes compliance with the 
requirements and restrictions listed in the ICF and in this protocol . 
Inclusion criteria for Parts  D, E, F, and G will be defined in a protocol amendment.  
5.2 Exclusion criteria  
5.2.1  Part A  
Participants are excluded from Part  A of the study if any of the following criteria apply:  
Medical  conditions  
1. Participant has any medical or psychiatric condition that, i n the opi[INVESTIGATOR_871], 
could jeopardize or would compromise the study participant’s ability to participate in this study.  
2. Deleted.  
3. Participant has a known hypersensitivity to any components of the study medication or 
comparable drugs (eg,  monoclonal antibodies, drugs targeting BMP signaling pathway).  
4. Active and clinically significant bacterial, fungal, or viral infection, known infections with 
hepatitis B, hepatitis C, known human immunodeficiency virus, or acquired 
immunodeficiency syn drome related illness.   
5. Deleted.  
6.  Participants with known tuberculosis (TB) infection, at high risk of acquiring TB infection, 
with latent TB infection, or current or history of nontuberculous mycobacteria infection.  
7a. Symptomatic central nervous s ystem (CNS) malignancy or metastases. Screening of 
asymptomatic participants without history of CNS metastases is not required. Participants 
with asymptomatic CNS lesions should have completed standard therapy for their CNS 
lesions prior to study enrollmen t. 
8. Current hematologic malignancies, for example acute or chronic leukemia.  
9. Chronic underlying infection (for example, unhealed draining abscess, fistula) that, in the 
view of the investigator, should preclude the participant from enrolling in the study.  
10. Prior organ or allogeneic stem -cell transplantation.  
11. Moderate or severe cardiovascular disease including:  
a. Presence of cardiac disease, including a myocardial infarction within 6 months prior to 
study entry, unstable angina pectoris, [LOCATION_001]  Heart Association Class  III/IV 
congestive heart failure, or uncontrolled hypertension.  
b. Documented major electrocardiogram (ECG) abnormalities at the investigator’s 
discretion (for example, symptomatic or sustained atrial or ventricular arrhythmias, 
second - or third -degree, atrioventricular block, bundle branch blocks, ventricular 
hypertrophy).  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 75 of 195 c. Major abnormalities documented by [CONTACT_51541] (for example, moderate or severe 
heart valve function defect and/or left ventricular ejection fraction <50%), eval uation 
based on the institutional lower limit of normal.  
d. Participant has experienced any of the following during the last 6 months: 
coronary/peripheral by[CONTACT_9292], cerebrovascular accident, transient ischemic attack, 
deep vein thrombosis, or symptomatic pulmonary embolism.  
12. Alanine transaminase (ALT) or aspartate aminotransferase (AST) are ≥2xULN (if liver 
metastases are present: ≥5xULN).  
13. Alkaline phosphatase  (ALP) is ≥3xULN (if liver metastases are present: ≥5xULN).  
14. Bilirubin ≥1.5xULN (isolate d bilirubin >1.5xULN is acceptable if bilirubin is fractionated 
and direct bilirubin <35%).  
15a. Current or chronic history of liver disease, or known hepatic or biliary abnormalities 
other than liver metastases (with the exception of Gilbert’s syndrome, a symptomatic 
gallstones, or biliary stent provided bilirubin levels do not exceed limits as per Exclusion 
Criterion #14).  
For study participants with a baseline result ≥2xULN for ALT, AST, or ≥3xULN ALP, or 
≥1.5xULN total bilirubin, the presence of liver me tastases must be recorded in the electronic 
Case Report Form (eCRF).  
16b. QTc >450msec (note: The QTc is the QT interval corrected for heart rate according to 
Fridericia’s formula [QTcF]; it is either machine -read or manually over -read).  
Prior/Concomitant therapy  
17. Participant is taking a prohibited medication or has taken a prohibited medication as defined 
in Section  6.5.5 . 
18. Treatment with biologic  agents (such as monoclonal antibodies including marketed drugs) 
within  28 days prior to dosing.  
Prior/Concurrent clinical study experience  
19a. Current enrollment or past participation within the last 28 days before signing of consent in 
this or any other  clinical study involving an IMP.  
Other exclusions  
20. Participant has impaired renal function as indicated by [CONTACT_89408] >1.5xULN.  
21. Participant has experienced any major surgery within [ADDRESS_386000] administration 
of the medic ation under investigation in the study.  
22a. International normalized ratio (INR), prothrombin time (PT), or activated partial 
thromboplastin time (aPTT) as follows:  
− In the absence of therapeutic intent to anticoagulate the participant:  
◦ INR >1.5xULN or PT >1.5xULN or aPTT >1.5xULN, or  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 76 of 195 ◦ In the presence of therapeutic intent to anticoagulate the participant: INR or PT or 
aPTT not within therapeutic limits (according to the medical standards at the 
institution) or participant has not been on a stable dose of an ticoagulant for at least 
2 weeks prior to dosing.  
5.2.2  Part A1  
Participants are excluded from Part A1  of the study if any of the following criteria apply:  
Medical conditions  
1. Participant has any medical or psychiatric condition that, in the opi[INVESTIGATOR_153172], 
could jeopardize or would compromise the study participant’s ability to participate in this 
study.  
2. Participant has a known hypersensitivity to any components of the study medication or 
comparable drugs (eg, monoclonal antibodies, drugs target ing BMP signaling pathway).  
3. Active and clinically significant bacterial, fungal, or viral infection, known infections with 
hepatitis B, hepatitis C, known human immunodeficiency virus, or acquired 
immunodeficiency syndrome related illness.  
4.  Participants with known tuberculosis (TB) infection, at high risk of acquiring TB infection, 
with latent TB infection, or current or history of nontuberculous mycobacteria infection.  
5. Symptomatic central nervous system (CNS) malignancy or metastases. Scr eening of 
asymptomatic participants without history of CNS metastases is not required. Participants 
with asymptomatic CNS lesions should have completed standard therapy for their CNS 
lesions prior to study enrollment.  
6. Current hematologic malignancies, for example acute or chronic leukemia.  
7. Participants with evidence or history of bleeding diathesis.  
8. Chronic underlying infection (for example, unhealed draining abscess, fistula) that, in the 
view of the Investigator, should preclude the participant from enrolling in the study.  
9. Prior organ or allogeneic stem -cell transplantation.  
10. Moderate or severe cardiovascular disease including:  
a. Presence of cardiac disease, including a myocardial infarction within 6 months prior to 
study entry, unstable angi na pectoris, [LOCATION_001] Heart Association Class III/IV 
congestive heart failure, or uncontrolled hypertension.  
b.  Documented major electrocardiogram (ECG) abnormalities at the Investigator’s 
discretion (for example, symptomatic or sustained atrial or ventricul ar arrhythmias, 
second - or third -degree, atrioventricular block, bundle branch blocks, ventricular 
hypertrophy).  
c. Major abnormalities documented by [CONTACT_51541] (for example, moderate or severe 
heart valve function defect and/or left ventricular ejectio n fraction <50%), evaluation 
based on the institutional lower limit of normal.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_386001] 6 months: 
coronary/peripheral by[CONTACT_9292], cerebrovascular accident, transient ischemic attack, 
deep vein throm bosis, or symptomatic pulmonary embolism.  
Organ Function  
11. Participant has inadequate bone marrow function, including the following:  
a. ANC<1.5x109/L. 
b. Platelet count<100x109/L. 
c. Hemoglobin<9.0g/dL (or 5.5mmol/L).  
12. Prothrombin time or aPTT outside normal range, or international normalized ratio (INR) 
≥1.5.  
13. Participant has impaired renal function as indicated by [CONTACT_89408] >1.5x upper limit of 
normal (ULN) or calculated creatinine clearance of <50mL/min on the bases of the Cockroft -
Gault glomerula r filtration rate estimation (Appendix 2 [Section  11.2 ] with formula).  
14. Alanine transaminase (ALT) or aspartate aminotransferase (AST) are ≥2xULN ( if liver 
metastases present ≥5xULN).  
15. Bilirubin ≥1.5xULN  
16. Current or chronic history of liver disease, or known hepatic or biliary abnormalities other 
than liver metastases (with the exception of Gilbert’s syndrome, asymptomatic gallstones, or 
biliar y stent provided bilirubin levels do not exceed limits as per Exclusion Criterion #12).  
17. QTc >450msec (note: The QTc is the QT interval corrected for heart rate according to 
Fridericia’s formula [QTcF]; it is either machine -read or manually over -read).  
Prior/Concomitant therapy  
18. Participant is taking a prohibited medication or has taken a prohibited medication as defined 
in Section  6.5.6 . 
19. Parti cipant is receiving therapeutic or prophylactic anticoagulation therapy.  
20. Treatment with biologic agents (such as monoclonal antibodies including marketed drugs) 
within 28 days prior to dosing.  
Prior/Concurrent clinical study experience  
21. Current enro llment in another clinical study, unless it is an observational (noninterventional) 
clinical study or the follow -up period of an interventional study.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 78 of 195 5.2.3  Part B 
Participants are excluded from Part  B of the study if any of the following criteria apply:  
Medical  conditions  
1. Participant has any medical or psychiatric condition that, in the opi[INVESTIGATOR_871], 
could jeopardize or would compromise the study participant’s ability to participate in this 
study.  
2a. Participant has a known hypersensitivity to  any study medications or components of the 
study medications or comparable drugs (eg, trifluridine or tipi[INVESTIGATOR_13071], 
monoclonal antibodies, drugs targeting BMP signaling pathway).  
3. Participant is unable to swallow tablets.  
4. Participant has h ereditary problems of galactose intolerance, total lactase deficiency, or 
glucose -galactose malabsorption.  
5. Participant has active and clinically significant bacterial, fungal, or viral infection, known 
infections with hepatitis B, hepatitis C, known hum an immunodeficiency virus, or acquired 
immunodeficiency syndrome related illness.  
6. Participant has known TB infection, is at high risk of acquiring TB infection, or has current 
or history of nontuberculous mycobacteria infection.  
7a. Participant has symp tomatic CNS malignancy or metastases. Screening of asymptomatic  
participants without history of CNS metastases is not required. Participants with 
asymptomatic CNS lesions should have completed standard therapy for their CNS lesions 
prior to study enrollme nt. 
8. Participant has current hematologic malignancies, eg, acute or chronic leukemia.  
9. Participant has chronic underlying infection (eg, unhealed draining abscess, fistula) that, in 
the view of the investigator, should preclude the participant from enrolling in the study.  
10. Participant has prior organ or allogeneic stem -cell transplantation.  
11. Participant has moderate or severe cardiovascular disease including:  
a. Presence of cardiac disease, including a myocardial infarction within 6 months prior t o 
study entry, unstable angina pectoris, [LOCATION_001] Heart Association Class  III/IV 
congestive heart failure, or uncontrolled hypertension.  
b. Documented major ECG abnormalities at the investigator’s discretion (for example, 
symptomatic or sustained atrial or ve ntricular arrhythmias, second - or third -degree 
atrioventricular block, bundle branch blocks, ventricular hypertrophy).  
c. Major abnormalities documented by [CONTACT_51541] (for example, moderate or severe 
heart valve function defect and/or left ventricular ejection fraction <50%), evaluation 
based on the institutional lower limit of normal.  
d. Participant has experienced any of the following during the last 6 months: 
coronary/peripheral by[CONTACT_9292], cerebrovascular accident, transient ischemic attack, 
deep vei n thrombosis, or symptomatic pulmonary embolism.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_386002] administration 
of the medication under investigation in the study.  
13. Participant has serum potassium, magnesium, or calci um levels outside the institutional 
normal limits.  
Participants with electrolyte levels outside of the normal range will be eligible if these values 
are corrected upon retesting following any necessary supplementation.  
Organ function  
14. Participant has in adequate bone marrow function, including the following:  
a. ANC <1.5x109/L 
b. Platelet count <100x109/L 
c. Hemoglobin <9.0g/dL (or 5.5mmol/L)  
Participants with hemoglobin ≥8.0g/dL but <9.0g/dL may receive erythrocyte transfusions to 
achieve a hemoglobin level ≥9.0g/ dL. Initial treatment must not begin until 2 days after the 
erythrocyte transfusion and after the confirmation of hemoglobin ≥9.0g/dL.  
15. Participant has impaired renal function as indicated by [CONTACT_89408] >1.5x upper limit of 
normal (ULN) or calcula ted creatinine clearance of <50mL/min on the bases of the Cockroft -
Gault glomerular filtration rate estimation (Appendix 2 [Section  11.2] with formula) . 
16. Alanine transaminase or AST are ≥2xULN (if liver metastases are present: ≥5xULN).  
For study participants with a baseline result ≥2xULN for ALT and/or AST, the presence of 
liver metastases must be recorded in the eCRF.  
17. Bilirubin ≥1.5xULN  
18. Curre nt or chronic history of liver disease or known hepatic or biliary abnormalities other 
than liver metastases (with the exception of Gilbert’s syndrome, asymptomatic gallstones, or 
biliary stent, provided bilirubin levels do not exceed limits as per Exclusi on Criterion #17).  
19. International normalized ratio, PT, or aPTT as follows:  
a. In the absence of therapeutic intent to anticoagulate the participant, INR or PT or aPTT 
>1.5xULN, or  
b. In the presence of therapeutic intent to anticoagulate the participant, INR  or PT or aPTT 
not within therapeutic limits (according to the medical standards at the institution) or 
participant has not been on a stable dose of anticoagulant for at least 2 weeks  
20b. QTc >450msec (note: The QTc is the QTcF; it is either machine -read or manually over -
read).  
Prior/Concomitant therapy  
21. Participant is taking a prohibited medication or has taken a prohibited medication as defined 
in Section  6.5.7   within 28 days of starting study treatment . 
22. Participant has received prior treatment with TFD/TPI.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 80 of 195 23. Administration of a live, attenuated vaccine (eg, live attenuated influenza vaccine [LAIV], 
measles, mumps, and rubella [MMR], varicella; FluMist®) within 28  days of starting study 
treatment and for up to 3 months after the final dose of IMP  or anticipation that such vaccine 
will be required during the study.  
Prior/Concurrent clinical st udy experience  
24. Current enrollment in another clinical study, unless it is an observational (noninterventional) 
clinical study or the follow -up period of an interventional study.  
5.2.4  Part C 
Participants are excluded from Part  C of the study if any of the fo llowing criteria apply:  
Medical  conditions  
1. Participant has any medical or psychiatric condition that, in the opi[INVESTIGATOR_871], 
could jeopardize or would compromise the study participant’s ability to participate in this 
study.  
2a. Participant has a known hypersensitivity to any study medications or components of the 
study medications or comparable drugs (eg, oxaliplatin, fluorouracil, calcium 
folinate/leucovorin, monoclonal antibodies, drugs targeting BMP signaling pathway).  
3. Participant has a history of hypersensitivity to oxaliplatin or other platinum -based drugs.  
4. Participant has a ctive and clinically significant bacterial, fungal, or viral infection, known 
infections with hepatitis B, hepatitis C, known human immunodeficiency virus, or a cquired 
immunodeficiency syndrome related illness.  
5. Participants has known TB infection, is at high risk of acquiring TB infection, or has current 
or history of nontuberculous mycobacteria infection.  
6a. Participant has s ymptomatic CNS malignancy or metastases. Screening of asymptomatic  
participants without history of CNS metastases is not required. Participants with 
asymptomatic CNS lesions should have completed standard therapy for their CNS lesions 
prior to study enrollment.  
7. Participant has c urrent hematologic malignancies, eg, acute or chronic leukemia.  
8. Participant has c hronic underlying infection (eg, unhealed draining abscess, fistula) that, in 
the view of the investigator, should preclude the participant from enrolling in the study.  
9. Participant has p rior organ or allogeneic stem -cell transplantation.  
10. Participant has m oderate or severe cardiovascular disease including:  
a. Presence of cardiac disease, including a myocardial infarction within 6 months prior to 
study entry, unstable angi na pectoris, [LOCATION_001] Heart Association Class  III/IV 
congestive heart failure, or uncontrolled hypertension.  
b. Documented major ECG abnormalities at the investigator’s discretion (for example, 
symptomatic or sustained atrial or ventricular arrhythmias, secon d- or third -degree 
atrioventricular block, bundle branch blocks, ventricular hypertrophy).  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 81 of 195 c. Major abnormalities documented by [CONTACT_51541] (for example, moderate or severe 
heart valve function defect and/or left ventricular ejection fraction <50%), eval uation 
based on the institutional lower limit of normal.  
d. Participant has experienced any of the following during the last 6 months: 
coronary/peripheral by[CONTACT_9292], cerebrovascular accident, transient ischemic attack, 
deep vein thrombosis, or symptomatic pulmonary embolism.  
11. Participant has experienced any major surgery within [ADDRESS_386003] administration 
of the medication under investigation in the study.  
12. Participant has serum potassium, magnesium, or calcium levels outside the institu tional 
normal limits.  
Participants with electrolyte levels outside of the normal range will be eligible if these values are 
corrected upon retesting following any necessary supplementation.  
Organ function  
13a. Participant has inadequate bone marrow functio n, including the following:  
a. ANC <2.0x109/L 
b. Platelet count <100x109/L 
c. Hemoglobin <9.0g/dL (or 5.5mmol/L)  
Participants with hemoglobin ≥8.0g/dL but <9.0g/dL may receive erythrocyte transfusions to 
achieve a hemoglobin level ≥9.0g/dL. Initial treatment must n ot begin until 2 days after the 
erythrocyte transfusion and after the confirmation of hemoglobin ≥9.0g/dL.  
14. Participant has impaired renal function as indicated by [CONTACT_89408] >1.5x upper limit of 
normal (ULN) or calculated creatinine clearance of <50mL/min on the bases of the Cockroft -
Gault glomerular filtration rate estimation (Appendix 2 [Section  11.2] with formula).  
15. Alanine transaminase o r AST are ≥2xULN (if liver metastases are present: ≥5xULN).  
For study participants with a Baseline result ≥2xULN for ALT and/or AST, the presence of 
liver metastases must be recorded in the eCRF.  
16. Bilirubin ≥1.5xULN.  
17. Current or chronic history of li ver disease or known hepatic or biliary abnormalities other 
than liver metastases (with the exception of Gilbert’s syndrome, asymptomatic gallstones, or 
biliary stent, provided bilirubin levels do not exceed limits as per exclusion criterion #16).  
18. International normalized ratio, PT, or aPTT as follows:  
a. In the absence of therapeutic intent to anticoagulate the participant, INR or PT or aPTT 
>1.5xULN, or  
b. In the presence of therapeutic intent to anticoagulate the participant, INR or PT or aPTT 
not within therapeutic limits (according to the medical standards at the institution) or 
participant has not been on a stable dose of anticoagulant for at least 2 weeks  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 82 of 195 19b. QTc >450msec (note: The QTc is the QTcF; it is either machine -read or manually over -
read). 
Prior/Concomitant therapy  
20. Known dihydropyrimidine dehydrogenase deficiency or thymidylate synthetase gene 
polymorphism predisposing the participant to 5 -fluorouracil toxicity.  
21. Participant is taking a prohibited medication or has taken a prohib ited medication as defined 
in Section  6.5.8   within 28 days of starting study treatment.  
22. Administration of a live, attenuated vaccine (eg, LAIV, M MR, varicella; FluMist®) within 
28 days of starting study treatment  and for up to 3 months after the final dose of IMP,  or 
anticipation that such vaccine will be required during the study.  
Prior/Concurrent clinical study experience  
23. Current enrollment in another clinical study, unless it is an observational (noninterventional) 
clinical study or the follow -up period of an interventional study.  
Other exclusions  
24. Participant has known or suspected pernicious anemia or other anemias due to vitamin B12 
deficiency.  
Exclusion criteria for Parts D, E, F, and G will be defined in a subsequent protocol amendment.  
5.3 Lifestyle restrictions  
No restrictions are required.  
5.4 Screen failures  
Prior to dosing, the study physician or medically qualified designee  will assess  participant 
eligibility and confirm suitability for study treatment. Screen failures are defined as participants 
who consent to participate in the clinical study but are not subsequently assigned to study 
treatment. A minimal set of screen failure informa tion is required to ensure transparent reporting 
of screen failure participants to meet the Consolidated Standards of Reporting Trials publishing 
requirements and to respond to queries from regulatory authorities. Minimal information 
includes demography, s creen failure details, eligibility criteria, and any serious adverse event 
(SAE).  
Due to the ongoing COVID -19 pandemic, or a potential re -emergence of COVID -19, some 
participants may be unable to complete Screening procedures (for instance, due to local 
pandemic restrictions or the need to self -isolate following close contact [CONTACT_80063]). These 
participants should be considered screen failures. These and other i ndividuals who do not fully 
meet the criteria for participation in this study (screen failure) may be rescreened at the 
discretion of the investigator and by [CONTACT_313586] a case -dependent nature 
(dependent on the reason for the initial screen failure).  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 83 of 195 6 STUDY TREATMENTS  
Study treatment is defined as an y investigational treatment(s), marketed product(s), placebo , or 
medical device (s) intended to be administered to a study participant according to the study 
protocol.  
6.1 Treatments administered  
6.1.1  Part A  
In Part  A, UCB6114 will be administered as described in the Schedule of Activities ( Table  1-4). 
A summary of the study treatment to be administered is provided in Table  6-1. 
Table  6-1: Treatments administered in Part  A 
IMP  UCB6114  
Type  Drug  
Dose formulation  UCB6114  
Unit dose strength(s)  100mg/mL  
Dosage level(s)  100mg, 250mg, 500mg, 1000mg, and 2000mg. Doses will be 
administered Q2W  
Route of administration  iv infusion  
Use Experimental  
Sourcing  IMP will be supplied by [CONTACT_313587].  
Packaging and labeling  Study intervention will be provided in 100mg/mL solution in glass  vials. 
Each vial will be labeled as required per  country requirement.  
IMP=investigational medicinal product; iv=intravenous(ly); Q2W=every 2 weeks  
6.1.2  Part A1  
A new dose formulation will be used in Part A1. UCB6114 will be administered as described in 
the Schedule of Activities ( Table  1-5 and Table  1-6) and as per defined cohort ( Table  6-6). A 
summary of the study treatment to be administere d is provided in Table  6-2. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 84 of 195 Table  6-2: Treatments administered in Pa rt A1 
IMP  UCB6114  
Type  Drug  
Dose formulation (new)  UCB6114  
Unit dose strength(s)  100mg/mL  
Dosage level(s)  2000mg, 3000mg, 4000mg. Doses will be administered Q2W, Q3W, or 
Q4W as per defined cohort  
Route of administration  iv infusion  
Use Experimental  
Sourcing  IMP will be supplied by [CONTACT_313587].  
Packaging and labeling  Study intervention will be provided in 100mg/mL solution in glass  vials. 
Each vial will be labeled as required per country requirement.  
IMP=investigational medicinal product; iv=intravenous(ly); Q1W=one weekly; Q2W=every 2 weeks, Q3W=every 
3 weeks, Q4W=every 4 weeks.  
6.1.3  Part B  
UCB6114 and TFD/TPI [INVESTIGATOR_313507] B (Table  1-7). A summary of the study treatments to be administered in Part  B is provided 
in Table  6-3.  
Table  6-3: Study treatments in Part  B 
Product Name  [CONTACT_18338]6114  Lonsurf®  
Intervention name  [CONTACT_18338]6114  Trifluridine/tipi[INVESTIGATOR_14965] (active ingredients: 
trifluridine and tipi[INVESTIGATOR_13071])  
Type  Drug  Drug  
Dose formulation  Solution for 
injection/infusion 
containing UCB6114 at 
100mg/mL (as in Part A); 
for excipi[INVESTIGATOR_313508] -coated tablets containing 
Trifluridine (15 or 20mg) and tipi[INVESTIGATOR_14965] 
(6.14mg or 8.19mg ); for excipi[INVESTIGATOR_313509](s)  100mg/mL  Lonsurf 15mg /6.14mg (white);  
Lonsurf 20mg/8.19mg (pale red)  
Dosage level(s)  Planned dose levels:  
500mg Q2W  
1000mg Q2W  
2000mg Q2W  35mg/m2/dose administered bid on 
Days [ADDRESS_386004] Name  [CONTACT_18338]6114  Lonsurf®  
Use Experimental  Experimental (combination product)  
IMP and NIMP  IMP IMP 
Sourcing  Will be supplied by [CONTACT_313588], subsidiary, or 
designee.  
Packaging and labeling  UCB6114 will be provided 
as a 100mg/mL solution in 
glass vials. Each vial will be 
labeled as required per 
country requirements.  Lonsurf will be provided in its original 
packaging. All IMP will be labeled as 
required per country requi rements.  
Excipi[INVESTIGATOR_313510], pregelatinized (maize)  
Stearic acid  
Film coating  
Lonsurf 15mg/6.14mg film -coated 
tablets  
Hypromellose  
Macrogol (8000)  
Titanium dioxide (E171)  
Magnesium stearate  
Lonsurf 20mg/8.19mg film -coated 
tablets  
Hypromellose  
Macrogol (8000)  
Titanium dioxide (E171)  
Iron oxide red (E172)  
Magnesium stearate  
Printing ink  
Shellac  
Iron oxide red (E172)  
Iron oxide yellow (E172)  
Titanium dioxide (E171)  
Indigo carmine aluminium lake (E132)  
Carnauba wax  
Talc 
Current/Former name [CONTACT_313633] -102 
bid=twice daily; HCl=hydrochloride; IMP=investigational medicinal product; iv=intravenous(ly); NIMP=non -
investigational medicinal product; Q2W=every 2 weeks  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 86 of 195 6.1.4  Part C  
UCB6114 and mFOLFOX6 chemotherapy will be administered as described in the Schedule of 
Activities for Part  C (Table  1-8). UCB6114 must always be administered prior to mFOLFOX6 
chemotherapy.  
A summary of the study treatment to be administered in Part  C is provided in Table  6-4.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
  
Confidential  Page 87 of 195 Table  6-4: Treatments administered in Part  C 
Product Name  [CONTACT_18338]6114  Oxaliplatin  Leucovorin  Fluorouracil  
Intervention 
name  [CONTACT_18338]6114  Part of mFOLFOX6 
chemotherapy regimen  Part of mFOLFOX6 
chemotherapy regimen  Part of mFOLFOX6 
chemotherapy regimen  
Type  Drug  Drug  Drug  Drug  
Dose 
formulation  Solution for 
injection/infusion 
containing UCB6114 at 
100mg/mL, (as in Part A) 
for excipi[INVESTIGATOR_313511] (5mg/mL), for 
excipi[INVESTIGATOR_313512] 
(10mg/mL), for excipi[INVESTIGATOR_841] s 
see below  Solution for injection 
containing fluorouracil 
(25 or 50mg/mL), for 
excipi[INVESTIGATOR_313513](s)  100mg/mL  5mg/mL  10mg/mL  25mg/mL;  
50mg/mL  
Dosage level(s)  Planned dose levels:  
500mg Q2W  
1000mg Q2W  
2000mg Q2W  85mg/m2 Q2W  400mg/m2 Q2W  400mg/m2 Q2W, followed 
by 1200mg/m2/day on 
Day 1 and 2 (2400mg/m2 
over 46 hours)  
Route of 
administration  iv infusion  iv infusion  iv infusion  iv bolus, then continuous 
infusion via infusor  
Use Experimental  Experimental (as part of 
mFOLFOX6 
chemother apy) Experimental (as part of 
mFOLFOX6 
chemotherapy)  Experimental (as part of 
mFOLFOX6 
chemotherapy)  
IMP  IMP  IMP IMP IMP 
Sourcing  Will be supplied by [CONTACT_313589], subsidiary, or 
designee.  Provided centrally by [CONTACT_313590], subsidiary, or 
designee.  Provided centrally by [CONTACT_313590], subsidiary, or 
designee.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
  
Confidential  Page 88 of 195 Table  6-4: Treatments administered in Part  C 
Product Name  [CONTACT_18338]6114  Oxaliplatin  Leucovorin  Fluorouracil  
Packaging and 
labeling  UCB6114 will be provided 
in 100mg/mL solution in 
glass vials. Each vial will 
be labeled as required per 
country requirement.  Oxaliplatin will be 
provided in its original 
packaging. All IMP will be 
labeled as required p er 
country requirements.  Leucovorin will be 
provided in its original 
packaging. All IMP will 
be labeled as required per 
country requirements.  Fluorouracil will be 
provided in its original 
packaging. All IMP will 
be labeled as required per 
country requireme nts. 
Excipi[INVESTIGATOR_313514]/Former 
name(s) or 
alias(es)  Not applicable  Eloxatin®  Calcium folinate  5-fluorouracil, 5 -FU 
FU=fluorouracil; IMP=investigational medicinal product; iv=intravenous(ly); mFOLFOX6=leucovorin 400mg/m2 on Day 1, 5 -fluorouracil 400mg/m2 
on Day 1 + 1200mg/m2/day on Day 1 and Day 2, and oxaliplatin 85mg/m2 on Day 1; Q2W=every 2 weeks  
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 89 of 195 6.2 Preparation, handling, storage, and accountability requirements  
6.2.1  UCB6114  
The 100mg/mL solution will be diluted to a concentration calculated to give the planned dose 
over a constant infusion duration. Details of the dilution factors and the infusion rates to achieve 
this are given in the investigational medicinal product (IMP) Handling Manual.  
Study drug product (ie, IMP) must be stored under refrigerated conditions (2°C to 8 °C/35.6°F to 
46.4°F). Further instructions regarding drug preparation and dosing will be contained in the 
IMP Handling Manual, which will be provided to each clinical site.  
The investigator (or designee) must confirm appropriate temperature conditions have  been 
maintained during transit for all study treatment received and any discrepancies are reported and 
resolved before use of the study treatment.  
Only participants enrolled in the study may receive study treatment and only authorized site staff 
may supply or administer study treatment. All study treatments must be stored in a secure, 
temperature controlled, and monitored (manual or automated) area in accordance with the 
labeled storage conditions with access limited to the investigator and authorized  site staff.  
The investigator, institution, or the head of the medical institution (where applicable) is 
responsible for study treatment accountability, reconciliation, and record maintenance 
(ie, receipt, reconciliation, and final disposition records).  
In case an out -of-range temperature is noted, it must be immediately reported as per instructions 
contained in the IMP Handling Manual.  
Further guidance and information for the final disposition of unused study treatment are provided 
in the IMP Handling Manu al. 
Preparation, handling, storage and accountability requirements are described in the IMP 
Handling Manual.  
6.2.2  TFD/TPI  
[INVESTIGATOR_313515] (SmPC) 
for details on formulations and storage.  
6.2.[ADDRESS_386005], damaged (due to breakage or wastage), not used, partially 
used, disposed of at the study site, or returned to the Sponsor or designee m ust also be recorded 
on the appropriate forms. All supplies and pharmacy documentation must be made available 
throughout the study for UCB (or designee) to review.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 90 of 195 The investigator (or designee) is responsible for retaining all used, unused, and partially used 
containers of study medication until returned or destroyed.  
The investigator may assign some of the investigator’s duties for drug accountability at the study 
site to an appropriate pharmacist/designee.  
The investigator must ensure that the study medi cation is used only in accordance with the 
protocol.  
Periodically, and/or after completion of the clinical phase of the study, all used (including empty 
containers)/partially used, unused, damaged, and/or expi[INVESTIGATOR_313516] (in which case the site should provide the 
appropriate certification or confirmation of destruction), regulations, and UCB Standard 
Operating Procedures, or returned to UCB (or designee). Investigational me dicinal product 
intended for the study cannot be used for any other purpose than that described in this protocol.  
6.3 Measures to minimize bias: Randomization and blinding  
This is an open -label study.  
6.[ADDRESS_386006] be recorded on the 
accountability log. Study participant compliance for TFD/TPI [INVESTIGATOR_313517] B will be evaluated through 
the use of a participant diary and the drug accountability log o n which the number of TFD/TPI 
[INVESTIGATOR_313518]. Drug 
accountability must be performed in the presence of the participant in order to obtain any 
explanations regarding discrepancies with the dosing  regimen.  
Drug accountability must be recorded on the accountability log.  
6.5 Concomitant medication(s)/treatment(s)  
Permitted and prohibited concomitant medications during Part A, Part A1, Part  B, and Part  C are 
defined below. Permitted concomitant medication s for subsequent modules Part  A1, Part  D, 
Part E, Part  F, and Part  G will be described in subsequent protocol amendments.  
6.5.1  Permitted concomitant treatments (medications and therapi[INVESTIGATOR_014]) 
during Part  A 
The following concomitant medications are permitted during Part A of the study:  
• Medications intended solely for supportive care (eg, treatments for nausea, vomiting, and 
diarrhea)  
• Therapeutic use of steroids equivalent to prednisone 10mg/day  
• Bisphosphonate therapy  
• Hormonal contraceptives/hormonal replacement therapy  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 91 of 195 • Continuation of gonadotropin -releasing hormone (GnRH) agonist therapy for participants 
with prostate cancer  
• Continuation of antiestrogen therapy (eg, aromatase inhibitor) for participants with breast 
cancer  
6.5.2  Permitted concomitant treatments (medicat ions and therapi[INVESTIGATOR_014]) 
during Part  A1 
The following concomitant medications are permitted during Part A1 of the study:  
• Medications intended solely for supportive care (eg, treatments for nausea, vomiting, and 
diarrhea)  
• Therapeutic use of steroids equivalent t o prednisone ≤10mg/day  
• Bisphosphonate therapy or therapy with RANK ligand inhibitor  
• Hormonal contraceptives/hormonal replacement therapy  
• Palliative radiotherapy to specific sites of disease is permitted if considered medically 
necessary by [CONTACT_093]. Palliative radiotherapy specifically refers to radiotherapy for 
symptom relief only.  
• Participants who experience infusion -associated symptoms may be treated symptomatically 
as per standard practice.  
6.5.3  Permitted concomitant treatments (medicatio ns and therapi[INVESTIGATOR_014]) 
during Part  B  
The following concomitant medications and/or treatments are permitted during Part  B of the 
study:  
• Medications intended solely for supportive care (eg, treatments for nausea, vomiting, and 
diarrhea).  
• Bisphosphonate therapy o r therapy with RANK ligand inhibitor.  
• Hormonal contraceptives/hormonal replacement therapy.  
• Therapeutic use of steroids equivalent to prednisone ≤10mg/day.  
• Palliative radiotherapy to specific sites of disease is permitted if considered medically 
necessary by [CONTACT_093]. Palliative radiotherapy specifically refers to radiotherapy 
symptom relief only.  
• Participants who experience infusion -associated symptoms may be treated symptomatically 
as per standard practice.  
• Granulocyte colony -stimulating factor (G -CSF) or pegylated G -CSF for the management of 
neutropenia related toxicities. (Note: prophylactic pegylated G -CSF in Cycle 1 is not 
permitted.)  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 92 of 195 6.5.4  Permitted concomitant treatments (medications and therapi[INVESTIGATOR_014]) 
during Part  C 
The following concomitant medication s and/or treatments are permitted during Part  C of the 
study:  
• Medications intended solely for supportive care (eg, treatments for nausea, vomiting, and 
diarrhea).  
• Bisphosphonate therapy or therapy with RANK ligand inhibitor.  
• Hormonal contraceptives/hormona l replacement therapy.  
• Therapeutic use of steroids equivalent to prednisone ≤10mg/day.  
• Palliative radiotherapy to specific sites of disease is permitted if considered medically 
necessary by [CONTACT_093]. Palliative radiotherapy specifically refers to radiotherapy 
symptom relief only.  
• Participants who experience infusion -associated symptoms may be treated symptomatically 
as per standard practice.  
• Granulocyte colony -stimulating factor (G -CSF) or pegylated G -CSF for the management of 
neutropenia related t oxicities. (Note: prophylactic pegylated G -CSF in Cycle 1 is not 
permitted.)  
6.5.5  Prohibited concomitant treatments (medications and therapi[INVESTIGATOR_014]) 
during Part  A 
The following concomitant medications are prohibited during Part  A of the study:  
• Any concurrent antican cer treatment within 28 days or 5 half -lives (whichever is shorter) 
prior to first dose of study medication (eg, cytoreductive therapy, radiotherapy [with the 
exception of palliative bone -directed radiotherapy], immunotherapy, biological therapy, or 
cytoki ne therapy [with the exception of erythropoietin])  
• Any investigational drug within 28 days prior to start of study medication  
• Herbal remedies or vitamins used as anticancer treatments  
• Any herbal remedies with immunostimulating properties (eg, mistletoe ext ract) or known to 
potentially interfere with major organ function (eg,  hypericin)  
Concomitant treatment considered necessary for the participant’s well -being may be given at the 
discretion of the investigator but should be discussed with the study physicia n or medically 
qualified designee  whenever possible. If there is a clinical indication for one of these 
medications specifically prohibited during the study, discontinuation from the study medication 
may be required.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 93 of 195 6.5.6  Prohibited concomitant treatments (medi cations and therapi[INVESTIGATOR_014]) 
during Part  A1 
The following concomitant medications are prohibited during Part A1 of the study:  
• Any concurrent anticancer treatment within 28 days or 5 half -lives (whichever is shorter) 
prior to first dose of study medication (eg, c ytoreductive therapy, radiotherapy [with the 
exception of palliative bone -directed radiotherapy], immunotherapy, biological therapy, or 
cytokine therapy [with the exception of erythropoietin])  
• Any investigational drug within 28 days prior to start of study  medication  
• Herbal remedies or vitamins used as anticancer treatments  
• Any herbal remedies with immunostimulating properties (eg, mistletoe extract) or known to 
potentially interfere with major organ function (eg, hypericin)  
• Any anticoagulation therapy unti l after biopsies are obtained  
Concomitant treatment considered necessary for the participant’s well -being may be given at the 
discretion of the Investigator but should be discussed with the study physician or medically 
qualified designee whenever possible.  If there is a clinical indication for one of these 
medications specifically prohibited during the study, discontinuation from the study medication 
may be required.  
6.5.7  Prohibited concomitant treatments (medications and therapi[INVESTIGATOR_014]) 
during Part  B 
The following c oncomitant medications are prohibited during Part  B of the study:  
• Any concurrent anticancer treatment within 28 days or 5 half -lives (whichever is shorter) 
prior to first dose of study medication (eg, cytoreductive therapy, radiotherapy 
immunotherapy, biol ogic therapy, or cytokine therapy [with the exception of erythropoietin])  
• Treatment with mitomycin C or nitrosoureas within 6 weeks of starting study medication  
• Any investigational drug within 28 days prior to start of study medication  
• Herbal remedies or v itamins used as anticancer treatments  
• Any herbal remedies with immunostimulating properties (eg, mistletoe extract) or known to 
potentially interfere with major organ function (eg, hypericin)  
Concomitant treatment considered necessary for the participant’s  well-being may be given at the 
discretion of the investigator but should be discussed with the study physician or medically 
qualified designee whenever possible. If there is a clinical indication for one of these 
medications specifically prohibited during  the study, discontinuation from the study medication 
may be required.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 94 of 195 6.5.8  Prohibited concomitant treatments (medications and therapi[INVESTIGATOR_014]) 
during Part  C 
The following concomitant medications are prohibited during Part C of the study:  
• Any concurrent anticancer treatment within 28 days or 5 half -lives (whichever is shorter) 
prior to first dose of study medication (eg, cytoreductive therapy, radiotherapy 
immunotherapy, biologic therapy, or cytokine therapy [with the exception of erythropoietin])  
• Treatment with mit omycin C or nitrosoureas within 6 weeks of starting study medication  
• Any investigational drug within 28 days prior to start of study medication  
• Herbal remedies or vitamins used as anticancer treatments  
• Any herbal remedies with immunostimulating properties (eg, mistletoe extract) or known to 
potentially interfere with major organ function (eg, hypericin)  
The following should be avoided during Part C of the study:  
• Concurrent administration of 5 -fluorouracil and CYP2C9 substrates. Five -fluorouracil is a 
CYP2C9  inhibitor and possible drug interaction with 5 -fluorouracil and CYP2C9 substrates 
has been reported.  
− Possible drug interaction with oxaliplatin, 5 -fluorouracil, and warfarin has been reported. 
For participants maintained on warfarin, weekly INR is recomm ended until a stable 
warfarin dose is established, and then every 2 weeks.  
− Possible drug interaction with 5 -fluorouracil and phenytoin or fosphenytoin has been 
reported and may occur at any time. Close monitoring is recommended; 5 -fluorouracil 
may increase  the serum concentration of these 2 agents.  
• Concomitant administration of medicinal product with a known potential to prolong the QT 
interval as QT interval prolongation and ventricular arrhythmias can occur with oxaliplatin.  
• Co-administration of medicinal  products known to be nephrotoxic.  
Concomitant treatment considered necessary for the participant’s well -being may be given at the 
discretion of the investigator but should be discussed with the study physician or medically 
qualified designee whenever poss ible. If there is a clinical indication for one of these 
medications specifically prohibited during the study, discontinuation from the study medication 
may be required.  
6.5.[ADDRESS_386007] be recorded.  
6.6 Dose modificat ion 
6.6.1  Part A and Part A1  
The justification for the UCB6114 start dose for Part  A is presented in Section  4.3.1 . 
In Part  A, the decision to proceed to the  next dose level (either an escalation or a de -escalation) 
will be made by [CONTACT_313591], and available preliminary PK and/or PD data obtained 
in at least 3 participants at the prior dose level (Section  [IP_ADDRESS]  ). Further data obtained from any 
previous dose level may also contribute to this decision.  
The planned escalation scheme is given in Section  [IP_ADDRESS] . 
[IP_ADDRESS]  Dose escalation scheme  
A summary of the planned UCB6114 dose levels for dose escalation in Part  A is provided in 
Table  6-5. A dose range up to 2000mg Q2W iv was selected based on the following:  
1. Exposure and predicted gremlin -1 suppression levels associated with antitumor activity at 
different dose levels in noncli nical pharmacology models  
2. Pharmacokinetics of UCB6114 in cynomolgus monkeys scaled to humans  
3. Findings of 13 -week GLP toxicity studies in cynomolgus monkeys and rats  
Table  6-5: Dose escalation steps and justification (Part A)  
Cohorta Dose (mg) 
[approximate 
mg/kgb] Predicted C av,ss 
[90% prediction 
interval] (μg/mL)c Justification  
1 100 [1.4]  20.4 [13.4 -31.0]  The starting dose of 100mg Q2W iv was 
selected as described in Section  4.3.1 . 
The anticipated safety margin is >100 -fold. 
2 250 [3.6]  51.3 [33.5 -77.5]  Corresponds to a 2.[ADDRESS_386008] 
dose level and will give similar inhibition 
should the turnover half -life of gremlin -1 in 
humans be .  
3 500 [7.1]  102 [67.0 -155.0]  Corresponds to a 2 -fold increase over the 
previous dose level.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 96 of 195 Table  6-5: Dose escalation steps and justification (Part A)  
Cohorta Dose (mg) 
[approximate 
mg/kgb] Predicted C av,ss 
[90% prediction 
interval] (μg/mL)c Justification  
4 1000 [14.3]  204 [134.0 -310.0]  The lowest dose to show qua litative 
improvement in survival in the 
ApcMin;Vil1 -Grem -1 model was 15mg/kg BIW. 
A dose of 1000mg Q2W is expected to provide 
similar exposure in humans.  
Also, assuming a gremlin -1 level of 100ng/mL 
and a turnover half -life of 2h in humans, 
1000mg  Q2W iv is predicted to inhibit 
approximately 95% of circulating gremlin -1. 
The anticipated safety margin is >10 -fold at this 
dose level.  
5 2000 [28.6]  408 [268.0 -620.0]  A dose of 30mg/kg BIW in ApcMin;Vil1 -Grem -1 
model showed improved survival compared 
with the control. A dose of 2000mg iv Q2W is 
expected to provide similar exposure in humans. 
No difference was observed between 30  and 
60mg/kg BIW in the ApcMin;Vil1 -Grem -1 
model,  and therefore, higher doses are likely not 
warranted.  
BIW=twice weekly; C av,ss=avera ge concentration at steady state; h=hour; iv=intravenous(ly); 
PK=pharmacokinetic(s); Q2W=every  2 weeks  
a Dose levels administered may be adapted according to emerging data, eg, dose escalation or de -escalation to an 
intermediate dose level. Not all dose le vels listed may be evaluated in this study.  
b Approximate mg/kg doses based on a 70kg person.  
c Predicted C av,ss was calculated from estimated cynomolgus monkey PK parameters following a single 
administration (UCB Research Study NCD3086) scaled to humans a nd predicted at steady state. The estimated 
between -subject variability of clearance (coefficient of variation of 26.3%) was assumed to apply to human study 
participants.  
The proposed dose escalation and dose schedule may be adapted based on the following:  
• Cohort -by-cohort safety assessment and available PK data  
• Any available PD biomarker data  
• Data collected in ongoing nonclinical studies  
Characterization of the dose -concentration -effect relationship (ranging from potential minimum 
effective doses to maximu m effective doses) is important to determine the therapeutic window 
for UCB6114 for later clinical development.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 97 of 195 After the  fifth cohort in Part A has been determined, an additional module (Part  A1) has been 
included to evaluate alternative dosing schedules  (see Table  6-6). The rationale for Part  A1 
includes the following:  
• Evaluation of a less frequent (Q3W or Q4W) dosing schedule is considered desirable to 
enable UCB6114 to be combined with a range of other tr eatments or to reduce patient 
burden.  
• Administration with a shorter infusion time may be desirable to reduce patient’s burden.  
The dosing schedules planned in Part A1 are given in Table  6-6. 
Table  6-6: Planned dose optimization scheme for Part  A1 
Cohort  Dosing and infusion time  Purpose  
Cohort  1a 2000mg Q2W  
60-minute iv infusion (33.33mg/min)  
28-day treatment cycles  To assess safety, PK and PD of 2000mg dose 
of new dose formulation.  
Cohort  2 2000mg Q2W  
30-minute iv infusion (66.67mg/min)  
28-day treatment cycles  To establish a shorter infusion time (30 
minutes) to reduce the burden/allow for easier 
combination with other anti -tumor agents.  
Cohort  3 3000mg Q3W  
90-minute iv infusion (33mg/min)  
21-day treatment cycles  To assess safety, PK and PD of less frequent 
dosing to allow combination with an ti-tumor 
agents given in a 3 -weekly cycle.  
Cohort  4 4000mg Q4W  
120-minutes iv infusion (33mg/min)  
28-day treatment cycles  To assess less frequent dosing to allow 
combination with SOC treatments given in a 
4-weekly cycle.  
a Reference, ie, same dosing sche dule as in Part A Cohort 5 but with new dose formulation. All subsequent cohorts 
will receive the new dose formulation.  
iv=intravenous(ly); min=minute(s); PD=pharmacodynamics; PK=pharmacodynamics; Q2W=every 2 weeks; 
Q3W=every 3 weeks; Q4W=every 4 weeks, SOC=standard of care  
[IP_ADDRESS]  Within participant dose modification in Part A  
For participants who experience dose -limiting toxicity, dose adjustments are permitted if it is 
considered in the best interest of the participant to continue therapy at the discretion of the 
investigator, in consultation with the Sponsor.  
Participants who fail to receive the second planned dose of UCB6114 within 7 days of the 
scheduled administration day, during the DLT Observation Period , for reasons not related to 
toxicity will be replac ed by a new participant in that cohort. The replaced participant may still 
continue participation in the study. Safety data for replaced participants will be included in all 
summary data and any DLTs experienced by [CONTACT_313592] (Part A) or suitability of the dosing schedule (Part A1).  
[IP_ADDRESS]  Within participant dose modification in Part A1  
Dose adjustments and/or changes in dosing schedule are not permitted.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 98 of 195 6.6.2  Part B 
The justification for the UCB6114 start dose for Part B is presented in Section  4.3.3. 2.1. 
In Part  B, the decision to proceed to the next dose level (either an escalation or a de -escalation) 
will be made by [CONTACT_313593]  [IP_ADDRESS] . Further data obtained from any 
previous dose level may also contribute to this decision.  
The planned dose escalation scheme is given in Section  [IP_ADDRESS] . 
[IP_ADDRESS]  Dose escalation scheme  
A summary of the planned UCB6114 dose levels for dose escalation in Part  B is provided in 
Table  6-7.  
Table  6-7: Dose escalation steps and justification (Part B)  
Dose 
Level  Dose 
(mg)  Justification  
1 500 The starting dose selected for Part B is the Part A Cohort 3 dose (anticipated to 
be 500mg Q2W iv); see Section  [IP_ADDRESS]  for details.  
[ADDRESS_386009] dose to show a qualitative improvement in survival in the 
ApcMin;Vil1 -Grem -1 model was 15mg/kg of Ab7326 mIgG1 administered BIW 
sc as monotherapy from an age of 21 days. A dose of 1000mg Q2W iv is 
expected to provide similar exposure in humans.  
A dose of 1000mg is expec ted to provide an exposure approximately 50% of 
that given in combination with 5 -fluorouracil where survival relative to either 
monotherapy was increased in the ApcMin;Vil1 -Grem -1 model when dosing 
from an age of 35 days (30mg/kg BIW sc [for 6 weeks follow ed by 30mg/kg 
QW thereafter]).  
3 2000  A dose of 2000mg is expected to provide the same exposure in humans as that 
given in combination with 5 -fluorouracil where survival relative to either 
monotherapy was increased in the ApcMin;Vil1 -Grem -1 model when dosing 
from an age of 35 days.  
In a separate study where  Ab7326 mIgG1 was administered as monotherapy 
from an age of 21 days, no difference was observed between 30  and 60mg/kg 
BIW sc in the ApcMin;Vil1 -Grem -1 model,  and therefore, higher doses  of 
UCB6114 are likely not warranted.  
BIW=twice weekly; h=hour; iv=intravenous(ly); PK=pharmacokinetic(s); Q2W=every  2 weeks; 
sc=subcutaneous(ly)  
[IP_ADDRESS]  UCB6114 dose modifications  
Study  participants who experience Grade 4 (life -threatening) nonhematologic toxicity, including 
diarrhea and mucositis, which  is at least possibly related  to UCB6114, will be discontinued from 
treatment . 
Treatment with UCB6114 may temporarily be suspended for up to 3 weeks beyond the 
scheduled treatment day until toxicities are re solved to CTCAE Grade 2 or less. If UCB6114 is 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 99 of 195 held for more than 3 weeks beyond the scheduled treatment day, then the participant will be 
discontinued from treatment and will be followed up for safety and efficacy per the Schedules of 
Activities for Part  A (Table  1-4), Part  B (Table  1-7), and Part  C (Table  1-8).  
For permitted adjustments of the infusion rate in case of AEs refer to the IMP Handling Manual. 
Participants who experience severe or life-threatening infusion -related events (CTCAE Grade 3 
or 4) will not receive further infusions. Hypersensitivity/infusion -related events should be 
managed per institutional guidelines. Premedication with steroids may be administered at the 
discretion of the investigator.  
[IP_ADDRESS]  TFD/TPI [INVESTIGATOR_313519]/TPI -related AEs are allowed as described below. A maximum of 
3 dose reductions are permitted to a minimum of 20mg/m2/dose.  
Participants who permanently discontinue TFD/TPI [INVESTIGATOR_313520] e to TFD/TPI -related toxicity 
will have the option to continue treatment with UCB6114 alone if, in the view of the 
investigator, the participant is deriving benefit.  
In the case of hematological toxicities, TFD/TPI [INVESTIGATOR_313521]  6-8. In the case of hematological and nonhematological 
toxicities, the dose may be modified according to the cri teria stated in Table  6-9. Reductions will 
be made in accordance with BSA ( Table  6-10). 
Table  6-8: TFD/TPI [INVESTIGATOR_313522]  <0.5x109/L ≥1.5x109/L 
Platelets  <50x109/L ≥75x109/L 
TFD/TPI=trifluridine/tipriacil  
a Resumption criteria applied to the start of the next cycle for all participants regardless of whether the interruption 
criteria were met.  
 
Table  6-9: TFD/TPI [INVESTIGATOR_313461] -
hematological toxicities  
Adverse reaction  Recommended dose modifications  
Febrile neutropenia.  
CTCAE Grade 4 neutropenia (<0.5x109/L) or 
thrombocytopenia (<25x109/L) that results in more 
than 1 week’s delay in start of next cycle.  
CTCAE Grade 3 or Grade 4 nonhematologic AEs; 
except for Grade 3 nausea and/or vomiting 
controlled by [CONTACT_313594].  Interrupt dosing until toxicity resolves to Grade 1 
or baseline.  
When resuming dosing, decrease the dose level 
by 5mg/m2/dose from the previous dose level 
(Table  6-10). 
Dose reductions are permitted to a minimum 
dose of 20mg/m2/dose bid.  
Do not increase dose after it has been reduced.  
AE=adverse event; bid=twice daily; CTCAE=  Common Terminology Criteri a for Adverse Events; 
TFD/TPI=trifluridine/tipriacil  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 100 of 195  
Table  6-10: TFD/TPI [INVESTIGATOR_313523] (m2) Dose (mg)  Tablets per dose  Total daily 
dose (mg)  15mg/6.14mg  20mg/8.19mg  
Level 1 dose reduction: from 35mg/m2 to 30mg/m2 
30mg/m2 <1.09  30 2 0 60 
1.09 to 1.24  35 1 1 70 
1.25 to 1.39  40 0 2 80 
1.40 to 1.54  45 3 0 90 
1.55 to 1.69  50 2 1 100 
1.70 to 1.94  55 1 2 110 
1.95 to 2.09  60 0 3 120 
2.10 to 2.28  65 3 1 130 
≥2.29  70 2 2 140 
Level 2 dose reduction: from 30mg/m2 to 25mg/m2 
25mg/m2 <1.10  25a 2a 1a 50a  
1.10 to 1.29  30 2 0 60 
1.30 to 1.49  35 1 1 70 
1.50 to 1.69  40 0 2 80 
1.70 to 1.89  45 3 0 90 
1.90 to 2.09  50 2 1 100 
2.10 to 2.29  55 1 2 110 
≥2.30  60 0 3 120 
Level 3 dose reduction: from 25mg/m2 to 20mg/m2 
20mg/m2 <1.14  20 0 1 40 
1.14 to 1.34  25a 2a 1a 50a 
1.35 to 1.59  30 2 0 60 
1.60 to 1.94  35 1 1 70 
1.95 to 2.09  40 0 2 80 
2.10 to 2.34  45 3 0 90 
≥2.35  50 2 1 100 
BSA=body surface area; TFD/TPI=trifluridine/tipriacil  
a At a total daily dose of 50mg, study participants should take 1x20mg/8.19mg tablet in the morning and 
2x15mg/6.14mg tablets in the evening.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 101 of 195 6.6.3  Part C 
The justification for the UCB6114 start dose for Part  C is presented in Section  [IP_ADDRESS].2 . 
In Part  C, the decision to proceed to the next dose level (either an escalation o r a de -escalation) 
will be made by [CONTACT_313593]  [IP_ADDRESS] ). Further data obtained from any 
previous dose level may also contribute to this decision.  
The planned escalation scheme is given in Section  [IP_ADDRESS] . 
[IP_ADDRESS]  Dose escalation scheme  
A summary of the planned UCB6114 dose levels for dose escalation in Part  C is provided in 
Table  6-11.  
Table  6-11: Dose escalation steps and justification (Part C)  
Dose 
Level  Dose 
(mg)  Justification  
1 500 The starting dose selected for Part C is the Part A Cohort 3 dose (anticipated to 
be 500mg Q2W iv); see Section  [IP_ADDRESS]  for details.  
[ADDRESS_386010] dose to show a qualitative improvement in survival in the 
ApcMin;Vil1 -Grem -1 model was 15mg/kg of Ab7326 mIgG1 administered BIW 
sc as monotherapy from an age o f 21 days. A dose of 1000mg Q2W iv is 
expected to provide similar exposure in humans.  
A dose of 1000mg is expected to provide an exposure approximately 50% of 
that given in combination with 5 -fluorouracil where survival relative to either 
monotherapy was increased in the ApcMin;Vil1 -Grem -1 model when dosing 
from an age of 35 days (30mg/kg BIW sc [for 6 weeks followed by 30mg/kg 
QW thereafter]).  
3 2000  A dose of 2000mg is expected to provide the same exposure in humans as that 
given in combination with 5 -fluorouracil where survival relative to either 
monotherapy was increased in the ApcMin;Vil1 -Grem -1 model when dosing 
from an age of 35 days.  
In a separate study where  Ab7326 mIgG1 was administered as monotherapy 
from an age of 21 days, no difference was observed between 30  and 60mg/kg 
BIW sc in the ApcMin;Vil1 -Grem -1 model,  and therefore, higher doses of 
UCB6114 are likely not warranted.  
BIW=twice weekly; h=hour; iv=intravenous(ly); PK=pharmacokinetic(s); Q2W=every  2 weeks; 
sc=subcutaneous(ly)  
[IP_ADDRESS]  UCB6114 dose modifications  
Study  participants who experience Grade 4 (life -threatening) nonhematologic toxicity, including 
diarrhea and mucositis, which  is at least possibly related  to UCB6114, will be discontinued from 
treatment . 
Treatment with UCB6114 may temporarily be suspended for up to 3 weeks beyond the 
scheduled treatment day until toxicities are resolved to CTCAE Grade 2 or less. If UCB6114 is 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 102 of 195 held fo r more than 3 weeks beyond the scheduled treatment day, then the participant will be 
discontinued from treatment and will be followed up for safety and efficacy per the Schedule of 
Activities.  
For permitted adjustments of the infusion rate in case of AEs,  refer to the IMP Handling Manual. 
Participants who experience severe or life -threatening infusion -related events (Grade 3 or 4) will 
not receive further infusions. Hypersensitivity/infusion -related events should be managed per 
institutional guidelines. Pr emedication with steroids may be administered at the discretion of the 
investigator.  
[IP_ADDRESS]  mFOLFOX6 dosing  
Please refer to the individual package inserts for details on formulations and storage.  
Antiemetic premedication prior to administration of chemotherapy is  recommended and sites 
should follow their institutional standard of care.  
The recommended administration of mFOLFOX6 is shown in Table  6-12. 
Table  6-12: mFOLFOX6 dosing  
Drug  Dose  Administration  
Oxaliplatina 85mg/m2 iv in 250 to 500mL glucose 5% over 2 hours  
Leucovorina 400mg/m2 iv in 250mL glucose 5% over 2 hours  
5-Fluorouracil  400mg/m2 iv bolus  
5-Fluorouracil  2400mg/m2 iv over 46 hours via an infusor  
mFOLFOX6=leucovorin 400mg/m2 on Day 1, 5 -fluorouracil 400mg/m2 on Day 1 + 1200mg/m2/day on Day 1 
and Day 2, and oxaliplatin 85mg/m2 on Day 1; iv=intravenous(ly)  
a Oxaliplatin and leucovorin may be infused over the same two -hour period by [CONTACT_2329] a Y -site connector placed 
immediately before the infusion site.  
Within the study, mFOLFOX6 is administered every 14 days in 28 -day treatment cycles up to a 
maximum of 6 cycles.  
[IP_ADDRESS]  mFOLFOX6 dose modifications  
Dose modifications for mFOLFOX6 -related AEs are allowed as described below. A maximum 
of 2 dose level reductions a re permitted.  
Participants who permanently discontinue treatment (all or individual drugs of the mFOLFOX6 
regimen) due to toxicity will be considered for continuation of treatment with UCB6114 if, in the 
view of the investigator, the participant is derivi ng benefit.  
Dose levels for individual drugs are as follows:  
• Oxaliplatin:  
− Starting dose: 85mg/m2 
− Dose Level -1: 65mg.m2 
− Dose Level -2: 50mg/m2 
• 5-fluorouracil iv bolus:  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 103 of 195 − Starting dose: 400mg/m2 
− Dose Level -1: 320mg/m2 
− Dose Level -2: 200mg/m2 
• 5-fluorouracil infusion over 46 hours:  
− Starting dose: 2400mg/m2 
− Dose Level -1: 2000mg/m2 
− Dose Level -2: 1600mg/m2 
No dose adjustments are required for leucovorin.  
[IP_ADDRESS].1  Dose modifications for neurological toxicity  
If neurological symptoms (ie, paresthesia, dysesthesia) occur, oxaliplatin dosage adjustments 
should be made as outlined in Table  6-13. No dose adjustments of 5 -fluorouracil are 
recommended for neurotoxicity.  
Table  6-13: Dose modification for oxaliplatin -related neurological toxicity  
CTCAE (v5.0)  
Toxicity grade  Duration of toxicity  
Transient  
(≥1 day and ≤14 days)  Persistent  
(present at start of next treatment)  
[ADDRESS_386011] time: reduce one dose level  
2nd time: reduce one dose level  Discontinue  
4 Discontinue  Discontinue  
CTCAE=Common Terminology Criteria for Adverse Events  
[IP_ADDRESS].2  Dose modifications for hematological toxicity  
Recommended dose modifications for oxaliplatin and 5 -fluorouracil for hematological toxicity 
are outlined in Table  6-14. 
Table  6-14: Dose modification for hematological toxicity  
Prior to Dosing  
(Day 1 or Day 15)  Toxicity  Dose level for subsequent cycles  
 CTCAE (V5.0) 
Toxicity Grade  ANC  
(x109/L) Oxaliplatin  5-Fluorouracil  
If ANC <1.2 on Day 1 or Day 15, 
hold treatment and perform 
weekly blood counts.  1 ≥1.2 Maintain dose level  Maintain dose level  
2 1.0 to <1.2  Maintain dose level  Maintain dose level  
3 0.5 to <1.0  Reduce 1 dose level  Maintain dose level  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 104 of 195 Table  6-14: Dose modification for hematological toxicity  
Prior to Dosing  
(Day 1 or Day 15)  Toxicity  Dose level for subsequent cycles  
If ANC is ≥1.[ADDRESS_386012] 
ANC result of the delayed weeks.  
If ANC remains <1.2 after 2 
weeks, discontinue treatment.  4 <0.5 Reduce 1 dose level  Omit iv bolus and 
reduce infusion 
1 dose level  
 CTCAE (V5.0) 
Toxicity Grade  Platelets  
(x 109/L) Oxaliplatin  5-Fluorouracil  
If platelets <75 on Day 1 or Day 
15, hold treatment. Perform 
weekly blood counts.  
If platelets ≥[ADDRESS_386013] 
platelets result of the delayed 
weeks.  
If platelets remain <75 after 
2 weeks, discontinue treatment.  1 ≥75 Maintain dose level  Maintain dose level  
2 50 to <70  Maintain dose level  Maintain dose level  
3 10 to <50  Reduce 1 dose level  Maintain dose level  
4 <10 Reduce 2 dose 
levels  Maintain dose level  
ANC=absolute neutrophil count; CTCAE=  Common Terminology Criteria for Adverse Events; iv=intravenous(ly)  
[IP_ADDRESS].3  Dose modifications for non -hematological, non -neurological toxicity  
Recommended dose modifications for non -hematological, non -neurological toxicity are outlined 
in Table  6-15. Along with dose modifications, supportive treatment should be initiated per 
institutional guidelines.  
Table  6-15: Dose modification for non -hematological, non -neurological toxicity  
Prior to Dosing  
(Day 1 or Day 15)  Toxicity  Dose level for subsequent 
cycles  
 CTCAE (V5.0) 
Toxicity Grade  Diarrhea  Oxaliplatin  5-Fluorouracil  
If diarrhea ≥2 on Day 1 or 
Day 15, hold treatment. 
Perform weekly assessments.  
If diarrhea is <Grade [ADDRESS_386014] 
Grade experienced.  1 Increase of <4 stools/day, 
or mild increase in 
colostomy output  Maintain 
dose level  Maintain dose 
level  
2 Increase of 4 to 6 
stools/day, or moderate 
increase in colostomy 
output; limiting 
instrumental ADL  Maintain 
dose level  Maintain dose 
level  
3 Increase of ≥7 stools/day; 
hospi[INVESTIGATOR_374]; 
severe increase in Maintain 
dose level  Reduce 1 dose 
level of iv bolus 
and infusion  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 105 of 195 Table  6-15: Dose modification for non -hematological, non -neurological toxicity  
Prior to Dosing  
(Day 1 or Day 15)  Toxicity  Dose level for subsequent 
cycles  
If diarrhea remains ≥Grade 2 
after 2 weeks, discontinue 
treatment.  colostomy output; 
limiting self -care ADL  
4 Life threatening 
consequences; urgent 
intervention indicated  Reduce 1 
dose level  Reduce 1 dose 
level of iv bolus 
and infusion  
 CTCAE (V5.0) 
Toxicity Grade  Stomatitis/Mucositis  Oxaliplatin  5-Fluorouracil  
If stomatitis ≥Grade 2 on Day 
1 or Day 15, hold treatment. 
Perform weekly assessments.  
If stomatitis <Grade [ADDRESS_386015] 
Grade experienced.  
If stomatitis remains 
>Grade 2 after 2 weeks, 
discontinue treatment.  1 Minimal symptoms with 
normal oral intake  Maintain 
dose level  Maintain dose 
level  
2 Moderate pain, analgesics 
indicated; altered oral 
intake  Maintain 
dose level  Maintain dose 
level  
3 Severe pain; unable to 
adequately aliment or 
hydrate orally  Maintain 
dose level  Reduce 1 dose 
level of iv bolus 
and infusion  
4 Life-threatening 
consequen ces, urgent 
intervention indicated  Reduce 1 
dose level  Reduce 1 dose 
level of iv bolus 
and infusion  
ADL=activities of daily living; CTCAE=  Common Terminology Criteria for Adverse Events; iv=intravenous(ly)  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 106 of 195 6.7 Criteria for study hold or dosing stoppage  
Detailed procedures for reporting SAEs and other safety events (including Rapid Alert 
Procedures) that may meet study or individual study part hold criteria are provided in 
Appendix  6 (Section  11.6). 
The study or individual study part will be immediately suspended (ie, any participant who has 
not received dose(s) of UCB6114 at the time of study/study part suspension will not be 
administered UCB6114 )  if [ADDRESS_386016] possibly related to UCB6114 administration by [CONTACT_313595] : 
• Death  
• Life-threatening organ failure requiring intervention to prevent death or permanent d isability 
(eg, respi[INVESTIGATOR_313524], renal failure requiring dialysis, heart failure 
requiring hemodynamic support).  
The SMC will be consulted for both study/study module suspension  and potential restart (details 
can be found in the SMC charter).  
The management of ongoing participants may be discussed on an individual basis with the 
inverstigator and the participants taking into account the benefit/ risk assessment , unless asked 
by [CONTACT_313596]/or a regulatory authority/ies not to do so . 
Enrolment of new participants into the study or individual study module will not be restarted 
until:  
• Sponsor and the SMC have agreed a risk mitigation strategy which meets the requirements of 
any regul atory authority/ies to whom details of the AE have been submitted, and  
• Based on local policies,  the Independent Ethics Committee s (IEC s)/Institutional Review 
Board s (IRB s) have been notified , and  
• Where applicable, regulatory authorities have been notifie d and have approved a substantial 
amendment for study restart.  
6.8 Treatment after the end of the study  
The planned duration of study treatment is 2 cycles. Participants may, however, remain on study 
for additional cycles if they are receiving therapeutic bene fit (SD, PR, or CR) or until they fulfill 
one of the criteria for study discontinuation. Upon discontinuation of treatment, participants will 
be referred to appropriate follow -up care per the investigator’s judgment.  
7 DISCONTINUATION OF S TUDY MEDICATION AND  
PARTICIPANT DISCONTI NUATION/WITHDRAWAL  
7.1 Discontinuation of study medication  
The IMP will be discontinued if any of the stoppi[INVESTIGATOR_313525] (see Section  7.2). 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 107 of 195 7.1.1  Liver Chemistry Stoppi[INVESTIGATOR_313526] a potential case of drug -induced liver injury 
depends on the participant’s individual baseline values and unde rlying conditions. Participants 
who present with the following laboratory abnormalities should be evaluated further to 
definitively determine the etiology of the abnormal laboratory values:  
• Participants with AST or ALT and total bilirubin baseline values w ithin the normal range 
who subsequently present with AST or ALT ≥3xULN concurrent with a total bilirubin 
≥2xULN.  
• For participants with pre -existing ALT OR AST OR total bilirubin values above the ULN, 
the following threshold values should be used in the def inition mentioned above:  
− For participants without liver metastases: AST or ALT value ≥2 times the baseline values 
AND  ≥3xULN  
− For participants with liver metastases: AST or ALT value ≥2 times the baseline values 
AND ≥8xULN  
Concurrent with  
• For participants w ith preexisting values of total bilirubin above the normal range: Total 
bilirubin ≥2 times the baseline values OR if the value reaches ≥3xULN (whichever is lower).  
The participant should return to the investigational site and be evaluated as soon as possible, 
preferably within 24 hours from awareness of the abnormal results. This evaluation should 
include laboratory tests, detailed history and physical assessment, and the possibility of hepatic 
neoplasia (primary or secondary) should be considered. In  addition to repeating measurements of 
AST and ALT, laboratory tests should include albumin, creatine kinase, total bilirubin, direct and 
indirect bilirubin, gamma -glutamyl transferase, prothrombin time/ international normalized ratio , 
and ALP . A detailed h istory, including relevant information, such as review of ethanol, 
acetaminophen, recreational drug and supplement consumption, family history, occupational 
exposure, sexual history, travel history, history of contact [CONTACT_4490] a jaundiced person, surgery, 
blood transfusion, history of liver or allergic disease, and work exposure, should be collected. 
Further testing for acute hepatitis A, B, or C infection and liver imaging (eg, biliary tract) may be 
warranted. All cases confirmed on repeat testing as meeting t he laboratory criteria defined above, 
with no other cause for liver function test abnormalities identified at the time should be 
considered potential Hy’s Law cases irrespective of availability of all the results of the 
investigations performed to determin e etiology of the abnormal liver function tests. Such 
potential Hy’s Law cases should be reported as SAEs.  
Interruption of the study medication should be considered by [CONTACT_82378] a participant 
meets one of the conditions outlined above.  
7.1.2  QTc Stop pi[INVESTIGATOR_2121]  
A participant who meets either bulleted criterion based on the average of triplicate ECG readings 
will be withdrawn from study medication.  
• QTc >500msec OR Uncorrected  QT >600msec  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 108 of 195 • Change from baseline of QTc >60msec  
For participants with under lying bundle branch block, follow the discontinuation criteria listed in 
Table  7-1. 
Table  7-1: Bundle Branch Block discontinuation criteria  
Baseline QTc with Bundle Branch Block  Discontinuation QTc threshold with Bundle 
Branch Block  
< 450msec  > 500msec  
450 to 480msec  ≥ 530msec  
If a clinically significant finding is identified (including, but not limited to, changes from 
baseline in QTcF after enrollment), the investigator, study physician, or medically qualified 
designee will determine if the participant can continue in the study and if any cha nge in 
participant management is needed. This review of the ECG printed at the time of collection must 
be documented. Any new clinically relevant finding should be reported as an AE.  
See the Schedules of Activities for Part  A (Table  1-4), Part A1 ( Table  1-5 and Table  1-6), Part  B 
(Table  1-7), and Part  C (Table  1-8) for data to be collected at the time of treatment 
discontinuation and follow -up and for any further evaluations that need to be completed.  
7.1.[ADDRESS_386017] discontinue study treatment if they experience any of the following:  
1. There is confirmation of a pregnancy during the study, as evidenced by a positive pregnancy 
test. 
2. The participant experiences unacceptable toxicity.  
− For information on do se delays due to drug -related toxicity, see Section  6.6.1  (Part  A and 
Part A1), Section  6.6.2  (Part  B), and Section  6.6.3  (Part  C). Participants will discontinue 
treatment, unless,  in the opi[INVESTIGATOR_871], they are experiencing clinical benefit 
and it is in their best interest to continue treatment. For these participants, treatment may 
continue at a reduced dose at the discretion of the investigator and Sponsor.  
3. The part icipant has documented evidence of progressive disease.  
− Participants with progressive disease before the end of Cycle [ADDRESS_386018] be reimaged 
within 2 cycles of treat ment.  
4. The participant, for any reason, requires treatment with another therapeutic agent or modality 
for his/her cancer (with the exception of palliative bone -directed radiotherapy). In this case, 
discontinuation from the study treatment must occur before introduction of the new agent or 
modality.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 109 of 195 5. Participant takes prohibited concomitant medications as defined in this protocol.  
Participants who discontinue the study medication and/or study early will have end -of-study 
(SFU) procedures performed as shown in the Schedules of Activities for Part  A (Table  1-4), Part 
A1 (Table  1-5 and Table  1-6), Part  B (Table  1-7), and Part  C (Table  1-8). 
See the Schedules of Activities for Part  A (Table  1-4), Part A1 ( Table  1-5 and Table  1-6), Part  B 
(Table  1-7), and Part  C (Table  1-8) for data to be collected at the time of study treatment 
discontinuation and follow -up and for any further evaluations that need to be completed.  
7.1.4  Temporary discontinuation of study medication  
A treatm ent dose may be withheld if a participant experiences toxicity as described in 
Section  [IP_ADDRESS]   (Part A), Section  [IP_ADDRESS]  Part A1), Section  [IP_ADDRESS]  (Part B), and Section  [IP_ADDRESS]  
(Part C).  
Participants who fail to receive the second planned dose of UCB6114 within 7 days of the 
scheduled administration day du ring the DLT Observation Period  for reasons not related to 
toxicity will be replaced by a new participant in that cohort.  
Treatment with UCB6114 may temporarily be suspended for up to 3 weeks beyond the 
scheduled treatment day until toxicities are resolved to CTCAE Grade 2 or less. If UCB6114 is 
held for more than 3 weeks beyond the scheduled treatment day, then the participant will be 
discontinued from treatment and will be followed up for safety per sch edule of assessment.  
7.2 Participant discontinuation/withdrawal from the study  
The criteria for enrollment must be followed explicitly. A Treatment Allocation/Enrolment Plan 
and management process (IVRS) may be utilized to ensure strict compliance.  
Participan ts are free to withdraw from the study at any time, without prejudice to their continued 
care.  
A participant may withdraw from the study at any time at his/her own request, or may be 
withdrawn at any time at the discretion of the investigator for safety or  compliance reasons.  
Participants should be withdrawn from the study if any of the following events occur:  
1. Participant withdraws his/her consent.  
2. Participant develops an illness or comorbidity that would interfere with his/her continued 
participation.  
3. The investigator considers it in the best interest of the participant to be withdrawn. If this 
decision is made because of an SAE or a clinically significant laboratory value, then 
appropriate supportive measures are to be taken. UCB or its designee is to be alerted 
immediately.  
4. Participant is noncompliant with the study visit schedule.  
If the participant withdraws consent for disclosure of future information, the Sponsor  may retain 
and continue to use any data collected before such a withdrawal of consent.  
If a participant withdraws from the study, he/she may request destruction of any samples taken 
and not tested, and the investigator must document this in the site study records.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 110 of 195 If any participant withdraws/is withdrawn from the study, the site will attempt to contact [CONTACT_313597]. However, participants 
will not be followed up if they have withdrawn their consent to  do so.  
The primary reason for withdrawal from the study should be documented on the appropriate 
eCRF page.  
Investigators should inform the study physician or medically qualified designee  in the event that 
a participant is withdrawn from the study.  
Partic ipants who withdraw from the study before receiving study medication will be replaced.  
7.[ADDRESS_386019] be taken if a participant fails to return to the clinic for a required 
study visit:  
• The site must attempt to contact [CONTACT_313598] e of maintaining the assigned visit 
schedule and ascertain whether or not the participant wishes to and/or should continue in the 
study.  
• Before a participant is deemed lost to follow -up, the investigator, study physician, or 
medically qualified designee  must make every effort to regain contact [CONTACT_6635] (at 
least 1 phone call and 1 written message to the participant), and document his/her effort (date 
and summary of the phone call and copy of the written message in the source documents), to 
compl ete the final evaluation . All results of these evaluations and observations, together with 
a narrative description of the reason(s) for removing the participant, must be recorded in the 
source documents. The eCRF must document the primary reason for withdr awal.  
Should the participant continue to be unreachable, he/she will be considered to have withdrawn 
from the study with a primary reason of lost to follow -up documented in the eCRF.  
7.[ADDRESS_386020] individualized benefit -risk 
discussions with study participants during Screening and the course of the study. Such 
discussions should take into consideration the ongoing assessment of the study participant’s 
medical status as well as the COVID -[ADDRESS_386021] elicit from the participant any suspected or known exposure to COVID -19 or a confirmed 
COVID -19 positive diagnosis. To accommodate potential COVID -19 restrictions, the study 
procedures may be adapted. Such adaptations may include replacing in -clinic visits with video 
consultations, flexibility in the timing and/or location of assessment collection, and any other 
changes deemed necessary until such restrictions are lifted. Clinical sites may arr ange for virtual 
study visits or home visits to continue collection of safety and PK data. Participants who miss 
doses due to a positive COVID -[ADDRESS_386022] the right to stop or terminate the study at any time, for any ethical, 
medical, or scientific reason, while considering the rights, safety, and well -being of the 
participant(s).  
Study site participation may be discontinued if UCB, the investigator, the IRB/ethical review 
board, or the regulatory authority deems it necessary for any scientific, medical, or ethical 
reason. The study will be discontinued if UCB, while considering the rights, safety, and 
wellbeing of the participan t(s), deems it necessary for any scientific, medical, or ethical reason.  
9 STUDY ASSESSMENTS AN D PROCEDURES  
Study procedures and their timing are summarized in the Schedules of Activities for Part  A 
(Table  1-4), Part A1 ( Table  1-5 and Table  1-6), Part  B (Table  1-7), and Part  C (Table  1-8). Study 
procedures and their timing for modules subsequent to Parts  A, A1, B, and C will be described in 
a planned protocol amendment.  
Protocol waivers or exemptions are not allowed.  
Immediate safety concerns should be discussed with the Sponsor immediately upon occurrence 
or awareness to determine if the participant should continue or discontinue study treatment.  
Adherence to the study design requirements, including those specified in the Schedules of 
Activities for Par t A (Table  1-4), Part A1 ( Table  1-5 and Table  1-6), Part  B (Table  1-7), and 
Part C (Table  1-8), is essential and required for study conduct.  
All Screening evaluations must be completed and reviewed to confirm that potential participants 
meet all eligibility criteria. The investigator will maintain a Screening log to record details of all 
participants screened and to confirm eligibility or record reasons for Screening failure, as 
applicable.  
Procedures conducted as part of the participant’s  routine clinical management (eg, blood count) 
and obtained before signing of the ICF may be utilized for Screening or baseline purposes 
provided the procedures met the protocol -specified criteria and were performed within the time 
frame defined in the Sch edules of Activities for Part  A (Table  1-4), Part A1 ( Table  1-5 and 
Table  1-6), Part B (Table  1-7), or Part  C (Table  1-8), as applicable.  
In Part A , the maximum amount of blood collected from each participant during Screening will 
be approximately 8 to 10mL. In the case of liver function abnormalities considered potenti al 
Hy’s Law cases where the liver -specific ALP must be separated from the total ALP in 
participants with bone metastases, an additional volume of 2mL of blood will be collected.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 112 of 195 The maximum amount of blood collected from each participant over the duration of Cycle 1 of 
Part A are indicated in Table  9-1. 
Table  9-1: Total blood volume collected during Cycle 1 of Part A  
Sample  Number of samples  Volume of sa mple  Total blood 
volume  
Hematology  4 <2mL  8mL  
Biochemistry  4 <2mL  8mL  
Coagulation  2 <2mL  4mL  
Pregnancy (if applicable)a 1 2mL  2mL  
Pharmacodynamics (PD)  12 various (2.5 to 20mL)  83.5mL  
Immunogenicity (ADA)  3 5mL  15mL  
Total  38 - 180.5mL  
ADA=antidrug antibody  
Note: Repeat or unscheduled samples may be taken in addition, for safety reasons or for technical issues with the 
samples.  
a This volume could be increased by 2mL per visit if serum pregnancy test is performed in stead of urine for second 
pregnancy assessment during this cycle.  
The maximum amount of blood collected from each participant during Cycle [ADDRESS_386023]  
The maximum amount of blood collected from each participant during the SFU of Part A will be 
approximately 51.5mL.  
In Part A1 ,  
• The maximum amount of blood collected from each participant during Screening  will be 
approximately 42 to 44mL (if pregnancy test is applicable). In the case of liver function 
abnormalities considered potential Hy’s Law cases where the liver -specifi c ALP must be 
separated from the total ALP in participants with bone metastases, an additional volume of 
2mL of blood will be collected.  
• The maximum amount of blood collected from each participant over the duration of Cycle 1  
is indicated in Table  9-2. 
• The maximum amount of blood collected from each participant during Cycle [ADDRESS_386024]. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 113 of 195 • The maximum amount of blood collected from each participant during Cycle [ADDRESS_386025]. If the on -treatment biopsy is not performed an additional volume of up 
to 9mL could be collected for additi onal PK and circulating Gremlin -1 assessment.  
• The maximum amount of blood collected from each participant from Cycle 4 onwards  will 
be approximately 46.5mL for Cohorts 1 and 2, and 42.5mL for Cohorts 3 and 4. This volume 
will be increased by [CONTACT_8622] 7mL (2mL  per cycle if serum pregnancy test is performed instead 
of urine pregnancy test and 5mL every third cycle [Cycle 6, Cycle 9] for immunogenicity).  
• The maximum amount of blood collected from each participant during the SFU Visit will be 
approximately 47.5mL . 
Table  9-2: Total blood volume collected during Cycle 1 of Part A1  
Cohorts  
 
 
Sample   
 
Volume of 
sample  Cohorts 1, 2, 4  Cohort 3  
N° of 
samples  Total blood 
volume  N° of  
samples  Total blood 
volume  
Hematology  <2mL  2 <4mL  1 <2mL  
Biochemistry  <2mL  2 <4mL  1 <2mL  
Coagulation  <2mL  1 2mL  1 2mL  
Pregnancy (if 
applicable)a  2mL  1 2mL  1 2mL  
PD various (2.5 to 
20mL)  7 43.5mL  4 16mL  
Immunogenicity (ADA)  5mL  1 5mL  1 5mL  
Total  - - 80.5mL  - 49mL  
ADA=antidrug antibody; N°=number; PD=pharmacodynamics; PK=pharmacokinetics  
a This volume could be increased by 2mL per visit if serum pregnancy test is performed instead of urine for second 
pregnancy assessment during  this cycle.  
Note: Repeat or unscheduled samples may be taken in addition, for safety reasons or for technical issues with the 
samples.  
In Parts B and C , the maximum amount of blood collected from each participant during 
Screening will be approximately 38 .5mL . In the case of liver function abnormalities considered 
potential Hy’s Law cases where the liver -specific ALP must be separated from the total ALP in 
participants with bone metastases, an additional volume of 2mL of blood will be collected.  
The maximum  amount of blood collected from each participant over the duration of Cycle 1 of 
Parts B and C is indicated in Table  9-3. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 114 of 195 Table  9-3: Total blood volume collected during Cycle 1 of Parts B and C  
Sample  Number of samples  Volume of sample  Total blood 
volume  
Hematology  4 <2mL  8mL  
Biochemistry  4 <2mL  8mL  
Coagulation  2 <2mL  4mL  
Pharmacodynamics (PD)  4 various (4 to 20mL)  32mL  
Immunogenicity (ADA)  1 5mL  5mL  
Total  19 - 77mLa 
Note: Repeat or unscheduled samples may be taken in addition, for safety reasons or for technical issues with the 
samples.  
a This volume could be increased by 2mL per visit at which serum pregnancy test is performed  
The maximum amount of blood collected from each participant during Cycle [ADDRESS_386026].  
9.1 Safety assessments  
Planned time points for all safety assessments are provided in the Schedules of Activities for 
Part A (Table  1-4), Part A1 ( Table  1-5 and Table  1-6), Part  B (Table  1-7), and Part  C 
(Table  1-8). Safety assessments for Parts A1, D, E, F, and G will be described in a protocol 
amendment.  
9.1.1  Physical examination  
The investigator or other designated clinician will perform a complete physical examination at 
Screening and on Cycle 1 Day 1 predose (Part A, Part A1 and Part C) or within 3 days prior to 
administration of any IMP (Part B). Physical examination will be symptom -directed at all other 
visits.  
A complete physical examination wil l include, at a minimum, head, eyes, ears, nose, and throat; 
general abdomen; lymph nodes; and cardiovascular, respi[INVESTIGATOR_696], gastrointestinal, neurological, 
musculoskeletal, hepatic, and genitourinary (as clinically indicated) systems. Weight will also be 
measured and recorded. Height will only be recorded at Screening.  
Signs and symptoms of concomitant disease and/or conditions should also be assessed.  
Investigators should pay special attention to clinical signs related to previous serious illnesses.  
Clinic ally relevant findings or worsening of previous findings will be recorded in the eCRF as an 
AE. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_386027] 5 minutes before the recording.  When coinciding with blood sample draws for PK, 
ECG  assessment should be performed prior to blood sample collection, such that the blood 
sample is collected at the nominal time.  
The 3 ECG tracings should be obtained as closely as possible in succession, within 2 to 
10 minutes at each time point.  
All ECGs will be evaluated for any clinically relevant changes by [CONTACT_093].  
Electrocardiograms may  be collected for central reading. During the visit, the assessment of the 
ECG by [CONTACT_313599].  
9.1.4  Echocardiograms  
Echocardiograms will be collected from all participants acco rding to the Schedules of Activities 
for Part  A (Table  1-4), Part A1 ( Table  1-5 and Table  1-6), Part  B (Table  1-7), and Part  C 
(Table  1-8). Left ventricular ejection fraction will be measured and recorded  in the eCRF 
expressed as a percentage.  
9.1.5  Clinical safety laboratory assessments  
Hematology, blood chemistry, coagulation, and urinalysis will be collected at the time points 
described in the Schedules of Activities for Part  A (Table  1-4), Part A1 ( Table  1-5 and 
Table  1-6), Part  B (Table  1-7), and Part  C (Table  1-8) and analyzed at a local laboratory. See 
Appendix 2 (Section  11.2) for the list of clinical laboratory tests to be performed.  
The investigator must review the laboratory report, document this review, and record any 
clinically relevant changes occurring during the study in the AE section of the eCRF. The 
laboratory reports must be filed with the source documents. Clinically significant abnormal 
laboratory findings are those which are not associated with the underlying disease, unless judged 
by [CONTACT_19448]’s condition.  
Chemistry, hematology, and coagulation (where applicable) results should be available for 
review prior to infusion of treatment.  
All laboratory test s with values considered clinically significantly abnormal during participation 
in the study or within 24 hours  after the final dose of study medication should be repeated until 
the values return to normal or baseline or are no longer considered clinically  significant by [CONTACT_313600].  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 116 of 195 If such values do not return to normal/baseline within a period of time judged reasonable by [CONTACT_1275], the etiology should be identified and the Sponsor notified.  
All protocol -required laboratory assessments, as defined in Appendix 2 (Section  11.2), must be 
conducted in accordance with the laboratory manual and the Schedules of Activities for Part  A 
(Table  1-4), Part A1 ( Table  1-5 and Table  1-6), Part  B (Table  1-7), and Part  C (Table  1-8). 
If laboratory values from nonprotocol -specified laboratory assessments performed at the 
institution’s local laboratory require a change in participant management or are considered 
clinically significant by [CONTACT_093] (eg, SAE or AE or dose modification), then the results 
must be recorded in the eCRF.  
9.1.6  Pregnancy testing  
Procedures for pregnancy testing and contraceptive use are provided in Appendix 4 
(Section  11.4). Pregnancy testing should be collected as described in the Schedules of Activities 
for Part  A (Table  1-4), Part A1 ( Table  1-5 and Table  1-6), Part  B (Table  1-7), and Part  C 
(Table  1-8). 
For female parti cipants of childbearing potential, a serum pregnancy test with sensitivity of at 
least 25mIU/mL will be performed on 2 occasions prior to starting study therapy, as follows: 
once at the start of Screening and once at the Day [ADDRESS_386028], the participant will be withdrawn from treatment but may remain in the  study 
(Section  9.2.5 ). 
9.2 Adverse events and serious adverse events  
Planned time points for AE and SAE reporting are provided in the Schedules of Activities for 
Part A (Table  1-4), Part A1 ( Table  1-5 and Table  1-6),Part  B (Table  1-7), and Part  C (Table  1-8). 
Reporting of AEs and SAEs for Parts D, E, F, and G will be described in a protocol amendment.  
The definitions of an AE or SAE can be found in Appendix 3 (Section  11.3). 
Adverse events will be reported by [CONTACT_2299] (or, when appropriate, by a caregiver, 
surrogate, or the participant’s legally authorized representative).  
The investigator, study physician , or medically qualified designee are responsible for detecting, 
documenting, and recording events that meet the definition of an AE or SAE and remain 
responsible for following up AEs that are serious, considered related to the study treatment 
(UCB6114, TF D/TPI [Part B], any individual component of mFOLFOX6 [Part C], or more than 
1 of the treatments) or study procedures, or that caused the participant to discontinue the study 
treatment or study (see Section  7). 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 117 of 195 All non -serious events of COVID -19 or associated with COVID -19 should be reported as either 
“suspected COVID -19” or “confirmed COVID -19” utilizing the standard AE form. If additional 
assessments ( e.g. additional labs) are performed by [CONTACT_779], they should be reported on 
unscheduled visit CRF pages per standard practice.  
All serious events of COVID -19 or associated with COVID -19 should be reported as either 
“suspected COVID -19” or “confirmed COVID -19”, along with additional relevant data, to UCB 
Patient Safety utilizing the electronic SAE form and in accordance to the timelines outlined 
within the protocol.  
9.2.1  Time period and frequency for collecting AE and SAE information  
All AEs and SAEs will be col lected from the signing of the ICF until the follow -up visit at the 
time points specified in the Schedules of Activities for Part  A (Table  1-4), Part A1 (Table  1-5 
and Table  1-6), Part  B (Table  1-7), and Part  C (Table  1-8). 
In order to ensure complete safe ty data collection, all AEs occurring during the study (ie,  after 
the signing of the ICF), including any pretreatment and posttreatment periods required by [CONTACT_12695], must be reported in the eCRF even if no study medication was taken but specific study 
procedures were conducted. This includes all AEs not present prior to the initial visit and all AEs 
that recurred or worsened after the initial visit.  
All SAEs will be recorded and reported to the Sponsor  or designee within 24 hours, as indicated 
in Appendix 3 (Section  11.3). The investigator will submit any updated SAE data to the Sponsor  
within [ADDRESS_386029] and report to UCB (or its representative) any 
SAEs (even if the investigator is certain that they are in no way associated with the study 
medication), up to the Safety Follow -up Visit for each participant, and to also infor m participants 
of the need to inform the investigator of any SAE within this period. Serious AEs that the 
investigator thinks may be associated with the study medication must be reported to UCB 
regardless of the time between the event and the end of the st udy. 
The method of recording, evaluating, and assessing causality of AE and SAE and the procedures 
for completing and transmitting SAE reports are provided in Appendix 3 (Section  11.3). 
9.2.2  Method of detecting AEs and SAEs  
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended and 
non-leading verbal questioning of the participant is the preferred method to inquire about 
AE occurren ces. 
9.2.3  Follow -up of AEs and SAEs  
After the initial AE/SAE report, the investigator is required to proactively follow each participant 
at subsequent visits/contacts. All SAEs and non -serious AEs of special interest (as defined in 
Section  9.2.6  and Section  9.2.7 , respectively), will be followed until resolution, stabilization, the 
investigator determines that it is no longer clinically significant, the event is otherwise explained, 
or the participant is lost to follow -up (as defined in Section  7.3. Further information on follow -up 
procedures for AEs and SAEs is given in Appendix 3 (Section  11.3). 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 118 of 195 9.2.4  Regulatory reporting requirements for SAEs  
Prompt notification by [CONTACT_313601] a study 
treatment under clinical investigation are met.  
The Sponsor  has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the  safety of a study treatment under clinical investigation. The 
Sponsor  will comply with country -specific regulatory requirements relating to safety reporting to 
the regulatory authority, IRB/IEC , and investigators.  
Investigator safety reports must be prepa red for suspected unexpected serious adverse reactions 
according to local regulatory requirements and Sponsor policy and forwarded to investigators as 
necessary.  
An investigator who receives an investigator safety report describing a SAE or other specific 
safety information (eg, summary or listing of SAEs) from the Sponsor  will review and then file it 
along with the IB and will notify the IRB/IEC, if appropriate according to local requirements.  
9.2.[ADDRESS_386030] immediately inform the Sponsor within 24 hours 
of learning of the pregnancy and should follow the procedures outlined in Appendix 4 
(Section  11.4). 
Female participants should be withdrawn from the study as soon as pregnancy is known (by 
[CONTACT_18463]), and the following should be completed:  
• The participant should return for a Safety Follow -up Visit.  
• The participant should immediately stop the intake of the study medication or be 
down -titrated as instructed at the Safety Follow -up Visit.  
• A Final Visit should be scheduled 3 months after the participant has discontinued her study 
medication.  
Abnormal pregnancy outcomes (eg, spontaneous abortion, fetal death, stillbirth, congenital 
anomalies, e ctopic pregnancy) are considered SAEs.  
9.2.[ADDRESS_386031]/compound.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 119 of 195 For UCB6114, the following event requires immediate reporting (within 24 hours regardless of 
seriousness) to UCB:  
• Hy’s Law  
− Potential Hy’s Law, defined as ≥3xULN ALT or AST with coexisting ≥2xULN total 
biliru bin in the absence of ≥2xULN ALP, with no alternative explanation for the 
biochemical abnormality (ie, without waiting for any additional etiologic investigations 
to have been concluded). Follow -up information should be reported if an alternative 
etiology is identified during investigation and monitoring of the participant.  
− Study participants who have evidence of liver metastases may be considered to have an 
alternate etiology for the described laboratory abnormalities.  
9.2.[ADDRESS_386032] been exp osed to UCB6114. Thus, no serious AEs with a possible 
causal relationship to the IMP (ie, suspected serious adverse reactions [SARs]) have been 
observed in humans. Therefore, all suspected SARs will be considered unexpected and will be 
reported as such.  
Death due to disease progression will not be recorded as a SAE and will be recorded in the 
survival eCRF. However, if death might be due to other causes, it should be timely reported as a 
SAE.  
9.2.9  Infusion -related reactions (hypersensitivity reactions)  
Participa nts should be observed for at least [ADDRESS_386033] of diagnostic testing 
and continued monitoring. Further tests may include, but are not limited to cytokine 
measurements, immunoglobulin E levels, tryptase, complement parameters such as C3a, C5a 
measure ments when there is a suspi[INVESTIGATOR_313527] I or III hypersensitivity reaction.  
The results of all monitoring, including laboratory testing and other testing, should be made 
available to the study site and Sponsor.  
Premedication to prevent the onset of infusio n-related reactions may be allowed for individual 
study participants based on the Investigator recommendations and after consultation with the 
Sponsor and should be recorded in the eCRF.  
Procedures for reporting infusion -related reactions are the same as t hose for AEs and SAEs, as 
described in Appendix 3 (Section  11.3). 
9.[ADDRESS_386034], as early as possible, any 
safety concern(s) related to the study medication so that investigators, study participants, 
regulatory authorities, and IRBs/IECs will be informed appropriately and as early as possible.  
The study physician or medically q ualified designee/equivalent will conduct an ongoing review 
of safety data as they become available and perform ongoing SAE reconciliations in 
collaboration with the Patient Safety representative.  
As appropriate for the stage of development and accumulated  experience with the study 
medication, medically qualified personnel at UCB may identify additional safety measures 
(eg, AEs, vital signs, laboratory or electrocardiogram [ECG] results) for which data will be 
periodically reviewed during the course of the study. For information regarding the SMC, see 
Section  4.1.1  (all parts) ,  Section  [IP_ADDRESS]  (Part A), Section  4.1.3  (Part A1), Section  [IP_ADDRESS]   (Part 
B), and Section  [IP_ADDRESS]   (Part C).  
9.4 Treatment of overdose  
For this study, any dose of UCB6114 >20% above the prescribed dose within a 24 -hour time 
period will be considered an overdose. Overdose events are  only considered AEs or SAEs if 
there are associated clinical signs and symptoms.  
No specific information is available on the treatment of overdose for UCB6114.  
UCB6114 will not be self -administered by [CONTACT_87755]. In the event of inadvertently 
administering an overdose of UCB6114, the investigator should:  
1. Contact [CONTACT_313602].  
2. Closely monitor the participant for any AE/SAE and laboratory abnormalities until UCB6114 
can no longer be detected syste mically (at least 28 days).  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 121 of 195 4. Document the quant ity of the excess dose as well as the duration of the overdose in the 
eCRF . 
Decisions regarding dose interruptions or modifications will be made by [CONTACT_313603].  
For this study, overdose of the SOC combination therapi[INVESTIGATOR_313528] B (TFD/TPI) and Part C 
(mFOLFOX6) refers to the administration of a quantity of medicinal product given per 
administration or per day that is above th e recommended dose according to the authorized 
product information. This shall also take into account cumulative effects due to overdose. Please 
refer to the respective product information or SmPC for overdose management information.  
9.5 Pharmacokinetics  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 122 of 195 Table  9-4: Blood collection time points for PK analysis for Part A  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 123 of 195 Table  9-4: Blood collection time points for PK analysis for Part A  
Table  9-5: Blood collection time points for PK analysis for Part A1  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 124 of 195 Table  9-6: Blood collection time points for PK analysis for  Part B and Part C  
9.6 Efficacy assessments  
Planned time points for all tertiary/exploratory antitumor activity assessments are provided in the 
Schedules of Activities for Part  A (Table  1-4), Part A1 (Table  1-5 and Table  1-6), Part  B 
(Table  1-7), and Part  C (Table  1-8). Primary, secondary, and tertia ry/exploratory antitumor 
activity assessments for Parts A1, D, E, F, and G will be described in a protocol amendment.  
9.6.1  Tumor assessments  
Tumor assessments will be performed as outlined in the Schedules of Activities for Part  A 
(Table  1-4), Part A1 ( Table  1-5 and Table  1-6), Part  B (Table  1-7), and Part  C (Table  1-8). The 
same imaging technique used to characterize each identified and reported lesio n at Baseline will 
be employed in subsequent tumor assessments.  
Screening tumor assessments must be performed within [ADDRESS_386035] dose of 
UCB6114, and include at a minimum a computed tomography (CT) or magnetic resonance 
imaging (MRI) scan of  the chest, abdomen, and pelvis (if relevant), and any other areas of 
known or suspected disease. A CT or MRI scan that is dated prior to consent for this study may 
be used as the Screening assessment, where this has been performed as per standard care or at the 
end of a prior research study  
Thereafter, tumor assessments of the chest, abdomen, and pelvis (if applicable) and any other 
areas of disease found at Screening, or newly suspected at follow -up, are to be performed 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_386036] and MRI. Further tests may be required for assessing bone 
lesions and they will be performed at the investigator’s discretion and per clinical practice.  
The method of tumor assessment should follow the RECIST (Version 1.1) criteria detailed in 
Appendix 9 (Section  11.9). If subcutaneous masses or nodes are palpable (eg, bulky) and are 
assessable by [CONTACT_313604], the radiographic (CT/M RI) technique 
should be used for the assessment of target and non -target lesions. Assessment is to be performed 
at the site by [CONTACT_82163] (radiologist and clinical investigator) and results 
are to be recorded in the eCRF.  
In the even t of CR or PR, the tumor assessment should be confirmed. The confirmation 
assessment is done at least 4 weeks after the response is recorded, typi[INVESTIGATOR_313529]. If bone lesion assessments are a part of the tumor assessme nt, the bone 
assessments should be repeated at the time of the confirmation scan.  
Any redacted scan data may be collected for verification/central reading.  
9.6.2  ECOG Performance Status  
Measures of ECOG Performance Status will be taken at visits outlined in the Schedules of 
Activities for Part  A (Table  1-4), Part A1 ( Table  1-5 and Table  1-6), Part  B (Table  1-7), and 
Part C (Table  1-8). ECOG Performance Status will be determined according to the tabl e 
provided in Appendix 8 (Section  11.8) 
9.7 Genetics  
Planned time points for all genetic assessments are provided in the Schedules of Activities for 
Part A (Table  1-4), Part A1 ( Table  1-5 and Table  1-6), Part  B (Table  1-7), and Part  C 
(Table  1-8). Genetic assessments for Parts A1, D, E, F, and G will be defined in a protocol 
amendment.  
Where local regulation and IEC allow, an 8.5mL blood sample for deoxyribonucleic acid (DNA) 
isolation will be collected from participants and may be used to perform genetic analysis to help 
understand a participant’ s response to UCB6114.  
See Appendix 5 (Section  11.5) for information regarding genetic research. Details on processes 
for collection and shipment of these samples can be found in the laboratory manual.  
9.8 Pharmacodynamics  
Planned time points for all tertiary/exploratory PD assessments are provided in the Schedules of 
Activities for Part  A (Table  1-4), Part A1 ( Table  1-5 and Table  1-6), Part  B (Table  1-7), and 
Part C (Table  1-8). All tertiary/exploratory PD assessments for Pa rts  D, E, F, and G will be 
defined in a protocol amendment.  
Blood samples for PD analysis will be collected at the time points discussed in the following 
sections.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 126 of 195 Blood samples of various volumes may be collected for analysis in a range of PD assays 
(Table  9-1). In Part A, the number of blood samples and total volume collected per cycle and at 
the SFU  Visit will be as follows:  
• In Cycle 1, up to 12 bloo d samples totaling approximately 83.5mL  
• In Cycle 2, up to 5 blood samples totaling approximately 35.5mL  
• In Cycle 3, up to 5 blood samples totaling approximately 35.5mL  
• In Cycle 4, up to 4 blood samples totaling approximately 15.5mL  
• At the SFU Visit, up to 5 blood samples totaling approximately 35.5mL  
In Part A1, the number of blood samples and total volume collected per cycle and at the SFU 
Visit will be as follows:  
• In Screening, up to 4 blood samples totaling approximately 36 mL in each Cohort  
• Cycle 1, up to 7 blood samples totaling approximately 43.5mL in Cohorts 1, 2, 4 and up to 4 
blood samples totaling approximately 16mL in Cohort 3  
• In Cycle 2, up to 4 blood samples totaling approximately 31.5mL in each Cohort  
• In Cycle 3 up to 5 blood samples totaling approximately 35.5mL in each Cohort  
• From Cycle 4 onwards and at the SFU Visit up to 4 blood samples totaling approximately 
31.5mL in each Cohort  
One additional sample for circulating gremlin -1 (4mL) may be taken on the day of the on -
treatment biopsy if tak ing place on a day where no circulating gremlin -1 sample is scheduled.  
In Parts B and C, the number of blood samples and total volume collected per cycle and at the 
SFU Visit will be as follows:  
• In Screening, up to 3 blood samples totaling approximately 32 .5mL  
• In Cycle 1, up to 4 blood samples totaling approximately 32mL  
• In Cycle 2, up to 6 blood samples totaling approximately 56mL  
• From Cycle 3 onwards, up to 3 blood samples totaling approximately 28mL  
• At the SFU Visit, up to 3 blood samples totaling approx imately 28mL  
Tumor biopsies will also be collected during the study (see Section  9.8.7 ). 
9.8.1  Blood samples for circulating gremlin -1 
Whole blood samples of  approximately 4mL per time point will be collected and processed to 
serum  for measurement of total circulating gremlin -1 levels. Sampling time points throughout 
the study are outlined in the Schedules of Activities for Part  A (Table  1-4), Part A1 ( Table  1-5 
and Table  1-6), Part  B (Table  1-7), and Part  C (Table  1-8). Sampling collection times relative to 
dosing are detailed in Table  9-7 (Part A), in Table  9-8 (Part A1) and Table  9-9 (Part B and 
Part C). 
Instructions pertaining to sample collection, processing, storage, labeling, and shippi[INVESTIGATOR_313530].  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 127 of 195 Table  9-7: Sample time points for serum gremlin -1 analysis in Part A  
Cycle  Day Sampling time relative to dosing  Sampling time  
Cycle 1  Day 1  Baseline  Predose  
Day 2  +24h  Postdose on Cycle 1 
Day 1  
Day 15  Within 0.5h prior to dosing  Predose  
Subsequent cycles (up 
to and including 
Cycle  4) Day 1  Within 0.5h prior to dosing  Predose  
SFU Visit  On day of visit  On day of visit  NA 
h=hour; NA=not applicable; SFU=Safety Follow -Up 
Note: The time window for blood sample collection at the 24h PD time point postdose (Cycle Day 2) is ± 0.5h.  
Table  9-8: Sample time points for serum gremlin -1 analysis in Part A1  
Cyclea Day Sampling time relative to dosing  Sampling time  
Cycle 1  Day 1  Baseline  Predose  
Day 1  End of infusion (+15min)  Postdose  
Day 1  +4h (+1h)  Postdose  
Day 15b Within 0.5h prior to dosing/day of 
visit Predose/NA  
Cycle 2  Day 1  Within 0.5h prior to dosing  Predose  
Cycle 3  Day 1  Within 0.5h prior to dosing  Predose  
Day 1  +4h (+1h)  Postdose  
Cycle 4 onwards  Day 1  Baseline  Predose  
SFU Visit  On day of visit  On day of visit  NA 
a An additional sample should also be collected on the day of the on -treatment biopsy (only if taking place on a day 
where no serum gremlin -1 samples are scheduled)  
b Predose for a 2 -weekly cycle (Cohorts 1 and 2) but on day of visit for a 3 -weekly or a 4 -weekly cycle (Cohorts 3 
and 4)  
h=hour; NA=not applicable; SFU=Safety Follow -Up  
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 128 of 195 Table  9-9: Sample time points for serum gremlin -1 analysis in Part B and 
Part C 
Cycle  Day Sampling time relative to 
dosing with UCB6114  Sampling time  
Screening  Once between 
Day -28 and -1 NA NA 
Cycle 1  Day 15  Within 0.5h prior to dosing  Predose  
Cycle 2  Day 1  Within 0.5h prior to dosing  Predose  
Day 15  Within 0.5h prior to dosing  Predose  
Cycle 3 (onward)a Day 1  Within 0.5h prior to dosing  Predose  
SFU Visit  On day of visit  On day of visit  NA 
h=hour; NA=not applicable; SFU=Safety Follow -Up 
a To be completed in cycle 3 and thereafter in even cycles only (ie, Cycle 4, 6)  
9.8.2  Blood samples for serum protein analysis and blood transcriptomics  
In Part A and Part A1, whole blood samples of approximately 5mL per time point will be 
collected and processed to serum for analysis of protein markers. An additional whole blood 
sample of 2.5mL per time point may also be collected for potential transcriptomic analysis. 
Samples for analysis of protein markers or potential transcriptomic anal ysis will not be obtained 
in Part B or Part C.  
Sampling time points for these assays are detailed in Table  9-10 (Part A) and Table  9-11 
(PartA1) . 
Instructions pertaining to sample collection, processing, storage, labeling, and shippi[INVESTIGATOR_313530].  
Table  9-10: Sample time points for serum protein analysis and blood 
transcriptomics in Part A  
Cycle  Day Sampling time relative to 
dosing  Sampling time  
Cycle 1  Day 1  Baseline  Predose  
Day 15 Within 0.5h prior to dosing  Predose  
Subsequent cycles (up 
to and including 
Cycle  4) Day 1  Within 0.5h prior to dosing  Predose  
SFU Visit  On day of visit  On day of visit  NA 
h=hour; NA=not applicable; SFU=Safety Follow -Up 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 129 of 195 Table  9-11: Sample time points for serum protein analysis and blood 
transcriptomics in Part A1  
Cycle  Day Sampling time relative to dosing  Sampling time  
2-weekly and 4 -weekly cycles (Cohorts 1, 2 and 4)  
Screening  Day-14 to -1 Baseline   
Cycle 1  Day 15  Within 0.5h prior to dosing 
(Cohorts 1 and 2)/on day of visit 
(Cohort 4)  Predose(Cohorts 1 and 2)/ 
NA (Cohort 4)  
Subsequent cycles  Day 1  Within 0.5h prior to dosing  Predose  
SFU Visit  On day of 
visit On day of visit  NA 
3-weekly cycles (Cohort 3)  
Screening  Day-14 to -1 Baseline   
Cycle 2 onwards  Day 1  Within 0.5h prior to dosing  Predose  
SFU Visit  On day of 
visit On day of visit  NA 
h=hour; NA=not applicable; SFU=Safety Follow -Up 
 
9.8.3  Blood samples for circulating tumor DNA analysis  
Whole blood samples of approximately 20mL per time point will be collected and processed for 
analysis of circulating tumor DNA (ctDNA).  
Sampling time points are detailed in Table  9-12 (Part A), Table  9-13 (Part A1) and Table  9-14 
(Part B and Part C).  
Instructions pertaining to sample collection, processing, storage, labeling, and shippi[INVESTIGATOR_313530].  
Table  9-12: Sample time points for ctDNA analysis in Part A  
Cycle  Day Sampling time relative to 
dosing  Sampling time  
Cycle 1  Day 1  Baseline  Predose  
Day 15  Within 0.5h prior to dosing  Predose  
Subsequent cycles (up 
to and including 
Cycle  3) Day 1  Within 0.5h prior to dosing  Predose  
SFU Visit  On day of visit  On day of visit  NA 
ctDNA=circulating tumor DNA; h=hour; NA=not applicable; SFU=Safety Follow -Up 
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 130 of 195 Table  9-13: Sample time points for ctDNA analysis in Part A1  
Cycle  Day Sampling time relative to 
dosing  Sampling time  
2-weekly and 4 -weekly cycles (Cohorts 1, 2 and 4)  
Screening  Day-14 to -1 Baseline   
Cycle 1  Day 15  Within 0.5h prior to dosing 
(Cohorts 1 and 2)/on day of visit 
(Cohort 4)  Predose(Cohorts 1 
and 2)/ NA (Cohort 
4) 
Subsequent cycles  Day 1  Within 0.5h prior to dosing  Predose  
SFU Visit  On day of visit  On day of visit  NA 
3-weekly cycles (Cohort 3)  
Screening  Day-14 to -1 Baseline   
Cycle 2 onwards  Day 1  Within 0.5h prior to dosing  Predose  
SFU Visit  On day of visit  On day of visit  NA 
h=hour; NA=not applicable; SFU=Safety Follow -Up 
 
Table  9-14: Sample time points for ctDNA analysis in Part B and Part C  
Cycle  Day Sampling time relative to 
dosing with UCB6114  Sampling time  
Screening  Once between 
Day -28 and -1 NA NA 
Cycle 1  Day 15  Within 0.5h prior to dosing  Predose  
Cycle 2  Day 1  Within 0.5h prior to dosing  Predose  
Day 15  Within 0.5h prior to dosing  Predose  
Cycle  3 (onward)  Day 1  Within 0.5h prior to dosing  Predose  
SFU Visit  On day of visit  On day of visit  NA 
ctDNA=circulating tumor DNA; h=hour; NA=not applicable; SFU=Safety Follow -Up 
9.8.4  Blood samples for s erum bone turnover markers  
In Parts A, B, and C, whole blood samples of approximately 4mL per time point will be collected 
and processed to ser um for analysis of circulating markers of bone turnover. Sampling time 
points throughout the study are outlined in the Schedules of Activities for Part  A (Table  1-4), 
Part B (Table  1-7), and Part  C (Table  1-8).  
Sampling collection time points relative to dosing are detailed for Part A in Table  9-15 and for 
Parts B and C in Table  9-16. 
Instructions pertaining to sample collection processing, storage, labeling, and shippi[INVESTIGATOR_313531].  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 131 of 195 Table  9-15: Blood samples for serum bone turnover markers in Part A  
Cycle  Day Sampling time relative to 
dosing  Sampling time  
Cycle 1  Day 1  Baseline  Predose  
Day 15  Within 0.5h prior to dosing  Predose  
Subsequent cycles (up 
to and including 
Cycle  4) Day 1  Within 0.5h prior to dosing  Predose  
SFU Visit  On day of visit  On day of visit  NA 
h=hour; NA=not applicable; SFU=Safety Follow -Up 
Table  9-16: Blood samples for serum bone turnover markers in Parts B and C  
Cycle  Day Sampling time relative to 
dosing with UCB6114  Sampling time  
Cycle 1  Day 1  Baseline  Predose  
Day 15  Within 0.5h prior to dosing  Predose  
Cycle 2  Day 1  Within 0.5h prior to dosing  Predose  
Day 15  Within 0.5h prior to dosing  Predose  
Subsequent cycles 
(from cycle 3 onwards)  Day 1  Within 0.5h prior to dosing  Predose  
SFU Visit  On day of visit  On day of visit  NA 
h=hour; NA=not applicable; SFU=Safety Follow -Up 
9.8.5  Urine samples for urinary bone turnover markers  
In Parts A, B, and C, urine samples of approximately 30mL per time point will be collected for 
analysis of urinary markers of bone turnover. Sampling time points throughout the study are 
outlined in the Schedules of Activities for Part  A (Table  1-4), Part  B (Table  1-7), and Part  C 
(Table  1-8). 
Sampling collection times relative to dosing are detailed for Part A in Table  9-17 and for Parts B 
and C in Table  9-18. 
Instructions pertaining to sample collection processing, storage, labeling, and shippi[INVESTIGATOR_313530].  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 132 of 195 Table  9-17: Urine samples for urinary bone turnover markers in Part A  
Cycle  Day Sampling time  relative to 
dosing  Sampling time  
Cycle 1  Day 1  Baseline  Predose  
Day 15  Within 0.5h prior to dosing  Predose  
Subsequent cycles (up 
to and including 
Cycle  4) Day 1  Within 0.5h prior to dosing  Predose  
SFU Visit  On day of visit  On day of visit  NA 
h=hour;  NA=not applicable; SFU=Safety Follow -Up 
Table  9-18: Urine samples for urinary bone turnover markers in Parts B and C  
Cycle  Day Sampling time relative to 
dosing with UCB61 14 Sampling time  
Cycle 1  Day 1  Baseline  Predose  
Day 15  Within 0.5h prior to dosing  Predose  
Cycle 2  Day 1  Within 0.5h prior to dosing  Predose  
Day 15  Within 0.5h prior to dosing  Predose  
Subsequent cycles 
(from cycle 3 onwards)  Day 1  Within 0.5h prior to dosing  Predose  
SFU Visit  On day of visit  On day of visit  NA 
h=hour; NA=not applicable; SFU=Safety Follow -Up 
9.8.6  Blood samples for genetic analysis  
An 8.5mL blood sample will be taken predose Cycle 1 Day 1 (Part A) or at Screening (Part A1, 
Part B and Part C) for genetic analysis as described in Section  9.7. 
Instructions pertaining to sample collection, processing, storage, labeling, and shippi[INVESTIGATOR_313532]. A description of genetic analyses performed in 
this study is provided in Appendix 5 (Section  11.5). 
9.8.[ADDRESS_386037] given informed consent, 
biopsies may be performed unless tissue collection carries a high risk of mortality or is ot herwise 
contraindicated (to be determined at the discretion of the investigator).  
• During Part  A, these biopsies will be optional and collected at Screening and on Day 22.  
• During Part A1, these biopsies will be mandatory and collected at the following tim e points:  
− After eligibility assessment and before study drug administration (Baseline) between 
Day-28 and Day -1. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 133 of 195 − Within  [ADDRESS_386038] Cycle 1 Day 15 for 2 - or 4- weekly dosing schedule (ie, between 
Cycle 1 Day 15 and Cycle 2 Day 1 for Cohorts 1, 2 and 4) and within [ADDRESS_386039] 
Cycle  2 Day 1 for a 3 -weekly dosing schedule (ie, between Cycle 2 Day 1 and Cycle 2 
Day 15 for Cohort 3).  
Note: An additional blood sample each for PK and cGremlin -1 should be collected on the 
day of biopsy but only in cases where s amples for these endpoints are not already 
scheduled to be taken on the Day.  
In addition, if a historical tumor biopsy specimen had been obtained prior to the study 
participant’s entry into the study (eg, time of diagnosis), permission will be requested at  the 
time of informed consent to use the biopsy for PD analysis.  
• Tumor biopsies will not be obtained in Part B or Part C.  
Biopsies will be performed according to standard clinical practice for the participant’s indication 
and will be collected as outlined in the Schedules of Activities for Part  A and Part A1 
(Section  1.3). 
Biopsy samples may be processed to RNA and/or formalin fixed and paraffin embed ded. 
Ribonucleic acid samples may be used for transcriptomic analysis. Formalin -fixed and 
paraffin -embedded tissue may be used for transcriptomic analysis, immunohistochemistry, 
and/or protein expression analysis.  
Excess tumor samples that remain after PD assessments have been performed may be retained 
while research on UCB6114 or study medications of this class continues, but no longer than 
20 years (or other period according to local regulations). Tumor samples may be analyzed for 
additional biomarkers sp ecifically related to the mechanism of action of UCB6114 or cancer 
biology as warranted by [CONTACT_313605].  
Biopsy procedure in Part A1  
The most suitable lesion(s) to be biopsied should discussed between  the oncologist, radiologist, 
and/or colleague performing biopsy of cutaneous metastases or endoscopic biopsy, as 
appropriate.  
Tumor biopsies are mandatory, however biopsies are to be performed, and the potentially 
required local anesthesia administered, only if considered to be of low risk to the participant, as 
determined by [CONTACT_313606].  
It is preferred that up to 5 cores per biopsy, 18 -gauge in diameter and ≥1cm in length will be 
obtained duri ng each procedure, if considered safe and feasible. A single baseline biopsy core 
transferred to neutral buffered formalin  (NBF) will constitute a successful biopsy. If an initial 
attempt at a biopsy is unsuccessful, the patient will be given an option to proceed with a repeated 
attempt. If the baseline biopsy remains unsuccessful no further biopsies will be performed but 
the patient may remain on the study and receive study medication.  
If the study participant chooses not to undergo biopsies subsequent to  the baseline biopsy, he/she 
will be withdrawn from the study. Feasibility for the subsequent biopsies will be assessed by [CONTACT_3786]/the health care professional performing the biopsy and should include a 
consideration of patient safety. If the subs equent biopsy is deemed to be unsafe and/or not 
feasible , the study participant may remain on study and receive study medication.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_386040] scan, or MRI. Should a C T scan be needed for 
biopsy, the number of scans for each procedure will be limited to the minimum number and 
duration required to safely obtain the biopsy.  
Instructions pertaining to sample collection, processing, storage, labeling, and shippi[INVESTIGATOR_313533].  
9.8.8  Historical tumor samples  
If available, samples from study participants’ stored historical tumor biopsy specimen from the 
time of diagnosis or subsequent surgery may be sent to the analyzing laboratory. These samples  
will be analyzed for transcriptional and/or protein expression and the results may be compared 
with those obtained from the on -study biopsies where available.  
9.9 Biomarkers  
Collection of samples for other biomarker research is also part of this study and is described in 
Section  9.8. 
Planned tertiary/exploratory biomarker assessments for Parts D, E, F, and G will be defined in a 
protocol amendment.  
9.10 Immunoge nicity  
Antibodies to UCB6114 will be evaluated in serum samples collected from all participants 
according to the Schedules of Activities for Part  A (Table  1-4), Part A1 ( Table  1-5 and 
Table  1-6), Part B (Table  1-7), and Part  C (Table  1-8). On dosing days, these samples will be 
collected predose. These s amples will be tested by [CONTACT_115000] ’s designee.  All 
tertiary/exploratory ADA assessments for Parts D, E, F, and G will be described in a protocol 
amendment.  
Serum samples will be screened for antibodies binding to UCB6114 and the titer of confi rmed 
positive samples will be reported.  
The detection and characterization of antibodies to UCB6114  will be performed using validated 
assays by [CONTACT_23788].  
In Part A, a total of [ADDRESS_386041] cycle of treatment, for a total of 15mL ( Table 9-19). One sample of 5mL of blood will be 
collected for ADA analysis during C ycles 2, 3, and 4. If a participant continues on study beyond 
Cycle 4, an additional 5mL blood sample for ADA analysis (with concomitant sample for PK 
analysis) will be collected every 3  months (Cycle 7, Cycle 10, etc). An additional 5mL blood 
sample for A DA will be taken at the SFU Visit.  
In Part A1, [ADDRESS_386042] 
3 cycles (Cycles 1 to 3) and on Day [ADDRESS_386043] cycles thereafter (ie, Cycle 6, Cycle 9; 
Table  9-20). An additional 5mL blood sample for ADA will also be taken at the SFU Visit.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 135 of 195 In Part B and Part C, 1 sample of 5mL of blood will be collected for ADA analysis during 
Cycle  1 and Cycle 2 ( Table  9-21). From Cycle 3 onwards, an additional 5mL sample for ADA 
analysis (concomitant to a sample for PK analysis) will be collected in even -numbered cyc les 
only (Cycle 4, Cycle 6, etc). An additional 5mL blood sample for ADA will also be taken at the 
SFU Visit.  
Instructions pertaining to sample collection, processing, storage, labeling, and shippi[INVESTIGATOR_313530].  
Table 9-19: Blood sample time points for ADA analysis in Part A  
Cycle  Day Sampling time relative to 
dosing  Sampling time  
Cycle 1  Day 1  Baseline  Predose  
Day 15  Within 0.5h prior to dosing  Predose  
Day 22  On day of visit (taken at same 
time ±5min as PK sample is 
collected)  On day of visit  
Cycle 2  Day 1  Within 0.5h prior to dosing  Predose  
Cycle 3  Day 1  Within 0.5h prior to dosing  Predose  
Cycle 4  Day 1  Within 0.5h prior to dosing  Predose  
Cycle 7 (onward)  Every 3 months  Within 0.5h prior to dosing  Predose  
SFU Visit   On day of visit  On day of visit  NA 
ADA=antidrug antibody; h=hour; NA=not applicable; SFU=Safety Follow -up  
Table  9-20: Blood sample time points for ADA analysis in Part A1  
Cycle  Day Sampling time relative to 
dosing  with UCB6114  Sampling time  
Cycle 1  Day 1  Baseline  Predose  
Cycle 2  Day 1  Within 0.5h prior to dosing  Predose  
Cycle 3a onwards  Day 1  Within 0.5h prior to dosing  Predose  
SFU Visit   On day of visit  NA On day of visit  
ADA=antidrug antibody; h=hour; NA=not applicable; SFU=Safety Follow -Up 
a Cycle [ADDRESS_386044] cycle thereafter (ie, Cycle 6, Cycle 9 etc.)  
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 136 of 195 Table  9-21: Blood sample time points for ADA analysis in Part B and Part C  
Cycle  Day Sampling time relative to 
dosing  with UCB6114  Sampling time  
Cycle 1  Day 1  Baseline  Predose  
Cycle 2  Day 1  Within 0.5h prior to dosing  Predose  
Cycle 3 (onward)a Day 1  Within 0.5h prior to dosing  Predose  
SFU Visit   On day of visit  NA On day of visit  
ADA=antidrug antibody; h=hour; NA=not applicable;  SFU=Safety Follow -Up 
a To be completed in cycle 3 and thereafter in even cycles only (i.e., Cycle 4, 6) .  
10 STATISTICAL CONSIDER ATIONS  
A description of statistical methods follows and further details will be included in the Statistical 
Analysis Plan for each module.  
10.1 Definition of analysis sets  
Enrolled Set  
The Enrolled Set (ES) consists of all study participants who sign the Informed Consent Form.  
Safety Set  
The Safety Set (SS) will be used primarily for the analysis of safety data and will consist of all  
study participants who receive 1 or more full or partial doses of any study treatment.  
Per-protocol Set  
The Per -protocol Set (PPS) will include all study participants in the SS who do not have 
important protocol deviations that may substantially affect an titumor activity. The PPS will be 
the primary analysis set for the analysis of the exploratory antitumor activity endpoints.  
Pharmacokinetic Set  
The Pharmacokinetic Set (PKS) will include all study participants in the SS who have at least 
1 evaluable PK c oncentration (ie, a sample which is above the lower limit of quantitation and for 
which the date and time of the sample and prior date and time of dosing are known). Additional 
participants or specific samples may be excluded from the PKS at the discretion  of the Advanced 
Modeling and Simulation Scientist/Quantitative Clinical Pharmacology scientist.  
Pharmacokinetic analysis will be performed on the PKS.  
ADA Set  
The ADA Set (ADAS) will include all study participants in the SS who have at least 1 evaluable 
ADA assessment.  
Immunogenicity analyses will be performed on the ADAS.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 137 of 195 Pharmacodynamic Set  
The Pharmacodynamic Set (PDS) will include all study participants in the SS who have at least 
1 evaluable PD assessment (where appropriate, the sample should be abov e the lower limit of 
quantitation and the date and time of the sample should be known).  
Pharmacodynamic analysis will be performed on the PDS.  
DLT Evaluable Set  
The DLT Evaluable Set (DES) will include all study participants who, during the DLT 
assessment period:  
• Receive the planned dose of UCB6114 (Part A and Part A1)  
• Receive the planned dose of UCB6114 and at least 80% of the planned dose of TFD/TPI 
(Part  B)  
• Receive the planned dose of UCB6114 and at least 80% of the planned dose of mFOLFOX6 
(Part  C) 
• Stopped treatment because of a DLT (any part of the study)  
The DES will be used by [CONTACT_313607]/de -escalation decision making.  
10.2 General statistical considerations  
All analyses will be performed using SAS® Version 9.2 or higher (SAS Institut e, Cary, NC, US).  
Descriptive statistics will be used to provide an overview of the Baseline, safety, PK, PD, and 
other exploratory results. For categorical and ordinal variables, the number and percentage of 
participants in each category will be presente d. The denominator for the percentages will be 
based on the number of participants appropriate for the purpose of analysis. Unless otherwise 
noted, all percentages will be expressed to [ADDRESS_386045] deviation, minimum, and maximum.  
Definitions of Baseline for each variable, as applicable, will be included in the SAPs for each 
module.  
No formal hypothesis testing will be performed in Part A, Part A1, Part  B or Part  C. 
10.3 Planned safety and other analyses  
10.3.1  Safety analyses  
Safety will be assessed by [CONTACT_313608], SAEs, 
laboratory values, vital signs, echocardiograms, ECG results and physical examination. Eastern 
Cooperative Oncology Group performance status will also be assessed from a safety perspective. 
Unless specified otherwise, the safety analyses will be conducted for the SS defined in 
Section  10.1. The results of these analyses will be presented by [CONTACT_16051]. For the dose 
escalation modules of the study (Part  A, B, and C) tabulations will be provided by [CONTACT_313609]. For the dose optimization module of the study (Part  A1) tabulations will be provided by 
[CONTACT_13153]. For the expansion modules (Parts D, E, F, and G), tabulations will be 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_386046] dose of study treatment will also be counted as a 
TEAE. The reported AE term will be assigned a standardized preferred term using the current 
version of the Medical Dictionary for Regulatory Activities (MedDRA).  
The causal relationship between the occurrence of an AE and study medication will be judged by 
[CONTACT_093]. In the event that a participant experiences repeat epi[INVESTIGATOR_159389], then 
the event with the highest CTC AE severity grade and strongest causal relationship to study 
medication will be used for purposes of incidence tabulations.  
An overview of the number and percentage of participants who experience TEAEs will be 
presented. This summary will include the numbe r and percentage of participants with any 
TEAEs, serious TEAEs, related TEAEs (related to UCB6114, TFD/TPI [Part B], any individual 
component of mFOLFOX6 [Part C], or more than 1 of the treatments [Part B and Part C]), 
discontinuation due to TEAEs, CTCAE G rade 3 or 4 TEAEs, DLTs, AEs leading to death, and 
TEAEs leading to death; event counts will also be included against each of these categories.  
In addition, the following summaries will be presented by [CONTACT_7204], High 
Level Term and Preferr ed Term:  
• Incidence of all TEAEs, serious TEAEs, and non -serious TEAEs  
• Incidence of TEAEs by [CONTACT_313610]  
• Incidence of TEAEs leading to a temporary interruption and/or reduction in study treatment  
• Incidence of TEAEs leading to discontinuation of study treatment  
• Incidence of fatal TEAEs by [CONTACT_2073]  
• Incidence of adverse events of special interest (AESIs) (Hy’s Law – see Section  9.2.6 ) 
• Incidence of infusion -related (hypersensitivity) reactions  
For the dose escalation and optimization modules, the observed DLT rate in each dose cohort 
will be calculated by [CONTACT_313611]. Mul tiple 
concurrent AEs leading to DLT will be considered a single DLT.  
Deaths that occur on study (defined as during treatment or within 30 days of treatment 
discontinuation) will be reported in a participant listing, which will include the primary cause of 
death and the number of days between the date of the final dose of study medication and death.  
Observed values and changes from Baseline in clinical chemistry, hematology, urinalysis, and 
coagulation parameters will be summarized at each visit. In addition , for each of these 
parameters, the Baseline value, the minimum, maximum, average, and last post -Baseline value 
for each participant will be summarized by [CONTACT_313612]. These post -Baseline 
summary measures will be calculated based on laboratory assessments performed at the 
scheduled time points common to all cycles of study treatment.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 139 of 195 Laboratory values will be assigned severity grades when available using the NCI CTCAE 
criteria. Directional shifts in laboratory toxicity grades (compar ing Baseline grade with worst 
post-Baseline grade) will be analyzed using standard shift tables, presenting the number and 
proportion of participants and their maximum grade shift. For analytes without a CTCAE 
severity grade assigned, the shift table will present directional shifts from Baseline to above or 
below the laboratory standard normal range using the maximum increase and/or decrease 
observed throughout the course of treatment/observation.  
In addition, serial vital signs measurements will be obtaine d during participant’s UCB6114 
treatment and postdose (per the Schedules of Activities for Part  A [Table  1-4], Part A1 
[Table  1-5 and Table  1-6], Part B [Table  1-7], and Part  C [Table  1-8]). On the first day of each 
particip ant’s UCB6114 treatment, vital signs will be taken in conjunction with serial PK 
sampling. For each participant, the vital signs change from the predose value will be summarized 
in a descriptive manner.  
In Part  A, vital signs will be measured at multiple time points on treatment days (predose, 10min 
and 30min after the start of the infusion, at the end of infusion, and at 1 hour after the end of the 
infusion). In addition, on Cycle 1 Day 1, vital signs will also be assessed at 2 hours and 8 hours 
after the  end of the infusion. On non -dosing visits, vital signs will be measured prior to PK 
sampling.  
In Part A1, vital signs will be measured at multiple time points on treatment day (predose, 
10 minutes and 30  minutes after the start of the infusion, at the end  of the infusion and 2 hours 
after the end of the infusion. In addition, on Cycle 1 Day 1, vital signs will also be assessed at 5 
hours after the end of the infusion.  
In Part  B and Part  C, on Day 1 of Cycle 1, vital signs will be measured at multiple time  points 
(per the Schedules of Activities for Part  B [Table  1-7], and Part  C [Table  1-8]). At all other 
scheduled visits (Day 8, 15, and 22 of Cycle 1 and  Days 1 and 15 of all subsequent cycles of 
study treatment), vital signs will be measured prior to UCB6114 dosing on treatment days.  
Observed vital sign measurements and changes from Baseline will be summarized by [CONTACT_313613]. In addition, for each of the vital signs, the Baseline value, 
the minimum, maximum, average and last post -Baseline value for each participant will be 
summarized by [CONTACT_313612]. These post -Baseline summary measures will be 
calculated based on vital sign measurements performed at the scheduled time points common to 
all cycles of study treatment.  
For the multiple vital sign measurements on Day 1 of Cycle 1, changes from the predose value 
will be calculated at each postdose time point and summarized using descriptive statistics.  
In Part  A, on Days 1 and 15 of Cycle 1, ECGs will be performed at multiple time points relative 
to the dose of study treatment (predose, end of infusion, and [ADDRESS_386047] ing). At all other dosing visits (Days 1 and 15 of all subsequent cycles of study 
treatment), ECGs will be performed predose. On non -dosing visits, ECGs will be performed 
prior to PK sampling.  
In Part A1, ECGs will be performed at Screening; during Cycle 1  prior to dosing, at the end of 
the infusion, and 2 hours after the end of infusion; during each subsequent cycle prior to dosing 
with UCB6114 on Day 1.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 140 of 195 In Part  B and Part  C, on Days 1 and 15 of Cycle 1, ECGs will be performed at multiple time 
points relative to dosing with UCB6114 (predose, end of infusion, and [ADDRESS_386048] end of 
infusion prior to PK sampling). At all other UCB6114 dosing visits, ECGs wi ll be performed 
prior to dosing with any study medication and as per Schedule of Activities.  
Observed values and changes from Baseline for these ECG parameters will be listed and 
summarized by [CONTACT_16750]. The mean of the triplicate  measurements taken 
for each parameter will be used in the summary. In addition, for each of the ECG parameters, the 
Baseline value, the minimum, maximum, average and last post -Baseline value for each 
participant will be summarized by [CONTACT_313614]. These post -Baseline 
summary measures will be calculated based on ECG measurements performed at the scheduled 
time points common to all cycles of study treatment.  
All summaries and listings of ECG data will be based on the local (site) 12 -lead ECG 
measurements.  
Electrocardiograms will also be collected for central reading, the data from which will be 
analyzed and reported separately.  
Physical examination data will be listed only.  
Prior and concomitant medications will be coded to the generic term using the current version of 
the World Health Organization Drug Dictionary and will be tabulated by [CONTACT_313615].  
10.3.2  Analysis of Baseline and Demographic Variables  
Descriptive summaries of demographic and Baseline characteristics for  participants in the SS 
will be presented. For the dose escalation modules (Parts A, B and C) and the dose optimization 
module (Part  A1), Baseline and demographic data will be tabulated by [CONTACT_13153]. For 
Part B and Part  C, summaries may be present ed by [CONTACT_313616]. For the expansion modules (Parts D, E, F and G), 
participants will be tabulated by [CONTACT_178946].  
10.3.3  Other analyses  
[IP_ADDRESS]  Analysis of PK endpoints  
UCB6114 concentrations in  blood will be listed for the SS and summarized descriptively for the 
PKS at each scheduled assessment by [CONTACT_15994]. Where possible, key and other PK parameters 
will be determined after single and multiple doses using noncompartmental analysis and will al so 
be summarized descriptively. Key and other PK parameters are described in Table  10-1 and will 
be calculated where possible.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 141 of 195 Table  10-1: Pharmacokinetic parameters  
[IP_ADDRESS].1  Dose dependency  
The dose -dependency of PK parameters may be assessed.  
[IP_ADDRESS].2  Population PK  
The PK of UCB6114 administered as monotherapy in Part A and Part A1 may be assessed using 
a population analysis approach.  
[IP_ADDRESS]  Analysis of gen etic endpoints  
Possible relationships between variations in DNA sequence and the PD effects of UCB6114 will 
be explored using summary statistics and graphs.  
The analysis method and results for all genetic analysis will be reported separately to the main 
clinical study report.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 142 of 195 [IP_ADDRESS]  Analysis of PD endpoints  
The PD variables from blood samples and optional tumor samples will be summarized 
descriptively by [CONTACT_105975], dose level/schedule, treatment cycle, and overall. The relationship 
of PD variables with the tumor  response to UCB6114 will be explored using summary statistics 
and graphs.  
The analysis methods and results for all PD variables will be reported separately to the main 
clinical study report.  
[IP_ADDRESS]  Analysis of biomarker endpoints  
Biomarkers examined in this study will be analyzed as described in Section  [IP_ADDRESS] . 
[IP_ADDRESS]  Analysis of immunologic endpoints  
The ADA antibody status from the samples, participant classification according to ADA 
antibody status, changes from Baseline in titer over time, and the incidence of treatment -
emergent ADA positivity will be summarized by [CONTACT_11191]. Potential relationships between 
ADA and PK, PD, antitumor activity, and safety will also be explored.  
Hypersensitivity reactions are referenced in Section  10.3.1 .  
10.4 Planned ef ficacy/outcome analyses  
10.4.1  Analysis of antitumor activity/outcome endpoint  
The analysis of the primary antitumor activity/outcome endpoint in the expansion modules (Parts 
D, E, F, and G) will be the same as the analysis of the exploratory antitumor activity/o utcome 
endpoints in the dose escalation modules and will be further described, as applicable, in a 
planned protocol amendment.  
[IP_ADDRESS]  Antitumor activity  endpoint definitions  
The following are definitions of the antitumor activity  endpoints:  
Objective response rate (ORR) is defined as the percentage of participants with a best overall 
response (BOR) of complete response (CR) or partial response (PR).  
Disease control rate (DCR) is defined as the percentage of participants with a BOR of CR, PR, or 
SD. 
Best overall  response is defined for each study participant as the best overall tumor response 
designation, as determined by [CONTACT_313617], recorded 
between the first dosing date and the date of documented disease progression o r the date of 
subsequent anticancer therapy (systemic medication, surgery, or radiotherapy for cancer), 
whichever occurs first. Complete response or PR determinations included in the BOR assessment 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_386049] be confirmed by a second scan ≥[ADDRESS_386050] met the criteria for stable disease 
(SD)at least once after the start of study treatment at a minimum interval of no less than 6 to 8 
weeks. Table C in Section  11.9 (Appendix  9) provides the derivation of BOR when confirmation 
of CR and PR responses are required.  
Duration of response (DOR)  will be calculated for participants who achieve a CR or a PR and 
is defined as the time in days from the start date of the response to the first date that recurrent or 
progressive disease is objectively documented. For participants who die without objective 
disease progression, DOR will be censored on the date of death, regardless of cause. For 
participants who discontinue early without documented objective progressive disease, DOR will 
be censored at the date of their last available (scheduled or unscheduled) tumor assessment at  
which a lack of objective disease progression was determined. A sensitivity analysis will be 
performed taking into account both objective progressive disease and clinical disease 
progression, as determined by [CONTACT_093], in the calculation of DOR.  
Progression -free survival (PFS)  is defined as the time in days from first dosing date to the date 
of the first documented objective disease progression or death due to any cause, whichever 
occurs first. Participants who died without a documented objective d isease progression will be 
considered to have progressed on the date of their death. Participants who did not progress or die 
will be censored on the date of their last available (scheduled or unscheduled) tumor assessment. 
Participants who did not have an y on-study tumor assessments and did not die will be censored 
on the date of their first dose of study treatment. Participants who discontinued early without 
documented objective disease progression or death will be censored on the date of their last 
avail able (scheduled or unscheduled) tumor assessment at which a lack of objective disease 
progression was determined. Participants who started anti -cancer therapy without a prior 
documented objective disease progression will be censored on the date of their la st available 
(scheduled or unscheduled) tumor assessment prior to the initiation of the subsequent anti -cancer 
therapy. A sensitivity analysis will be performed taking into account both objective progressive 
disease and clinical disease progression, as det ermined by [CONTACT_093], in the calculation of 
PFS.  
Overall Survival (OS)  is defined for all participants in the study as the time in days from the 
date of first dosing to the date of death from any cause. Participants will be followed up to 
ascertain their survival status at the SFU Visit (within 30 days after their final dose of study 
treatment) and at the Final Visit (3 months after their final dose of study treatment); they will not 
be followed up beyond this time point. For participants who discont inued early from the study or 
discontinued study treatment due to disease progression and were not known to have died, OS 
will be censored on the date of last contact.  
[IP_ADDRESS]  Analysis of the antitumor activity  endpoints  
Unless specified otherwise, the antitumor a ctivity analyses will be conducted using the PPS with 
sensitivity analyses conducted using the SS (see Section  10.1). The results of these analyses wi ll 
be presented for each study part.  
Tumor response data, as determined using RECIST criteria, will be tabulated. Tabulations will 
be presented by [CONTACT_313618].  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 144 of 195 Exploratory analyses of selected antitumor activity endpoints may be performed based on 
subgroups of participants in the SS. Data permitting, the subgroups will be defined based on 
participant, disease, and treatment history information (eg, extent of prior anti -cancer therapy).  
For the antitumor activity endpoints ORR and DCR, the p roportion of participants achieving 
response, and, if data allow, the exact 95% confidence interval for this proportion will be 
estimated using the Clopper -Pearson method and presented for the response rates.  
Duration of response, PFS and OS will be summar ized descriptively using the Kaplan -Meier 
method with 95% CIs calculated using Greenwood’s formula. Duration of response and PFS 
rates at specific timepoints (3 months, 6 months, 12 months, etc.) will also be derived from the 
Kaplan -Meier estimation and pr esented together with associated 95% CIs.  
A full discussion of statistical methodology will be provided in the SAPs for each module.  
10.[ADDRESS_386051] been verified/coded/entered into a database, a data review will be perf ormed. 
The purpose of this review will be to check all protocol deviations, define the PPS, and check the 
quality of the data. The review will also help decide how to manage problems in the participants’ 
data (eg, missing values, withdrawals, dropouts, and  protocol deviations). Accepted deviations 
from theoretical time points will be described in the appropriate documents and included in the 
Trial Master File. After the pre -analysis review, resolution of all issues, and documentation of all 
decisions, the d atabase will be locked.  
10.[ADDRESS_386052] 1 dose of the study medication, 
regardless of whether they are deemed evaluable for the assessment of a dose level (ie, they 
receive the planned dose during Cycle 1 [2 treatment administrations]).  
Any participant who is discontinued from the study before receiving all doses of UCB6114 in 
Cycle [ADDRESS_386053] to continue 
treatment (see  Section  7.1.4 ).  
Nonevaluable participants may be replaced to ensure that at least 3 participants receive all 
assigned doses of therapy at each dose level/cohort, unless accrual to that cohort has stopped due 
to DLTs.  
Further details on any imputation of missing data will be included in the SAPs for each module.  
10.7 Planned interim analysis and data monitoring  
No formal interim analysis will b e conducted during this study; however, the SMC will regularly 
review all the safety, tolerability, and PK data as well as any available biomarker and ADA data 
for the dose escalation modules (Part A, Part B, Part C).  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 145 of 195 In Part A, Part B, and Part C, at the end of each cohort, the SMC will review all available safety, 
PK, ADA and biomarker data prior to any dose escalation/de -escalation decision. The 
composition and operation of the SMC will be clearly outlined in the SMC Charter. The PK data 
will be summariz ed after each cohort, in order to support escalation to the next proposed dose 
level.  
In Part A1, the SMC will review all the safety and tolerability of the sentinel participant in each 
cohort ([ADDRESS_386054] UCB6114 administration). The SMC will  also review available 
safety, tolerability, and PK data as well as any available biomarker and ADA data once 25%, 
50% and 100% study participants in Part A1 have completed the required 28 -day observation 
period.  
Before starting any subsequent study part, the Sponsor  will review all available safety, 
tolerability, PK, and PD biomarker endpoints from other final or ongoing study part.  
10.8 Determination of sample size  
10.8.1  Dose escalation modules  
The number of participants likely to be enrolled in Parts A, B, and C d epends on how many dose 
levels are needed to define the RP2D -M and the RP2D for combination therapy.  
In Part A, up to 42 eligible participants will be enrolled across 5 cohorts/dose levels. This 
assumes that all 5 planned dose levels are evaluated, that 1 dose level is added based on 
emerging data, and that, on average, each cohort includes an additional participant due to drop -
out/replacement and/or the modified rolling -6 design.  
In Part A1, up to 32 eligible participants will be enrolled across 4 alternat ive dosing schedules; [ADDRESS_386055] unacceptable level of toxicity. 
The probability of declaring a dose schedule (cohort) too toxic, given a toxicity rate greater than 
the maximum tolerable toxicity r ate (33%) is approximately 90% (Mokdad et al, 2018). 
However, the probability is reduced to 80% when the dose optimization module is considered 
independent of Part A. An administrative decision to stop enrolling into Part A1 may be made by 
[CONTACT_151079] a ny time.  
In Part B and Part C, up to [ADDRESS_386056] TFD/TPI 
[INVESTIGATOR_313534], respectively. However, add itional dose levels may be added based 
on emerging data and recommendations of the SMC. In each part of the study, between 3 and 9 
participants are expected to be enrolled per dose level depending on the observed 
toxicity/observation of DLTs. An administra tive decision to stop enrolling into Part B or Part C 
may be made by [CONTACT_313619].  
10.8.2  Expansion modules  
Participant numbers for Parts D, E, F, and G are based primarily on pragmatic considerations 
rather than formal statistical power considerations . A minimum sample size of 15 participants is 
proposed per expansion module (may be expanded to 30 participants). This sample size will 
allow the safety and antitumor activity of UCB6114 to be evaluated with reasonable confidence 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 146 of 195 prior to commencement of f urther clinical studies. Furthermore, based on well -established 
statistical principles (Gehan, 1961):  
• If no responses are seen in the first 15 consecutive participants enrolled, the chances of a 
response rate >20% are <4%.  
• If no responses are seen in 30 co nsecutive participants enrolled, the chances of a response 
rate >10% is <5%.  
For Parts F and G, in which UCB6114 will be evaluated in combination with another 
agent/regimen, response rates may be higher depending on the participant population and 
combination agent/regimen chosen.  
Accordingly, a clinically meaningful improvement in the response rate will be defined for 
Parts  F and G based upon the tumor type, line of therapy, and current SOC response probability. 
A 2-stage design (Simon, 1989) will be used to expand the cohorts should the observed response 
rate exceed the SOC expected response plus the clinically meaningful improvement threshold.  
11 SUPPORTING DOCUMENTA TION AND OPERATIONAL  
CONSIDERATIONS  
11.1 Appendix 1: Regulatory, ethical, and study oversi ght 
considerations  
11.1.1  Regulatory and ethical considerations  
The study will be conducted under the auspi[INVESTIGATOR_18279]/IEC, as defined in local regulations, 
International Council for Harmonisation  (ICH) -Good Clinical Practice  (GCP), and in accordance 
with the e thical principles that have their origin in the Declaration of Helsinki.  
The investigator/UCB will ensure that an appropriately constituted IRB/IEC that complies with 
the requirements of the current ICH -GCP version or applicable country -specific regulation s will 
be responsible for the initial and continuing review and approval of the clinical study. Prior to 
initiation of the study, the investigator/UCB will forward copi[INVESTIGATOR_18280], ICF, IB, 
investigator’s curriculum vitae (if applicable), advertisem ent (if applicable), and all other 
participant -related documents to be used for the study to the IRB/IEC for its review and 
approval.  
Before initiating a study, the investigator will have written and dated full approval from the 
responsible IRB/IEC for the  protocol.  
The investigator will also promptly report to the IRB/IEC all changes in the study, all 
unanticipated problems involving risks to participants or others, and any protocol deviations, to 
eliminate immediate hazards to participants.  
The investigat or will not make any changes in the study or study conduct without IRB/IEC 
approval, except where necessary to eliminate apparent immediate hazards to the participants. 
For minor changes to a previously approved protocol during the period covered by [CONTACT_313620], it may be possible for the investigator to obtain an expedited review by [CONTACT_1201]/IEC as 
allowed.  
As part of the IRB/IEC requirements for continuing review of approved studies, the investigator 
will be responsible for submitting periodic pr ogress reports to the IRB/IEC (based on IRB/IEC 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 147 of 195 requirements), at intervals appropriate to the degree of participant risk involved, but no less than 
once per year. The investigator should provide a final report to the IRB/IEC following study 
completion.  
UCB (or its representative) will communicate safety information to the appropriate regulatory 
authorities and all active investigators in accordance with applicable regulatory requirements. 
The appropriate IRB/IEC will also be informed by [CONTACT_313621], as specified 
by [CONTACT_59002]. Where applicable, 
investigators are to provide the Sponsor (or its representative) with evidence of such IRB/IEC 
notification.  
11.1.2  Financial disclosure  
Insurance co verage will be handled according to local requirements.  
Finance and insurance are addressed in the investigator and/or contract research organization  
(CRO) agreements, as applicable.  
11.1.3  Informed consent process  
Participant’s informed consent must be obtained and documented in accordance with local 
regulations, ICH -GCP requirements, and the ethical principles that have their origin in the 
principles of the Declaration of Helsinki.  
Prior to obtaining informed consent, information should be given in a language an d at a level of 
complexity understandable to the participant in both oral and written form by [CONTACT_093] (or 
study physician or medically qualified designee ). Each participant will have the opportunity to 
discuss the study and its alternatives with t he investigator.  
Prior to participation in the study, the ICF should be signed and personally dated by [CONTACT_2416], or his/her legal representative, and by [CONTACT_67622] (investigator, study physician, or medi cally qualified designee ). The 
participant or his/her legal representative must receive a copy of the signed and dated ICF. As 
part of the consent process, each participant must consent to direct access to his/her medical 
records for study -related monitori ng, auditing, IRB/IEC review, and regulatory inspection.  
If the ICF is amended during the study, the investigator (or the Sponsor, if applicable) must 
follow all applicable regulatory requirements pertaining to the approval of the amended ICF by 
[CONTACT_1201]/IE C and use of the amended form.  
11.1.4  Data protection  
UCB staff (or designee) will affirm and uphold the participant’s confidentiality. Throughout this 
study, all data forwarded to UCB (or designee) will be identified only by [CONTACT_313622].  
The investigator agrees that representatives of UCB, its study physician or medically qualified 
designee , representatives of the relevant IRB/IEC, or representatives of regulatory authorities 
will be allowed to review that portion of the participa nt’s primary medical records that directly 
concerns this study (including, but not limited to, laboratory test result reports, ECG reports, 
admission/discharge summaries for hospi[INVESTIGATOR_1684] a participant’s study 
participation, and auto psy reports for deaths occurring during the study).  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_386057] be informed that his/her personal study -related data will be used by [CONTACT_19490]. The level of disclosure must also be 
explained to the pa rticipant.  
The participant must be informed that his/her medical records may be examined by [CONTACT_19491], by 
[CONTACT_6667]/IEC members, and by [CONTACT_31198].  
11.1.5  Committees structure  
The SMC will comprise key Sponsor personnel and investigators from participating sites (see 
Section  4.1.1 ). Full details of the exact SMC composition will be provided in the SMC Charter.  
11.1.6  Data quality assurance  
All participant data relating to the study will be recorded in eCRF unless transmitted to the 
Sponsor or designee electronically (eg, laboratory data). The investigator is responsible for 
verifying that data entries are accurate and correct by [CONTACT_21496].  
The investigator must maintain accurate documentation (source data) that supports the 
information entered in the eCRF.  
The investigator must permit study -related monitoring, audits, IRB/IEC review, and regulatory 
agency inspections and provide direct access to source data documents.  
The Sponsor or designee is responsible for the data management of this study including qualit y 
checking of the data.  
Study monitors will perform ongoing source data verification to confirm that data entered into 
the eCRF by [CONTACT_1191], legible, contemporaneous, original, and 
attributable from source documents; that the safety and rights of participants are being protected; 
and that the study is being conducted in accordance with the currently approved protocol and any 
other study agreements, ICH GCP, and all applicable regulatory requirements.  
All essential documents mus t be retained by [CONTACT_313623]. The investigator will contact [CONTACT_313624]. The investigator will also notify UCB should he/she relocate or 
move the study -related files to a location other than that specified in the Sponsor’s trial master 
file. 
[IP_ADDRESS]  Electronic Case Report Form completion  
The inve stigator is responsible for prompt reporting of accurate, complete, and legible data in the 
eCRFs and in all required reports.  
Any change or correction to the eCRF after saving must be accompanied by a reason for the 
change.  
Corrections made after the inve stigator’s review and approval (by [CONTACT_3553] a 
password/electronic signature) will be reapproved by [CONTACT_093].  
The investigator should maintain a list of personnel authorized to enter data into the eCRF.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_386058] be accurate, clear, unambiguous, permanent, and capable of being 
audited. They should be made using some permanent form of recording (ink, typi[INVESTIGATOR_007], printing, 
optical disc). They should n ot be obscured by [CONTACT_18411] 
(such as removable self -stick notes).  
Source documents are original records in which raw data are first recorded. These may include 
hospi[INVESTIGATOR_307]/clinic records, charts, diaries, x -rays, laborator y results, printouts, pharmacy records, 
care records, ECG, or other worksheets. Source documents should be kept in a secure, limited 
access area.  
Source documents that are computer -generated and stored electronically must be printed for 
review by [CONTACT_294144] (eg,  ECG reports). Once printed, these copi[INVESTIGATOR_67548] a permanent part of the participant’s source documents. The 
investigator will facilitate the process for enabling the monitor to compare the content of the 
printout and the data stored in the computer to ensure all data are consistent.  
Electronic data records, such as Holter monitor records or electroencephalogram records, must 
be saved and stored as instructed by [CONTACT_18338] (or designee).  
11.1.8  Study and site clos ure 
Study site participation may be discontinued if UCB, the investigator, the IRB/ethical review 
board, or the regulatory authority deems it necessary for any scientific, medical, or ethical 
reason.  
The study will be discontinued if UCB, while considering  the rights, safety, and wellbeing of the 
participant(s), deems it necessary for any scientific, medical, or ethical reason.  
The Sponsor  designee reserves the right to close the study site or terminate the study at any time 
for any reason at the sole discr etion of the Sponsor. Study sites will be closed upon study 
completion. A study site is considered closed when all required documents and study supplies 
have been collected and a study -site closure visit has been performed.  
The investigator may initiate st udy-site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination.  
Reasons for the early closure of a study site by [CONTACT_23863]:  
• Failure  of the investigator to comply with the protocol, the requirements of the IRB/IEC or 
local regulatory authorities, the Sponsor ‘s procedures, or GCP guidelines  
• Inadequate recruitment of participants by [CONTACT_093]  
• Discontinuation of further study medi cation development  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_386059] editorial and ethical practice, the Sponsor will generally support publication o f 
multicenter studies only in their entirety and not as individual site data. In this case, a 
coordinating investigator [INVESTIGATOR_12992].  
Authorship will be determined by [CONTACT_27495].  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 151 of 195 11.2 Appendix 2: Clinical laboratory tests  
• Chemistry, hematology, and coagulation ( as described in the Schedules of Activities for 
Part A [Table  1-4], Part A1 ( Table  1-5 and Table  1-6), Part B [Table  1-7], and Part  C 
[Table  1-8]) results should be available for review prior to administration of treatment.  
• The tests detailed in the table below will be performed by [CONTACT_148219]. If 
the local or central laboratory results ar e used to make either a study treatment decision or 
response evaluation, the results must be entered into the eCRF . 
• Protocol -specific requirements for inclusion or exclusion of participants are detailed in 
Section  5.1 and Section  5.2 of this protocol.  
• Additional tests may be performed at any ti me during the study as determined necessary by 
[CONTACT_11006].  
Protocol -Required Safety Laboratory Assessments  
Laboratory 
Assessments  Parameters  
Hematology  Hemoglobin  
Hematocrit  
RBC count  
Platelet count  RBC Indices:  
MCV  
MCH  
MCHC  WBC Count with 
Differential:  
Absolute neutrophils  
Absolute lymphocytes  
Absolute monocytes  
Absolute eosinophils  
Absolute basophils  
Coagulation  aPTT and either PT or INR  
Clinical 
Chemistry1 ALT  AST  Alkaline 
phosphatase  Bicarbonate  
Sodium  Potassium  Magnesium  Chloride  
Calcium  Total bilirubin  BUN or urea  Glucose 
(non-fasted)  
Phosphorus or 
phosphate  Total protein  Uric acid  Amylase  
Albumin     
GGT  Cholesterol  Creatine kinase  CRP  
LDH  Lipase  Triglycerides  Serum creatinine  
Routine 
Urinalysis  • Specific gravity  
• pH, glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, 
leukocyte esterase by [CONTACT_5230]  
• Microscopic examination (if blood or protein is abnormal, including 
crystals)  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 152 of 195 Laboratory 
Assessments  Parameters  
Other Tests  Pregnancy tests:  
• Follicle -stimulating hormone and estradiol (as needed in women of 
non-childbearing potential only)  
• Serum or urine hCG pregnancy test (as needed for women of childbearing 
potential)  
Bone Turnover Markers:  
• Blood BAP, blood CTx, urinary NTx and urinary CtxII  (see Section  9.8) 
Tumor markers   
• eg, PSA, CA125, CA19 -9 
• If routinely measured, results of tumor markers will also be recorded in the  
eCRF  when availa ble during the participant’s participation in the study.  
All study -required laboratory assessments will be performed by a local laboratory. 
The results of each test must be entered into the  eCRF . 
NOTES:  
[ADDRESS_386060] abnormalities identified at the time, 
should be considered potential Hy’s Law cases irrespective of availability of all the results of the investigations 
performed to determine etiology of the abnormal liver function tests. Such potential Hy’s Law cases should be 
reported as SAEs.  
ALT=alanine aminot ransferase; aPPT=activated partial thromboplastin time; AST=aspartate aminotransferase; 
BAP=bone alkaline phosphatase; BUN=blood urea nitrogen;  eCRF =electronic Case Report Form; CRP=C -
reactive protein; CTx=C -terminal telopeptide; GGT=gamma glutamyl transfe rase; hCG=human chorionic 
gonadotropin; INR=international normalized ratio; LDH=lactate dehydrogenase; NTX=N -terminal telopeptide; 
PSA=prostate specific antigen; PT=prothrombin time; RBC=red blood cell; ULN=upper limit of normal; 
SAE=serious adverse event;  WBC=white blood cell  
Investigators must document their review of each laboratory safety report.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 153 of 195 The formula for the Cockroft -Gault glomerular filtration rate estimation is as follows:  
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 154 of 195 11.3 Appendix 3: Adverse events – Definitions and procedures for 
recording , evaluating, follow -up, and reporting  
Definition of AE  
AE Definition  
• An AE is any untoward medical occurrence in a patient or clinical study participant, temporally 
associated with the use of study medication, whether or not considered related to the study 
medication.  
• NOTE: An AE can therefore be any unfavorable and unintended sign (including an abnormal 
laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the 
use of study medication.  
 
Events Meeting  the AE Definiti on 
• Any abnormal laboratory test results (hematology, clinical chemistry, coagulation, or 
urinalysis) or other safety assessments (eg, ECG, radiological scans, vital signs measurements), 
including those that worsen from baseline, considered clinically sign ificant in the medical and 
scientific judgment of the investigator (ie, not related to progression of underlying disease).  
• Exacerbation of a chronic or intermittent pre -existing condition including either an increase in 
frequency and/or intensity of the condition.  
• New conditions detected or diagnosed after study medication administration even though it 
may have been present before the start of the study.  
• Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.  
• Signs, symptoms, or th e clinical sequelae of a suspected overdose of either study medication or 
a concomitant medication. Overdose per se will not be reported as an AE/SAE unless it is an 
intentional overdose taken with possible suicidal/self -harming intent. Such overdoses shou ld be 
reported regardless of sequelae.  
• “Lack of efficacy” or “failure of expected pharmacological action” per se will not be reported 
as an AE or SAE. Such instances will be captured in the antitumor activity  assessments. 
However, the signs, symptoms, and/ or clinical sequelae resulting from lack of antitumor 
activity  will be reported as AE or SAE if they fulfil the definition of an AE or SAE.  
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 155 of 195 Events NOT  Meeting the AE Definition  
• Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that leads to the 
procedure is the AE.  
• Situations in which an untoward medical occurrence did not occur (social and/or convenience 
admission to a hospi[INVESTIGATOR_307]).  
• Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present or 
detected at the start of the study that do not worsen.  
Definition of SAE  
If an event is not an AE per definition above, then it cannot be an SAE even if serious conditions 
are met (eg, hospi[INVESTIGATOR_1080]/symptoms of the disease under study, death due to 
progression of disease).  
An SAE is defined as any untoward medical occurrence that, at any dose:  
a. Results in death  
b. Is life -threatening  
The term ‘life -threatening’ in the definition of ‘serious’ refers to an event in which the participant was 
at risk of death  at the time of the event. It does not refer to an event, which hypothetically might have 
caused death, if it were more severe.  
c. Requires inpatient hospi[INVESTIGATOR_12993], hospi[INVESTIGATOR_91260] p articipant has been detained (usually involving at least an 
overnight stay) at the hospi[INVESTIGATOR_22771]/or treatment that would not have 
been appropriate in the physician’s office or outpatient setting. Complications that occur du ring 
hospi[INVESTIGATOR_1084]. If a complication prolongs hospi[INVESTIGATOR_9236], 
the event is serious. When in doubt as to whether “hospi[INVESTIGATOR_059]” occurred or was necessary, the AE 
should be considered serious.  
Hospi[INVESTIGATOR_5187] a pre -existing condition that did not worsen from baseline is 
not considered an AE.  
Hospi[INVESTIGATOR_313535]/assessments and for convalescence is not considered an AE.  
d. Results in persistent disability/incap acity  
• The term disability means a substantial disruption of a person’s ability to conduct normal life 
functions.  
• This definition is not intended to include experiences of relatively minor medical significance 
such as uncomplicated headache, nausea, vomitin g, diarrhea, influenza, and accidental trauma 
(eg, sprained ankle) which may interfere with or prevent everyday life functions but do not 
constitute a substantial disruption.  
e. Is a congenital anomaly/birth defect  
f. Important medical events:  
• Medical or scientific judgment should be exercised in deciding whether SAE reporting is 
appropriate in other situations such as important medical events that may not be immediately 
life-threatening or result in death or hospi[INVESTIGATOR_313536]. These events should usually be considered serious.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 156 of 195 • Examples of such events include, but are not limited to, potential Hy’s law, invasiv e or 
malignant cancers, intensive treatment in an emergency room or at home for allergic 
bronchospasm, blood dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_059], or 
development of drug dependency or drug abuse.  
Recording and Follow -Up of AE an d/or SAE  
AE and SAE Recording  
• When an AE/SAE occurs, it is the responsibility of the investigator to review all 
documentation (eg, hospi[INVESTIGATOR_1088], laboratory reports, and diagnostics reports) related 
to the event.  
• The investigator will then recor d all relevant AE/SAE information in the  eCRF . 
• It is not acceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s medical records 
to UCB/CRO in lieu of completion of the AE/SAE eCRF page.  
• There may be instances when copi[INVESTIGATOR_313537]. In this case, all participant identifiers, with the 
exception of the participant number, will be redacted on the c opi[INVESTIGATOR_313538].  
• The investigator will attempt to establish a diagnosis of the event based on signs, symptoms, 
and/or other clinical information. Whenever possible, the d iagnosis (not the individual 
signs/symptoms) will be documented as the AE/SAE.  
Assessment of Intensity  
Each must be categorized using the National Cancer Institute Common Terminology Criteria for 
Adverse Events (NCI CTCAE) v 5.0 
(https://ctep .cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Refere
nce_8.5x11.pdf).  
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 157 of 195 Assessment of Causality  
• The investigator is obligated to assess the relationship between study medication and each 
occurrence of each AE/SAE.  
• A “reasonable possibility” of a relationship conveys that there are facts, evidence, and/or 
arguments to suggest a causal relationship, rather than a relationship cannot be ruled out.  
• The investigator will use clinical judgment to determine the rel ationship.  
• Alternative causes, such as underlying disease(s), concomitant therapy, and other risk factors, 
as well as the temporal relationship of the event to study medication administration will be 
considered and investigated.  
• The investigator will also consult the IB and/or Product Information, for marketed products, in 
his/her assessment.  
• For each AE/SAE, the investigator must  document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causality.  
• There may be situ ations in which an SAE has occurred and the investigator has minimal 
information to include in the initial report to UCB. However, it is very important that the 
investigator always make an assessment of causality for every event before the initial 
transmis sion of the SAE data to UCB.  
• The investigator may change his/her opi[INVESTIGATOR_9242] -up information and 
send a SAE follow -up report with the updated causality assessment.  
• The causality assessment is one of the criteria used when determi ning regulatory reporting 
requirements.  
 
Follow -up of AEs and SAEs  
• The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by a UCB 
representative to elucidate the nature and/or causality of the AE or SAE as fully as possible. 
This may include additional laboratory tests or investigations, histopathological examinations, 
or consultation with other health care professionals.  
• An AE should be followed until it has resolved, has a stable sequelae, the investigator 
determines that it is no longer clinically significant, or the participant is lost to follow -up. This 
follow -up requirement applies to AEs, SAEs, and AEs of special interest.  
• New or updated inf ormation will be recorded in the originally completed  eCRF . 
• The investigator will submit any updated SAE data to UCB within 24 hours of receipt of the 
information.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 158 of 195 Reporting of SAEs  
SAE Reporting to UCB via an Electronic Data Collection Tool  
• The primary mechanism for reporting an SAE to UCB will be the electronic data collection 
tool. 
• If the electronic system is unavailable for more than 24 hours, then the site will use the paper 
SAE data collection tool (see next section).  
• The site will enter the SAE dat a into the electronic system as soon as it becomes available.  
• After the study is completed at a given site, the electronic data collection tool will be taken off -
line to prevent the entry of new data or changes to existing data.  
• If a site receives a report  of a new SAE from a study participant or receives updated data on a 
previously reported SAE after the electronic data collection tool has been taken off -line, then 
the site can report this information on a paper SAE form (see next section) or to the study  
physician or medically qualified designee by [CONTACT_756].  
• Contacts for SAE reporting can be found on page 3.  
 
SAE Reporting to UCB via Paper CRF  
• Facsimile transmission of the SAE paper CRF is the preferred method to transmit this 
information to the UCB.  
• In rare circumstances and in the absence of facsimile equipment, notification by [CONTACT_20021] a copy of the SAE data collection tool sent by [CONTACT_13187].  
• Initial notification via telephone does not replace the need for  the investigator to complete and 
sign the SAE CRF pages within the designated reporting time frames.  
• Contacts for SAE reporting can be found on page 3.  
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 159 of 195 11.4 Appendix 4: Contraceptive Guidance and Collection of 
Pregnancy Information  
Definitions  
Woman of Child bearing Potential  
A woman is considered fertile following menarche and until becoming post -menopausal unless 
permanently sterile (see below).  
Women in the following categories are not considered women of childbearing potential : 
1. Premenarchal  
2. Premenopausal female with 1 of the following:  
− Documented hysterectomy  
− Documented bilateral salpi[INVESTIGATOR_1656]  
− Documented bilateral oophorectomy  
Note: Documentation can come from the site personnel’s review of the participant’s medical 
records, medical examination, or medical  history interview.  
3. Postmenopausal female  
− A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal 
range may be used to confirm a postmenopausal  state in women not using hormonal 
contraception or hormonal replacement therapy (HRT). However, in the absence of 
12 months of amenorrhea, a single FSH measurement is insufficient.  
− Females on HRT and whose menopausal status is in doubt will be required to  use one of 
the non -estrogen hormonal highly effective contraception methods if they wish to 
continue their HRT during the study. Otherwise, they must discontinue HRT to allow 
confirmation of postmenopausal status before study enrollment.  
Contraception Gui dance  
Male participants  
Male participants with female partners of childbearing potential are eligible to participate if they 
agree to ONE of the following during this study : 
• Are abstinent from penile -vaginal intercourse as their usual and preferred lifesty le (abstinent 
on a long term and persistent basis) and agree to remain abstinent.  
• Agree to use a male condom plus partner use of a contraceptive method with a failure rate of 
<1% per year as described i n the table below when having penile -vaginal intercour se with a 
woman of childbearing potential  who is not currently pregnant.  
In addition, male participants must refrain from donating sperm for the duration of the study and 
after the final dose of study medication as follows:  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 160 of 195 1. For 3  months if participating in  Part A or Part A1 of the study;  
2. For [ADDRESS_386061] agree to remain abstinent from 
penile -vaginal intercourse or use a male condom during each epi[INVESTIGATOR_313539], after the final dose of study medication as follows:  
1. For 3  months if participating in Part A or Part A1 of the study;  
2. For 6  months if pa rticipating in Part B or Part C of the study.  
Female participants  
Female participants of childbearing potential are eligible to participate if they agree to use a 
highly effective method of contraception consistently and correctly as described in the table  
below . 
It is currently unknown whether trifluridine/tipi[INVESTIGATOR_14965] (Lonsurf®) may reduce the effectiveness of 
hormonal contraceptives, and therefore women using hormonal contraceptives should add a 
barrier contraceptive method.  
Highly Effective Contraceptive M ethods  
Highly Effective Contraceptive Methods That Are User Dependenta 
Failure rate of <1% per year when used consistently and correctly.  
Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of 
ovulationa  
• Oral 
• Intravaginal  
• Transdermal  
Progestogen only hormonal contraception associated with inhibition of ovulation  
• Oral 
• Injectable  
Highly Effective Methods That Are User Independentb 
 Implantable progestogen only hormonal contraception associated with inhibition of ovulation  
• Intrauterine device (IUD)  
• Intrauterine hormone -releasing system (IUS)  
• Bilateral tubal occlusion  
Vasectomized partner  
A vasectomized partner is a highly effective contraception method provided that the partner is the sole 
male sexual partner of the woman of childbearing potential  and the absence of sperm has been confirmed. 
If not, an additional highly effective method of  contraception should be used.  
Sexual abstinence  
Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual 
intercourse during the entire period of risk associated with the study medication. The reliability of sexual 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 161 of 195 abstinence needs to be evaluated in relat ion to the duration of the study and the preferred and usual 
lifestyle of the participant.  
NOTES:  
a) Typi[INVESTIGATOR_35818]. Use should be consistent 
with local regulations regarding the use of  contraceptive methods for participants participating in clinical studies.  
b) Hormonal contraception may be susceptible to interaction with the study medication, which may reduce the 
efficacy of the contraceptive method. In this case, 2 highly effective me thods of contraception should be utilized 
during the treatment period and after the final dose of study medication, as follows:  
1. For at least 3 months if participating in Part A or Part A1 of the study;  
2. For at least 6 months if participating in Part B or Part C of the study.  
Pregnancy testing  
• Women of childbearing potential  should only be included after a confirmed menstrual period 
and a negative highly sensitive serum pregnancy test.  
• Additional pregnancy testing should be performed at each visit during the treatment period 
and within 30 days after the final dose of study medication and as required locally.  
• Pregnancy testing will be performed whenever a menstrual cycle is missed or when 
pregnancy is otherwise suspected.  
• Pregnancy testing, with a se nsitivity of at least 25mIU/mL will be performed.  
Male participants with partners who become pregnant  
• The investigator will attempt to collect pregnancy information on any male participant’s 
female partner who becomes pregnant while the male participant is  in this study. This applies 
only to male participants who receive study medication.  
• After obtaining the necessary signed informed consent from the pregnant female partner 
directly, the investigator will record pregnancy information on the appropriate form  and 
submit it to the Sponsor  within 24 hours of learning of the partner’s pregnancy. The female 
partner will also be followed to determine the outcome of the pregnancy. Information on the 
status of the mother and child will be forwarded to the Sponsor . Generally, the follow -up will 
be at least 12 months after the delivery date. Any termination of the pregnancy will be 
reported regardless of fetal status (presence or absence of anomalies) or indication for the 
procedure.  
Female participants who become pregnant  
• Any female participant who becomes pregnant while participating in the study will 
discontinue study medication or be withdrawn from the study OR may request continuation 
of study medication.  
• The investigator will collect pregnancy information on a ny female participant who becomes 
pregnant while participating in this study. Information will be recorded on the appropriate 
form and submitted to the Sponsor  within 24 hours of learning of a participant’s pregnancy. 
The participant will be followed to de termine the outcome of the pregnancy. The investigator 
will collect follow -up information on the participant and the neonate, and the information 
will be forwarded to the Sponsor . Generally, the follow -up will be at least 12 months after 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 162 of 195 the delivery date.  Any termination of pregnancy will be reported, regardless of fetal status 
(presence or absence of anomalies) or indication for the procedure.  
• While pregnancy itself is not considered to be an AE or SAE, any pregnancy complication or 
elective termination o f a pregnancy will be reported as an AE or SAE. A spontaneous 
abortion is always considered to be an SAE and will be reported as such. Any post -study 
pregnancy related SAE considered reasonably related to the study medication by [CONTACT_313625]  9.2.5 . While the 
investigator is not obligated to actively seek this information in former study partic ipants, he 
or she may learn of an SAE through spontaneous reporting.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 163 of 195 11.5 Appendix 5: Genetics  
Use and analysis of DNA  
• Genetic variation may impact a participant’s response to study medication, susceptibility to, 
and severity and progression of disease. Variabl e response to study medication may be due to 
genetic determinants that impact the mechanism of action of the drug; disease etiology; 
and/or molecular subtype of the disease being treated. Therefore, where local regulations and 
IRB/IEC allow, a blood sample  will be collected for potential DNA analysis.  
• DNA samples may be used for research related to UCB6114 and/or advanced solid tumors 
(locally recurrent or metastatic). They may also be used to develop tests/assays including 
diagnostic tests related to UCB61 14 and/or interventions of this drug class and/or advanced 
solid tumors (locally recurrent or metastatic). Genetic research may consist of the analysis of 
one or more candidate genes or the analysis of genetic markers throughout the genome or 
analysis of t he entire genome (as appropriate).  
• DNA samples may be analyzed if it is hypothesized that this may help further understand the 
clinical data or  help resolve issues with the clinical data; for example, PK outliers or potential 
safety observations.  
• The sampl es may be analyzed as part of a multi -study assessment of genetic factors involved 
in the response to UCB6114 or study medications of this class to understand the participant ’s 
solid tumor or related conditions.  
• The results of any genetic analyses will be reported separately.  
• The Sponsor  will store the DNA samples in a secure storage space with adequate measures to 
protect confidentiality.  
• The samples will be retained while research on UCB6114 or study medications of this class 
continues, but no longer than 20  years (or other period according to local regulations) . 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 164 of 195 11.6 Appendix 6: Rapid Alert Procedures  
The aim of the Rapid Alert process is to stop the exposure to the study medication or concerned 
study procedure as soon as possible,  following a confirmed or suspected safety issue, preventing 
its reoccurrence in other study participants as described in the Rapid Alert Team charter. Upon 
occurrence of an SAE and/or another safety event which may constitute a study /study part  hold 
criterion, irrespective of its relationship with the study medication or the study conduct, the 
investigator should notify the study Sponsor as soon as possible  (ideally within 2 hours of 
becoming aware of the event) by [CONTACT_38733]:  
1. A phone call to th e study physician  to alert them a safety event has been identified.  
2. If the investigator is not able to reach the study physician,  they should call the 24 -hour rapid 
response helpline number. Upon receipt of a call from an investigator, the 24/[ADDRESS_386062] a physician from UCB who will return the call to the investigator.  
3. Additionally,  
a. For UCB’s RAVE® (ACQUIRE) study, complete the eCRF (S)AE page  
OR 
b. For non UCB’s RAVE (ACQUIRE) study or as back -up if UCB’s RAVE® (ACQUIRE) is 
down, send a completed “Investigator (S)AE Report Form for Development Drug (For Rapid 
Alert Studies)” to the fax/email for Rapid Alert provided at the front of the protocol.  
The form should include assessed seriousness, severity, and causality and should be filed in 
the Study Investigator’s File.  
Both the phone call and the completed fo rm from  the Investigator are crucial in assessing the 
safety of the study medication and in det ermining whether the event requires immediate 
action to place the study or individual study parts on hold and/or expedite reporting to the 
regulatory authorities. The (S)AE form should be completed in English and provided even if 
the data are incomplete, o r if it is obvious that more data will be needed in order to draw any 
conclusions about the diagnosis or causality. Additional information (eg, laboratory reports) 
received by [CONTACT_313626] [ADDRESS_386063] be summarized in English in the (S)AE form.  
During the call between the Investigator and the UCB physician  the safety issue will be 
discu ssed to determine if there is sufficient evidence to declare a protocol hold criteri on has been 
met for the entire study or for an individual study part . If the investigator and UCB physician 
agree a stoppi[INVESTIGATOR_313540], dosing of the study  may continue as per the study 
protocol and the discussion between the investigator and the UCB physician should be 
documented.  
In all other circumstances, the investigator will be instructed to suspend dosing and the UCB 
physician will arrange an urgent, internal UCB Rapid Alert Team meeting. The Rapid Alert 
Team will review the information provided at the call along with the (S)AE form to determine 
whether or not a protocol hold criterion for the entire study or for an individual study part has 
been met. If it is determined that no criterion have been met, UCB will contact [CONTACT_313627]. If it is determined a hold criterion has been met, UCB 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_386064] all investigators and notify them of the formal hold  (please re fer to Section  6.7 for 
further details ). 
If the investigator believes a protocol stoppi[INVESTIGATOR_313541] , and they are unable to contact [CONTACT_313628], 
they should postpone any further do sing until they have obtained feedback from UCB. In these 
circumstances dosing may be restarted if UCB and the investigator subsequently agree that no 
stoppi[INVESTIGATOR_105308].  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 166 of 195 11.7 Appendix 7:  Country -specific Requirements  
Not applicable.  
11.8 Appendix 8: ECOG Performance Status Scale  
ECOG Performance Status will be determined according to the following table:  
Grade  ECOG performance status scale  
0 Fully active, able to carry on all predisease performance without restriction  
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a 
light or sedentary nature (eg, light housework, office work)  
2 Ambulatory and capable of all selfcare but unable to carry out any  work activities. Up and 
about more than 50% of waking hours  
3 Capable of only limited self care, confined to bed or chair for more than 50% of waking 
hours  
4 Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair  
5 Dead  
ECOG=Eastern Cooperative Oncology Group  
11.9 Appendix 9: RECIST v1.[ADDRESS_386065] been adapted from Eisenhauer, 2009.  
11.9.1  Measurability of tumor at Baseline  
At Baseline, tumor lesions/lymph nodes will be categorized measurable or nonmeasurable as  
follows:  
Measurable Lesions  
Tumor lesions (extra/non -nodal lesions)  
Lesions that can be accurately measured in ≥1 dimension (longest diameter in the plane of 
measurement) with a minimum size of  
• 10mm or greater when assessed by [CONTACT_462] (slice thickness no greater than 5mm)  
• 10mm or greater when assessed by [CONTACT_4733] (lesions which cannot be accurately measured 
with calipers should be recorded as nonmeasurable)  
• 20mm by [CONTACT_13190] X -ray 
Malignant lymph nodes (nodal lesions)  
Malignant lymph nodes with the short axi s 15mm or greater when assessed by [CONTACT_4654] (CT slice 
thickness recommended to be no greater than 5mm)  
NOTE: The shortest axis is used as the diameter for malignant lymph nodes, longest axis for 
all other measurable lesions.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 167 of 195 Nonmeasurable lesions  
Nonmeasurable l esions will be considered as follows:  
• All other lesions, including small lesions (extra/ non -nodal lesions) with longest diameter 
less than 10mm  
• Malignant lymph nodes (nodal lesions) with ≥10 to <15mm short axis  
• Truly nonmeasurable lesions: such as pleural  or pericardial effusions, ascites, inflammatory 
breast disease, leptomeningeal disease, lymphangitic involvement of skin or lung, clinical 
lesions that cannot be accurately measured with calipers, abdominal masses identified by 
[CONTACT_297019].  
Special considerations regarding lesion measurability  
• Bone disease: Bone disease is nonmeasurable with the exception of soft tissue components 
that can be evaluated by [CONTACT_313629].  
• Previous local treatment: A previously irradiated lesion (or lesion subjected to other local 
treatment) is non -measurable unless it has progressed since completion of treatment.  
Normal sites  
• Cystic lesions: Simple cysts should not b e considered as malignant lesions and should not be 
recorded either as target or non -target disease. Cystic lesions thought to represent cystic 
metastases can be measurable lesions, if they meet the specific definition above. If non -cystic 
lesions are also  present in the same patient, these are preferred as target lesions.  
• Normal nodes: Nodes with short axis <[ADDRESS_386066] be  documented 
appropriately. If a baseline assessment is inadequate, subsequent statuses generally should be 
indeterminate.  
To assess objective response or future progression, overall tumor burden at Baseline should be 
estimated and compared to subsequent as sessments.  
Baseline documentation of target lesions  
All measurable lesions up to a maximum of 2 lesions per organ and 5 lesions in total and 
representative of all involved organs should be identified as target lesions at Baseline. Target 
lesions should be selected on the basis of size (longest lesions) and suitability for accurate 
repeated measurements. Record the longest diameter of each lesion, except in the case of 
pathological lymph nodes for which the short axis should be recorded. The sum of the diameters 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 168 of 195 (longest for non -nodal lesions, short axis for nodal lesions) for all target lesions at Baseline will 
be the basis for comparison to assessments performed during the study.  
• If two target lesions coalesce, the measurement of the coalesced mass is used. If a large target 
lesion splits, the sum of the par ts is used.  
• Measurements for target lesions that become small should continue to be recorded. If a target 
lesion becomes too small to measure, [ADDRESS_386067] disappeared; otherwise a default value of 5 mm should  be recorded.  
NOTE: When nodal lesions decrease to <10 mm (normal), the actual measurement should still be 
recorded.  
Baseline documentation of nontarget lesions  
All nonmeasurable disease is nontarget. All measurable lesions not identified as target lesions  are 
also included as non -target disease. Measurements are not required but rather assessments will be 
expressed as ABSENT, INDETERMINATE (not evaluable), PRESENT/NOT INCREASED 
(present), INCREASED (unequivocal progression). Multiple non -target lesions in one organ may 
be recorded as a single item on the eCRF (eg,  ‘multiple enlarged pelvic lymph nodes’ or 
‘multiple liver metastases’).  
11.9.[ADDRESS_386068] to determine if substitution is possible. If not, subsequent objective 
statuses are indeterminate.  
Target lesio ns 
• Complete Response (CR): Complete disappearance of all target lesions with the exception of 
nodal disease. All target nodes must decrease to normal size (short axis <10 mm). All target 
lesions must be assessed.  
• Partial Response (PR): Greater than or equal to 30% decrease under Baseline of the sum of 
diameters of all target measurable lesions. The short diameter is used in the sum for target 
nodes, while the longest diameter is used in the sum for all other target lesions. All target 
lesions must be as sessed.  
• Stable: Does not qualify for CR, PR or Progression. All target lesions must be assessed. 
Stable can follow PR only in the rare case that the sum increases by <20% from the nadir, but 
enough that a previously documented 30% decrease no longer holds.  
• Progressive disease: 20% increase in the sum of diameters of target measurable lesions above 
the smallest sum observed (over Baseline if no decrease in the sum is observed during 
therapy), with a minimum absolute increase of 5 mm.  
• Indeterminate. Progressi on has not been documented, and one or more target measurable 
lesions have not been assessed; or assessment methods used were inconsistent with those 
used at Baseline; or one or more target lesions cannot be measured accurately (eg, poorly 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 169 of 195 visible unless d ue to being too small to measure); or one or more target lesions were excised 
or irradiated and have not reappeared or increased.  
Nontarget lesions  
• CR: Disappearance of all nontarget lesions and normalization of tumor marker levels. All 
lymph nodes must be  ‘normal’ in size (<10 mm short axis).  
• NonCR/Nonprogressive disease: Persistence of any nontarget lesions and/or tumor marker 
level above the normal limits.  
• Progressive disease: Unequivocal progression of pre -existing lesions. Generally, the overall 
tumor burden must increase sufficiently to merit discontinuation of therapy. In the presence 
of SD or PR in target disease, progression due to unequivocal increase in non -target disease 
should be rare.  
• Indeterminate: Progression has not been determined and one o r more non -target sites were 
not assessed or assessment methods were inconsistent with those used at Baseline.  
New Lesions  
The appearance of any new unequivocal malignant lesion indicates progressive disease. If a new 
lesion is equivocal, for example due t o its small size, continued assessment will clarify the 
etiology. If repeat assessments confirm the lesion, then progression should be recorded on the 
date of the initial assessment. A lesion identified in an area not previously scanned will be 
considered a new lesion.  
FDG -PET scanning can be used to complement CT scanning in assessments of progression 
(particularly possible “new” disease). New lesions on the basis of FDG -PET imaging can be 
identified according to the following algorithm:  
• Negative FDG -PET a t Baseline, with a positive FDG -PET at follow -up is a sign of 
progressive disease based on a new lesion.  
• No FDG -PET at Baseline and a positive FDG -PET at follow -up: 
− If the positive FDG -PET at follow -up corresponds to a new site of disease confirmed by 
[CONTACT_4654], this is progressive disease.  
− If the positive FDG -PET at follow -up is not confirmed as a new site of disease on CT, 
additional follow -up CT scans are needed to determine if there is truly progression 
occurring at that site (if so, the date of progressive di sease will be the date of the initial 
abnormal FDG -PET scan).  
− If the positive FDG -PET at follow -up corresponds to a pre -existing site of disease on CT 
that is not progressing on the basis of the anatomic images, this is not progressive 
disease.  
Supplemental Investigations  
• If CR determination depends on a residual lesion that decreased in size but did not disappear 
completely, it is recommended the residual lesion be investigated with biopsy or fine needle 
aspi[INVESTIGATOR_337]. If no disease is identified, ob jective status is CR.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 170 of 195 • If progression determination depends on a lesion with an increase possibly due to necrosis, 
the lesion may be investigated with biopsy or fine needle aspi[INVESTIGATOR_313542].  
Subjective progression  
Participants requiring discontinu ation of treatment without objective evidence of disease 
progression should not be reported as progressive disease on tumor assessment eCRFs. This 
should be indicated on the Study Medication Discontinuation eCRF page as Clinical Progression. 
Every effort s hould be made to document progressive disease even after discontinuation of 
treatment.  
Evaluation of Response for an Individual Assessment Time Point  
In order to determine tumor response, the sum of all target lesions is calculated at Baseline and at 
each subsequent time point (every 2 cycles in this study). Initially, a separate response for target 
lesions is determined using Table A . Finally, the best overall respons e is determined as a 
composite of the target and non -target responses using Table B . 
Table A  Objective Response Status at each Evaluation for Participants with Nontar get 
Disease Only  
Nontarget diseases  New Lesions  Objective status  
CR No CR 
NonCR/nonprogressive disease  No NonCR/nonprogressive 
disease  
Indeterminate  No 
Indeterminate  
Unequivocal progression  Yes or No  progressive disease  
Any Yes progressive disease  
 
Table B  Overall Response (Target and Nontarget) at Each Assessment Time Point  
Target Lesions  Nontarget Lesions  New Lesions  Overall Response  
CR CR No CR 
CR NonCR/nonprogressive disease  No PR 
CR Indeterminate or Missing  No PR 
PR NonCR/nonprogressive disease, 
Indeterminate or Missing  No PR 
SD NonCR/nonprogressive disease, 
Indeterminate or Missing  No Stable  
Indeterminate or 
Missing  Nonprogressive disease  No Indeterminate  
Progressive disease  Any Yes or No  Progressive disease  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_386069] response determination in trials where confirmation of complete or partial response IS 
required: Complete or partial responses may be claimed only if the criteria for each are met at a 
subsequent time point as specified in the protocol (generally 4 weeks later). In this circumstance, 
the best overall response can be interpreted as in Table B . 
Table C  Best overall response when confirmation of CR and PR required  
Overall response  
First time point  Overall response  
Subsequent time point  BEST overall response  
CR CR CR 
CR PR Stable Disease, progressive 
disease, or PRa 
CR Stable Disease  Stable disease provided minimum 
criteria for stable disease duration 
met, otherwise, progressive 
disease  
CR Progressive Disease  Stable disease provided minimum 
criteria for stable disease duration 
met, otherwise, progressive 
disease  
CR NE Stable disease provided minimum 
criteria for stable disease duration 
met, otherwise, NE  
PR CR PR 
PR PR PR 
PR Stable Disease  Stable Disease  
PR Progressive Disease  Stable disease provided minimum 
criteria for stable disease duration 
met, otherwise, progressive 
disease  
PR NE Stable disease provided minimum 
criteria for stable disease duration 
met, otherwise, NE  
NE NE NE 
CR=complete response; NE=nonevaluable; PR=partial response  
a If a CR is truly met at the first time point, then any disease seen at a subsequent time point, even disease meeting 
PR criteria relative to Baseline, makes the disease progressive disease at that point (since disease must have 
reappeared after CR). Best response would depend on whether minimum duration for stable disease was met. 
However, sometimes “CR” may be claimed when subsequent scans suggest small lesions were likely still present 
and in fact the patient had PR, not CR at the first time point. Under these circumstances, the original CR should be 
changed to PR and the best response is PR.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 172 of 195 11.10  Append ix 10: Abbreviations and Trademarks  
ADA  antidrug antibody  
ADAS  ADA Set  
AE adverse event  
ALP  alkaline phosphatase  
ALT  alanine aminotransferase  
ANC  absolute neutrophil count  
aPTT  activated partial thromboplastin time  
AST  aspartate aminotransferase  
bid twice daily  
BIW  twice a week  
BMP  bone morphogenetic protein  
BOR  best overall response  
BSA  body surface area  
CNS  central nervous system  
CR complete response  
CRF  Case Report form  
CRC  colorectal cancer  
CRO  contract research organization  
CTCAE  Common Terminology Criteria for Adverse Events  
ctDNA  circulating tumor DNA  
DCR  disease control rate  
DES  DLT Evaluable Set  
DLT  dose-limiting toxicity  
DNA  deoxyribonucleic acid  
DOR  duration of response  
ECG  electrocardiogram  
ECOG  Eastern Cooperative Oncology Group  
eCRF  electronic Case Report form  
EGFR  epi[INVESTIGATOR_313543].
UCB   [ADDRESS_386070] in human  
FOLFOX  oxaliplatin, leucovorin, and 5 -fluorouracil (FOLFOX) regimen  
GCP  Good Clinical Practice  
G-CSF granulocyte colony -stimulating factor  
GLP  Good Laboratory Practice  
GnRH  gonadotropin -releasing hormone  
HMPS  hereditary mixed polyposis syndrome  
HPA  hypothalamic -pi[INVESTIGATOR_2117] -adrenal  
IB Investigator’s Brochure  
ICF Informed Consent Form  
ICH International  Council for Harmonisation  
IEC Independent Ethics Committee  
IgG4  human immunoglobulin G4  
IMP investigational medicinal product  
INR international normalized ratio  
IRB Institutional Review Board  
iv intravenous(ly)  
LAIV  live attenuated influenza vaccine  
mAb  monoclonal antibody  
MedDRA  Medical Dictionary for Regulatory Activities  
mFOLFOX6  modified FOLFOX 6 regimen (leucovorin 400mg/m2 on Day 1, 
5-fluorouracil 400mg/m2 on Day 1 + 1200mg/m2/day on Day 1 and 
Day 2, and oxaliplatin 85mg/m2 on Day 1)  
MMR  measles, mumps, and rubella  
MoA  mechanism of action  
MRI  magnetic resonance imaging  
mRNA  messenger ribonucleic acid  
MTD  maximum tolerated dose  
mTPI  [INVESTIGATOR_313544].
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 174 of 195 PD pharmacodynamic(s)  
PDS Pharmacodynamic Set  
PFS progression -free survival  
PK pharmacokinetic(s)  
PKS Pharmacokinetic Set  
PPS Per-protocol Set  
PR partial response  
PT prothrombin time  
Q2W  every 2 weeks  
Q3W  every 3 weeks  
Q4W  every 4 weeks  
QW once weekly  
QTcF  QT interval corrected for heart rate according to Fridericia’s formula  
RECIST  Response Evaluation Criteria in Solid Tumors  
RP2D  recommended Phase 2 dose  
RP2D -F recommended Phase 2  dose of UCB6114 when used in combination 
with FOLFOX  
RP2D -M recommended Phase 2 dose for monotherapy  
RP2D -T recommended Phase 2 dose of UCB6114 when used in combination 
with TFD/TPI  
[INVESTIGATOR_313545](ly)  
SD stable disease  
SFU Safety Follow -Up 
SLIT1/2  slit guidance ligand 1/[ADDRESS_386071] of care  
SS Safety Set  
SSC Study Steering Committee  
TFD/TPI  [INVESTIGATOR_313546]/tipi[INVESTIGATOR_313547].
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 175 of 195 11.11  Appendix 11: Protocol amendment history  
The Protocol Amendment Summary of Changes Table for the current amendment is located 
directly before the Table of Contents.  
Amendment 5 (14 Jan 2022)  
Overall Rationa le for the Amendment  
The overall rationale for Amendment [ADDRESS_386072] of Part A1 (dose 
optimization module), as summarized in the table below.  
This amendment is considered to be substantial based on the criteria set forth in Arti cle 10(a) of 
Directive 2001/20/EC of the European Parliament and the Council of the European Union.  
Section # and Name  [CONTACT_313634] A1 throughout 
the document, including the synopsis, 
objectives and endpoints, schema, 
schedules of activities, background, 
design, benefit -risk assessment, dose 
selection, selection and withdrawal 
criteria, treatments administered, 
concomitant medications, dose 
modifications, study a ssessments and 
procedures, statistical analyses, and 
appendices. When applicable, sections, 
tables and figures have been renumbered.  Addition to 
provide details for 
the conduct of 
Part A1 of the 
study  
Global  Part A1 ‘dose adaptation module’ was 
renamed ‘d ose optimization module’ for 
clarity.  Clarification  
1.1 Synopsis  
3 Objectives and endpoints  
Global  In secondary and tertiary endpoints, the 
wording ‘ dose level ’ was replaced by 
‘cohort’ to cover both dose level in Part A 
and dosing schedule in Part A1.  
The changes were also applied throughout 
the document, where relevant.  Update of the 
endpoints to 
include Part A1’s 
endpoints  
4.1 Overall design  The description of the Safety Monitoring 
Committee (SMC) and Study Steering 
Committee (SSC) are applicable fo r all 
study parts; thus, the information has been 
moved up in a separate section. 
Subsequent sections have been 
renumbered.  
Treatment duration text was updated to 
include “ criteria for discontinuation are 
met” , in line with the text provided in the 
study s ynopsis (new text in bold).  Simplification of 
the text  
 
 
 
 
 
Clarification  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 176 of 195 Section # and Name  [CONTACT_11029]  
4.2.3 Rationale for Part B and Part C  The rationale for selected indication for 
Part B and Part C was the same as for 
Part A1 and the corresponding text was 
moved from Section 4.2.3 to Section 
4.2.2.  
It was clarified that Ab7326mIgG1 is the 
murinized version of UCB6114.  Clarification  
5.2.3 P art B  
5.2.4 Part C  A correction was made in the exclusion 
criteria for Part A (criterion #7a), Part B 
(criterion #7a) and Part  C (criterion #6a): 
“Screening of symptomatic  asymptomatic 
participants without history of CNS 
metastases is not required ”.  Correction  
9.2.8 Anticipated serious adverse 
events  Clarification that death due to disease 
progression will not be recorded as a SAE 
but will be recorded in a survival 
electronic case report form (eCRF).  Clarification  
9.2.9 Infusion -related reactions 
(hypersensitivity reactions)  Clarifications of the procedures to be 
performed in case an infusion -related 
reaction occurs.  Clarification  
10 Statistical considerations  Clarification that a SAP will be developed 
for each module.  Clarification  
10.4 Analysis of the anti -tumor 
activity endpoints  Timepoints at which the duration of 
responses and PFS will be derived has 
been corrected to be in line with the 
statistical analysis plan.  Correction  
Global  Correction of spelling, grammar, or 
typographical er rors. Correction  
Document history  Type of amendment for protocol 
amendment 3.1 has been changed from 
‘substantial’ to ‘Not applicable’ as the 
substantial/nonsubstantial classification is 
irrelevant in US.  Correction  
 
Amendment 4 (17 June 2021)  
Overall Ra tionale for the Amendment  
The overall rationale for Amendment 4 is to incorporate regulatory agency -required local 
protocol amendments in 1 global amendment and perform some additional adjustments to the 
protocol. Summary of changes is given in the table b elow (changes already performed in one of 
the previous local amendments are identified by a footnote).  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 177 of 195 This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of 
Directive 2001/20/EC of the European Parliament and th e Council of the European Union.  
Section # and Name  [CONTACT_313635].  Addition of the 
IND number.  
Synopsis Table  1-2: Objectives and 
endpoints for the dose escalation 
modules in Part B and Part C  
3. Objectives and endpoints 
Table  3-2: Objectives and endpoints 
for the dose escalation modules in 
Part B and Part C  Pharmacodynamic endpoint related to 
protein marker levels has been updated as 
follows:  
“Change in protein marker levels in blood 
and tumor  tissue  by [CONTACT_313630]”.  Correction as no 
tumor biopsies are 
requested in Parts 
B and C of the 
study.  
[IP_ADDRESS] Dose -limiting toxicity 
determination and maximum 
tolerated dose definition (Part  A) Update of the definition of DLTs to 
confirm that they include any AE at least 
possibly related  to the study medication 
and fulfilling the specified criteria.a Correction.  
[IP_ADDRESS] Dose -limiting toxicity 
determination and maximum 
tolerated dose definition ( Part A) Revision of the DLT definition for Part A 
(update of the febrile neutropenia 
definition as per CTCAE v5.0 and 
addition of Grade 4 thrombocytopenia).a Correction.  
[IP_ADDRESS].1 Definition of DLT (Part B)  
[IP_ADDRESS].1 Definition of DLT (Part C)  Revision of  the DLT definition for Part B 
and Part C (addition of any Grade 4 
thrombocytopenia).a  Correction.  
5. Study population  
5.1.[ADDRESS_386073] unresectable 
disease (definition of the study population 
in Table  5.1; Part A: inclusion criterion 
#3b; Part B and Part C: inclusion criterion 
#3a).The precision was also added 
throughout the text when relevant.a 
The sentence at the end of Secti on 5.1.1, 
which mentioned that inclusion criteria 
for Parts A1, B, C, D, E, F, and G will be 
defined in a protocol amendment, has 
been moved at the end of Section  5.1.3; 
reference to Parts B and C has been 
deleted.  Clarification.  
 
 
 
 
 
 
 
Correction as 
inclu sion criteria 
for Part  B and 
Part C are now 
detailed in 
Sections  5.1.2 and 
5.1.3.  
5.1.2 Part B  Inclusion of ramucirumab as an option in 
the prior treatment regimen in Part  B 
(inclusion criterion #4a).a  Clarification.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 178 of 195 Section # and Name  [CONTACT_11029]  
5.2.1 Part A  
5.2.2 Part B  
5.2.3 Part C  Revision of the eligibility criteria to 
provide a single QTc cutoff, irrespective 
of the participant’s sex (Part A: exclusion 
criterion #16b, Part B: exclusion criterion 
#20b, Part C: inclusion criterion #19b).a 
The sentence at the end of Sec tion 5.2.1, 
which mentioned that exclusion criteria 
for Parts A1, B, C, D, E, F, and G will be 
defined in a protocol amendment, has 
been moved at the end of Section  5.2.3; 
reference to Parts B and C has been 
deleted.  Correction.  
 
 
 
 
Correction as 
exclusion  criteria 
for Part  B and 
Part C are now 
detailed in 
Sections  5.2.2 and 
5.2.3.  
5.2.2 Part B  
5.2.3 Part C  Clarification that all participants with 
known hypersensitivity to any of the study 
medications will be excluded from the 
study (exclusion criterion #2a).b Clarification of an 
exclusion 
criterion in Parts 
B and C.  
5.2.3 Part C  Alignment with the [LOCATION_006] prescribing 
information for oxaliplatin regarding the 
threshold for neutrophil count in 
exclusion criterion (exclusion criterion 
#13a).b  
Alignment with t he [LOCATION_006] prescribing 
information for calcium folinate regarding 
known or suspected pernicious anemia or 
other anemias due to vitamin B12 
deficiency (addition of exclusion criterion 
#24).b  Update of 
exclusion criteria 
in Part C.  
6.5.3 Permitted concomitant 
treatments (medications and 
therapi[INVESTIGATOR_014]) during Part C  
6.5.5 Prohibited concomitant 
treatments (medications and 
therapi[INVESTIGATOR_014]) during Part B  
 Clarification that the following should be 
avoided in Part C:a 
• Concomitant administration of 
medicinal product with a kn own 
potential to prolong the QT interval  
• Concurrent administration of 5 -
fluorouracil and CYP2C9 substrates  
• Co-administration of medicinal 
products known to be nephrotoxic  
Title and text of Section 6.5.5 has been 
modified to remove the information 
pertain ing only to Part C of the study. All 
the information applying to Part C has 
been copi[INVESTIGATOR_313548] a new section 
entitled : 6.5.6 Prohibited concomitant 
treatments (medications and therapi[INVESTIGATOR_014]) 
during Part  C.a Clarification.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 179 of 195 Section # and Name  [CONTACT_11029]  
6.5.7 Vaccines  Text has been corrected as follows:  
“Administration of live (including  
attenuated ) vaccines is not allowed during 
the conduct of the study and for up to 3 
months after the final dose of IMP.  
Administration of inactivated non-live 
vaccines is allowed during the study at  the 
discretion of the Investigator.”  Correction.  
[IP_ADDRESS] UCB6114 dose modifications 
(Part B)  
[IP_ADDRESS] UCB6114 dose modifications 
(Part C)  Deletion of the following sentence:  
“For participants who experience a DLT, 
dose adjustments are permitted if it is 
considered in the best interest of the 
participant to continue therapy at the 
discretion of the investigator, in 
consultation with the Sponsor.”a Clarification.  
[IP_ADDRESS] UCB6114 dose modifications 
(Part B)  
[IP_ADDRESS] UCB6114 dose modifications 
(Part C)  Additi on of any Grade  [ADDRESS_386074] been 
met.b Clarification.  
9. Study assessments and procedures  
Table 9 -2: Total blood volume 
collected during Cycle [ADDRESS_386075] has been 
moved  to the footnote of the table.  Correction/  
clarification.  
9. Study assessments and procedures  
Schedule of Activities  
 
 
 
 
Table  1-[ADDRESS_386076] be separated and used 
to assess the liver function instead of total 
ALP in participants with bone metastases 
and liver abnormalities considered as 
potential Hy’s low cases.  
Update of Footnote l (Tables 1 -5 and 1 -6). Update procedure 
for A LP 
assessment in 
case of liver 
abnormalities.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 180 of 195 Section # and Name  [CONTACT_11029]  
9.5 Pharmacokinetics  
9.10 Immunogenicity  Text pertaining to immunogenicity 
sampling was moved from the Section 
9.5 Pharmacokinetics to the 
9.10 Immunogenicity.  Clarification.  
9.8.4 Blood samples for s erum bo ne 
turnover markers  
 
 
 
Schedule of Activities  
Table  1-5 Schedule of Activities for 
Part B  
Table 1 -6 Schedule of Activities for 
Part C Deletion of the following sentence:  
“Samples for analysis of circulating 
markers of bone turnover will not be 
obtained in  Part B or Part C”  which was 
incorrect.a 
Deletion of the related footnote in the 
Schedule of Activities’ tables (footnote 
j).a  Correction.  
Schedule of Activities  
Table  1-5 Schedule of Activities for 
Part B  
Table 1 -6 Schedule of Activities for 
Part C Addition of the echocardiogram 
assessments in the study procedures for 
Part B and Part C to be in line with the 
assessments planned.c 
Addition of collection time -windows for 
blood PK sampling for Part B and Part C.  
Update in the time schedule of the vital 
sign measurements on Day 1 (2h [+1h] 
and 5h+ [1h] after the end of infusion)  Update Schedule 
of Activities for 
Part B and Part C.  
11.4 (Appendix 4)  Update the contraceptive requirements for 
males in Parts B and C in relation to 
sperm donation and pregnant or  
breastfeeding partners (6 months 
compared to 3  months in Part A).b 
 
Addition of the recommendation to use a 
barrier contraceptive in addition to the use 
of hormonal contraceptive for woman of 
childbearing potential receiving Lonsurf® 
in the body text.b 
Clarification that effective contraceptive 
method should be utilized for at last 6 
months for participant in Parts B and C 
(compared to 3  months in Part A)b Alignment of the 
appendices’ text 
with the exclusion 
criteria regarding 
contraception 
requirements.  
Clarification.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 181 of 195 Section # and Name  [CONTACT_11029]  
1.3 Schedule of Activities  Correction of a few typographical and 
formatting errors, deletion of footnote 
which was not applicable for a specific 
assessment (Table 1.4 [Part A], footnote n 
for “Blood collection for genetic 
analysis”), and a ddition of an existing 
footnote to 2 of the current procedures 
(Table 1.5 [Part B] and 1.6 [Part  C] 
footnote g added to Eligibility criteria and 
Medical history as they are not to be 
assessed in Cycle 2).   Correction.  
4.1.3 Part B - Dose escalation with 
TFD/TPI  
[IP_ADDRESS].2 Determination of 
maximum -tolerated dose  
4.1.4 Part C - Dose escalation with 
mFOLFOX6  
[IP_ADDRESS].2 Determination of 
maximum -tolerated dose  
Table 6 -2 Study Treatments in Part  B 
Table 6 -3 Treatments administered in 
Part C 
10.3.1 Safety analyses  
10.7 Planned interim analysis and 
data monitoring  
10.8.1 Dose escalation module  Clarification in the use of "cohort" and 
"dose level" for Part B and Part C.  Clarification.  
1.2 Schema  
Figure  1.3 ONC001 Part B  
Figure  1.4 ONC001 Part C  Clarification in the schematic 
representation of the dose escalation/DLT 
assessment period:  
• “Cohort” replaced by “dose level”,  
• Addition of the possibility of dose de -
escalation  
• Clarification that each dose level can 
include more than one cohort of 
participants.   Clarification.  
Global  The wording “Health Authorities” was 
replaced by “regulatory authorities”.  
Correction of a few typographical and 
formatting errors.   Correction.  
aThis change has been previously implemented in protocol amendment 3.1 (US)  
bThis change has been previously implemented in protocol amendment 3.2 ([LOCATION_006])  
cThis change has been previously implemented in protocol amendment 3.1 (US) but the timepoints at which the 
assessment should be performed have been further updated  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 182 of 195 Amendment 3 (07  Jan 2021)  
Overall Rationale for the Amendment  
The overall rationale for Amendment [ADDRESS_386077] of Parts B and C, as 
summarized in the table below.  
Section # and Name  [CONTACT_313636] 24h Rapid Response 
Helpline phone number.  Correction  
Global  Added text pertaining to dose 
escalation (combination therapy) 
modules Part B and Part C 
throughout the document, including 
the synopsis, objectives and 
endpoints, schema, sch edules of 
activities, background, design, 
benefit -risk assessment, dose 
selection, selection and withdrawal 
criteria, treatments administered, 
concomitant medications, dose 
modifications, and statistical 
analyses.  Addition to provide details for 
conduct of  Part B and Part C 
of the study  
Section 1.[ADDRESS_386078] 
changes to terminology in overall 
design.  Clarification  
Section 2.1 Study rationale  Added text clarifying types of 
tumors selected for Part A.  Clarification  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 183 of 195 Section # and Name  [CONTACT_9353] 5.2.1 Exclusion 
Criteria Part A  Exclusion criterion 22 renumbered 
as 22a. Text has been corrected 
from:  
“In the presence of therapeutic intent 
to anticoagulate the participant: INR 
or PT and aPTT…”  
to  
“In the presence of therapeut ic intent 
to anticoagulate the participant: INR 
or PT or aPTT…”  Correction  
Section 6.1.1 Part A, Table 
6-1 Treatments administered 
in Part A  Updated dose formulation row to 
clarify formulation.  Clarification  
Section 9.5 Pharmacokinetics  
and 
Section [IP_ADDRESS] Analysis of 
PK endpoints  Moved text and table pertaining to 
PK analyses from Section 9.5 to 
Section [IP_ADDRESS].  Correction  
Section [IP_ADDRESS] Analysis of 
PK endpoints  Added text specifying which PK 
concentrations will be disclosed on 
public registrie s for Part A, Part B, 
and Part C.  Addition  
Global  Correction of spelling, grammar, or 
typographical errors.  Correction  
Amendment 2 ([ADDRESS_386079] 2020)  
Overall Rationale for the Amendment  
The overall rationale for Amendment 2 is to clarify some of the study assessments and 
procedures and to add language related to the COVID -19 pandemic, as summarized in the table 
below. Minor (non -substantive) corrections to grammar and formatting are not captured in the 
table below.  
Section # and Name  [CONTACT_11029]  
11.2. Appendix 2 Clinical 
laboratory tests  Separated the terms “phosphorus or 
phosphate” and “albumin”  These are separate assessments  
7. Discontinuation of study 
medication and participant 
discontinuation/withdrawal  Section was restructured to clarify 
situations of:  
• participant discontinuation  
• treatment discontinuation  
• study/site discontinuation by 
[CONTACT_313631].  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 184 of 195 Section # and Name  [CONTACT_11029]  
5.[ADDRESS_386080] be recorded in the 
eCRF  Clarification  
7.1.3 Other criteria for 
discontinuation of study 
medication  • Added language allowing 
palliative bone -directed 
radiotherapy as concomitant 
treatment  
• Defined taking prohibited 
medications as defined 
elsewhere in the protocol as a 
criterion for discontinuation of 
study medication  • Excepts palliative bone -
directed radiotherapy from 
criteria for discontinuation 
of study medication  
• Clarification that 
prohibited medications 
leading to discontinuation 
of study medication are 
defined in elsewhere in the 
protocol  
[IP_ADDRESS]. Antitumor activity 
endpoint definitions  Overall survival (OS) was originally 
measured from date of study 
enrollmen t to date of death. Revised 
to measure OS from the date of first 
dosing to date of death.  Alignment of start of time -to-
event analysis for OS with the 
start of the time -to-event 
analysis for progression -free 
survival (PFS)  
7.1.3 Other criteria for 
discont inuation of study 
medication  Excepted palliative bone -directed 
radiotherapy from criteria for 
discontinuation  
 
Added Criterion No 5  Allows participants who 
receive bone -directed 
radiotherapy to stay on 
treatment  
Adds taking prohibited 
concomitant medications to 
the criteria for discontinuation  
7.1.4 Temporary 
discontinuation of study 
medication  Added language allowing temporary 
suspension of study medication for 
up to 3 weeks  Allows for suspension of 
treatment with study 
medication to resolve 
toxicities  
7.2 Participant 
discontinuation/withdrawal 
from the study  Added clarification that site will 
attempt to contact [CONTACT_313632].  Clarification  
7.4. COVID -19 Pandemic  Added a section on  COVID -19 
Pandemic  Gives guidance on how to 
adapt study processes, 
procedures, and timing to 
potential impacts of COVID -
19 
9.2 Adverse events and 
serious adverse events  Added language regarding collection 
of AEs and SAEs related to COVID -
19 Gives guidance  on how to 
report AEs and SAEs related 
to COVID -19 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 185 of 195 Section # and Name  [CONTACT_11029]  
9.2.5 Pregnancy  Replaced “early discontinuation 
visit” with “Safety Follow -up Visit” 
when specifying follow -up for 
positive pregnancy test  Accuracy  
10.6. Handling of dropouts or 
missing data  Added langua ge regarding missing 
doses due to the COVID -19 
Pandemic  Clarification on missing doses 
due to COVID -19 Pandemic  
Appendix 11. Protocol 
amendment history  In Amendment 1, the Summary of 
Changes table footnote “k” reference 
to Cycle 1 Day 15/16 was deleted.  Correction of an error in the 
Summary of Changes table 
from Amendment 1.  
Table 1 -3: Schedule of 
activities for Part  A 
(monotherapy dose 
escalation)  Footnote “z” was added to the 
coagulation and ECOG assessments 
on Cycle 1 Day 15/16  Clarification that coag ulation 
and ECOG in Cycle 1 is 
assessed on Day 15, not Day 
16. 
Flexibility in assessment collection 
for PK sampling and Screening 
procedures to accommodate potential 
impacts of the COVID -19 pandemic  Allows flexibility in study 
procedures to accommodate 
potential impacts of the 
COVID -19 pandemic  
Added survival census to SFU Visit.  Consistency with CRF  
Added language to footnote “ff” 
clarifying survival census at SFU 
Visit.  Consistency with CRF  
Added language to Footnote “k” 
allowing collection of laboratory 
tests from local laboratories  Allows flexibility in collection 
of laboratory test  
Added language to footnote “o” 
expanding window of PK 
assessments scheduled for Day [ADDRESS_386081] of study participants  
Exclusion Criterion No 13 was 
modified to remove separate 
conditions for study participants with 
bone metastases  Removed separation of liver -
specific AP from total AP for 
study participants with bone 
metastases  
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 186 of 195 Amendment 1 (11 Jun 2020)  
Overall Rationale for the Amendment  
Section # and 
Name  [CONTACT_313637].  Belgium has recently 
adopted a new Code of 
Companies and 
Associations, resulting in a 
mandatory change of the 
name [CONTACT_313638] “ société privée à 
responsabilité limitée ”, 
abbreviated “ SPRL ”, to 
“société à responsabilité 
limitée ”, abbreviated 
“SRL”. 
Section 1.1, 
Synop sis Number of participants statement updated.  For consistency with dose 
escalation text  
Timing of SFU visit updated and allowance for 
Final Visit to be conducted by [CONTACT_648].  Clarification  
Section 1.2, Schema  Footnote to the schema has been updated.  Clarification  
Section 1.[ADDRESS_386082] been deleted.  Reduction of participant 
assessment burden  
Blood collection for PK analysis row – samples 
deleted from Cycle 2 Day 2 and Final Visit.  Reduction of participant 
assessment burden  
Blood collection immunogenicity (ADA) row – 
samples deleted from Cycle 2 Day 15, Cycle 3 
onwards Day 15, and Final Visit.  Reduction of participant 
assessment burden  
Added new row for blood collection for ctDNA 
analysis.  Addition  
Added new row for survival census.  Addition  
Added new row for coagulation.  Addition  
Footnote a was corrected to delete reference to 
Day 2 of Cycle 2.  For consistency with 
deletion of Cycle 2 Day 2 
column  
Footnote b was deleted.  Clarification  
Footnote c was corrected to delete reference to 
Day 8 of Cycle 3 and Cycle 4 onwards.  For consistency with 
deletion of Cycle 3 Day 8 
column  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 187 of 195 Section # and 
Name  [CONTACT_313639] d has been added to the headings for 
colum ns Cycle 1 (Days 1 and 15), Cycle 2 (Day 
15), and Cycle 3 onwards (Days 1 and 15) to 
specify timing of predose and postdose safety 
assessments at these visits.  Clarification  
Footnote d has been revised to include 
coagulation.  Addition  
Footnote h has been revised to specify timing of 
ECG assessments due to reduction in number of 
assessments.  Reduction of participant 
assessment burden  
Footnote i has been revised to clarify use of urine 
vs serum pregnancy assessments.  Clarification  
Footnote j has been revised to correct a 
grammatical error.  Correction of grammatical 
error  
Footnote k was added to the Cycle [ADDRESS_386083] 
or MRI scan.  Clarification  
Footnote z was added to specify which procedures 
are assessed Day 15 only of Cycle  1. Clarification  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 188 of 195 Section # and 
Name  [CONTACT_313640] 3 onwards Day 1.  Addition 
Footnote bb was added to specify that 
echocardiograms will only be assessed at even -
numbered cycles from Cycle 3 onwards.  Clarification  
Footnote cc was added to clarify requirements for 
tumor assessments at SFU visit.  Clarification  
Footnote dd was added to clarify when tumor 
assessment is not required at SFU Visit.  Clarification  
Footnote ee was added to specify predose 
eligibility assessment at Cycle 1 Day 1.  Addition  
Footnote ff was added to clarify liver laboratory 
assessments in the case of bone metastases.  Clarification  
Footnote gg was added to specify completion of 
survival census.  Addition  
Footnote hh was added to clarify timing of 
complete and symptom -directed physical 
examinations.  Clarification  
Section 4.1 Overall 
design  Table 4 -1, row for Part  B: colorectal carcinoma 
changed to colorectal adenocarcinoma.  Consistency  
Sentence “Higher or lower doses may be 
considered based on emerging data.” has been 
deleted.  For consistency with dose 
escalation text  
Pancreatic carcinoma changed to pancreatic 
adenocarcinoma.  Consistency  
Section 4.1.1 Part  A 
– Monotherapy dose 
escalation  Specified 16 -day observation for participants who 
enroll after sentinel participant experiences a 
DLT.  Clarification  
Section 4.2 
Scientific rationale 
for study design  Clarification of design choices with expanded 
explanatory text.  Clarification  
Section 4.2.1 Dosing 
strategy  Clarified SMC role in dose decisions and role in 
adding additional dose levels. Clarified that doses 
above 2000mg require an amendmen t. Clarification  
Section 5, Table 5 -1 
Study population  Row Part  A: Term pancreatic carcinoma corrected 
to term pancreatic adenocarcinoma  
Rows Part  B, Part  D, and Part  F: Term colorectal 
carcinoma corrected to colorectal 
adenocarcinoma.  Consistency  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 189 of 195 Section # and 
Name  [CONTACT_31879] 5.1 
Inclusion criteria  Inclusion criterion 2 has been renumbered as 2a; 
terms pancreatic carcinoma and colorectal 
carcinoma corrected pancreatic adenocarcinoma 
and colorectal adenocarcinoma, respectively.  Consistency  
Inclusion criterion 3 has been renumbered as 3a 
and has been changed from “or” to “and”.  Clarification  
Section 5.2 
Exclusion criteria  Exclusion criterion 2 has been deleted.  Clarification  
Exclusion criterion 15 has been renumbered as 
15a; and has been modified to add history of 
biliary stent.  Clarification  
Exclusion criterion 19 has been renumbered as 
19a and has been modified to remove “or any 
other type of medical research”.  Correction  
New criterion: Exclusion criterion [ADDRESS_386084] 
adequate renal function  
New criterion: Exclusion criterion 21 has been 
added to exclude major surgery prior to study 
drug initiation.  Addition  
New criterion: Exclusion criterion 22 has been 
added to specify criteria for coagula tion 
parameters.   
Section 6.2.1 Drug 
accountability  Drug accountability procedure changed to use of 
drug accountability logs instead of eCRF.  Correction  
Section 6.4 
Treatment 
compliance  Drug accountability procedure changed to use of 
drug accountability logs instead of eCRF.  Correction  
Section 6.5.1 
Permitted 
concomitant 
treatments 
(medications and 
therapi[INVESTIGATOR_014]) during 
Part A Term “concomitant” was deleted from last 2 
bullets (redundant with sentence preceding 
bulleted list)  Correction  
Section 6.6.1, Table  
6-[ADDRESS_386085] to a substantial 
protocol amendment.  Clarification  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 190 of 195 Section # and 
Name  [CONTACT_9353] 8 Study 
assessments and 
procedures  Text has been added to specify the maximum 
amount of blood collected from participants 
during each part of the study.  Clarification  
Table 8 -1, coagulation added to sample types; 
number and volumes of samples updated, total 
blood volumes updated.  Reduction of participant 
assessment burden  
Section 8.1.[ADDRESS_386086] reporting.  Clarification  
Section 8.5 
Pharmacokinetics  Deleted PK sample collection from Final Visit.  Reduction of participant 
assessment  burden  
Section 8.5 Table 
8-3, Blood 
collection time 
points for PK 
analysis  Cycle 1, Day 15 (samples 9 and 10), Day  16 
(sample 11), and Day 22 (sample 12) sampling 
times and predose/postdose timepoints updated.  Correction  
Cycle 2, Day 1 (samples 13, 14,  and 15) sampling 
times and predose/postdose timepoints updated.  Correction  
First note in footnotes updated to reflect number 
of samples and blood volumes.  Correction  
New note added to footnotes to specify predose 
sample summarization in statistical an alysis.  Clarification  
Footnote a added to specify collection of Cycle [ADDRESS_386087] or MRI scan.  
Moved tumor assessments from Final Visit to 
SFU visit.  Correction  
Section 8.8 
Pharmacodynamics  Blood volumes updated.  Correction  
Section 8.8.3 Blood 
samples for 
circulating tumor 
DNA analysis  New section added.  Addition  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 191 of 195 Section # and 
Name  [CONTACT_9353] 8.8.[ADDRESS_386088] reduction in total number 
of samples taken during Cyc les 2, 3, and 4.  Reduction of participant 
assessment burden  
Table 8 -9 Blood sample timepoints for ADA 
analysis: Deletion of Day 15 samples for Cycles 
2, 3, and 4. Clarification of timing of sampling at 
SFU Visit. Comment column removed.  Clarification.  
Section 9.1 
Definition of 
analysis sets  Updated definitions of analysis sets, including 
deletion of FAS and addition of ADAS.  Consistency with SAP  
Section 9.2 General 
statistical 
considerations  Added text omitted in error from original version 
of protocol . Correction  
Section 9.3.1 Safety 
analyses  Updated planned analyses. Updated vital signs 
information.  Consistency with SAP  
Section 9.3.2 
Analysis of Baseline 
and demographic 
variables  Clarification of study parts.  Clarification  
[IP_ADDRESS] Analysis of 
PK endpoints  Updated planned analyses.  Consistency with SAP  
[IP_ADDRESS] Analysis of 
immunological 
endpoints  Updated planned analyses.  Consistency with SAP  
9.4.1 Analysis of 
primary antitumor 
activity/outcome 
endpoint  Updated terminology.  Consistency with SAP  
[IP_ADDRESS] Antitumor 
activity endpoint 
definitions  Clarification of definitions.  Consistency with SAP  
[IP_ADDRESS] Analysis of 
the antitumor 
activity endpoints  Updated planned analyses.  Consistency with SAP  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 192 of 195 Section # and 
Name  [CONTACT_11029]  
9.6 handling of 
dropouts or missing 
data Noted that further details will be provided in SAP.  Clarification  
Section 9.8.1 Dose 
escalation modules  Clarified text for addition of dose level based on 
emerging data.  Consistency with dose 
escalation scheme  
Section 10.2 
Appendix 2: Clinical 
laboratory tests  Added coagulation parameters as a row. Deleted 
coagulation tests from other Screening tests row. 
Changed “Other Screening Tests” to “Other 
Tests).  
BUN or urea creatinine changed to BUN or urea  
Added serum creatinine.  Clarification  
Section 10.[ADDRESS_386089] 
results bullet for events meeting the AE definition.  Clarification  
Section 10.9, 
Appendix 9: 
RECIST v1.[ADDRESS_386090] of abbreviations  Addition  
Global  Correction of spelling, grammar, or typographical 
errors.  Correction  
12 REFERENCES  
Brazil DP, Church RH, Surae S, Godson C, Martin F. BMP signaling: agony and antagony in the 
family. Trends Cell Biol. 2015;25(5):249 –64. 
Canalis E, Parker K, Zanotti S. Gremlin1 is required for skeletal development and postnatal 
skeletal homeostasis. J Cell Physiol. 2012;227(1):269 -77. 
Church RH, Ali I, Tate M , et al. Gremlin1 plays a key role in kidney development and renal 
fibrosis. Am J Physiol Renal Physiol. 2017;312(6):F1141 -57. 
Chen MH, Yeh YC, Shyr YM, et al. Expression of gremlin 1 correlates with increased 
angiogenesis and progression -free survival in patients with pancreatic neuroendocrine tumors. 
J Gastroenterol. 2013;48(1):101 -8. 
CPMP/ICH/135/95 Note for guidance on Good Clinical Practice (EMEA) Jul 2002.  
Davis H, Irshad S, Bansal M, et al. Aberrant epi[INVESTIGATOR_313549]1 expression initiates colonic 
tumor igenesis from cells outside the stem cell niche. Nat Med. 2015;21(1):[ADDRESS_386091] -derived Gremlin1 localises to epi[INVESTIGATOR_313550]. Oncotarget. 2019;10(45):4630 -9. 
Eisenhauer E A, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: 
revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228 -47. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 193 of 195 Fakih MG. Metastatic colorectal cancer: current state and future directions. J Clin Oncol. 
2015;33(16):1809 -24. 
Food and Drug Administration. Guidance for Industry. Drug -induced liver injury: premarketing 
clinical evaluation. US Dept of Health and Human Services, Center for Drug Evaluation and 
Research, Center for Biologics Evaluation and Research,  07/2009.  
Gazzerro E, Smerdel -Ramoya A, Zanotti S, et al. Conditional deletion of gremlin causes a 
transient increase in bone formation and bone mass. J Biol Chem. 2007;282(43):[ZIP_CODE] -57. 
Gehan EA. The determinatio of the number of patients required in a pr eliminary and a follow -up 
trial of a new chemotherapeutic agent. J Chronic Dis. 1961;13:346 -53. 
ISO [ZIP_CODE]:2011 Clinical Investigations of medical devices for human subjects – Good Clinical 
Practice.  
James LP, Letzig L, Simpson PM, Capparelli E, et al. Pharmacokinetics of Acetaminophen -
Adduct in Adults with Acetaminophen Overdose and Acute Liver Failure. Drug Metab Dispos. 
2009;37:1779 -84. 
Ji Y, Wang SJ. Modified toxicity probability interval design: a safer and more reliable method 
than the 3 + 3 design  for practical phase I trials. J Clin Oncol. 2013;31(14):1785 -1791. 
doi:10.1200/JCO.2012.45.7903  
Jindal S, Greenseid K, Berger D, Santoro N, Pal L. Impaired gremlin 1 (GREM1) expression in 
cumulus cells in young women with diminished ovarian reserve (DOR).  J Assist Reprod Genet. 
2012;29(2):159 -62. 
Kosinski C, Li VS, Chan AS, et al. Gene expression patterns of human colon tops and basal 
crypts and BMP antagonists as intestinal stem cell niche factors. Proc Natl Acad Sci [LOCATION_003]. 
2007;104(39):[ZIP_CODE] -23. 
López Nava rro E, Ortega FJ, Francisco -Busquets E, et al. Thyroid hormone receptors are 
differentially expressed in granulosa and cervical cells of infertile women. Thyroid. 
2016;26(3):466 -73. 
Liu Y, Li Y, Hou R, Shu Z. Knockdown GREM1 suppresses cell growth, angioge nesis, and 
epi[INVESTIGATOR_018] -mesenchymal transition in colon cancer. J Cell Biochem. 2019;120(4):5583 -96. 
Mármol I, Sánchez -de-Diego C, Pradilla Dieste A, Cerrada E, Rodriguez Yoldi MJ. Colorectal 
carcinoma: a general overview and future perspectives in colorectal cancer. Int J Mol Sci. 
2017;18(1)pii:E197.  
Mitola S, Ravelli C, Moroni E, et al. Gremlin is a novel agonist of the major proangiogenic 
receptor VEGFR2. Blood. 2010;116(18):3677 -80. 
Mokdad AA, Xie XJ, Zhu H, Gerber DE, Heitjan DF. Statistical justification of expansion 
cohorts in Phase 1 cancer trials. Cancer. 2018;124(16):3339 -3345.  
Moriarity A, O'Sullivan J, Kennedy J, Mehigan B, McCormick P. Current targeted therapi[INVESTIGATOR_313551]: a review. Ther Adv Med Oncol. 2016;8(4):276 -93. 
Mulloy B, Rider CC. The bone morphogenetic proteins and their antagonists. Vitam. Horm. 
2015;99:63 –90. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   26 Jun 2023  
Clinical Study Protocol Amendment 6 UCB6114  ONC001  
   
Confidential  Page 194 of 195 Müller II, Chatterjee M, Schneider M, et al. Gremlin -1 inhibits ma crophage migration inhibitory 
factor -dependent monocyte function and survival. Int J Cardiol. 2014a;176(3):[ADDRESS_386092] of counterbalance between macrophage 
migration inhibitory factor and its inhibitor Gremlin -1 in patients with coronary artery disease. 
Atherosclerosis. 2014b;237(2):426 -32. 
Nikanjam M, Liu S, and Kurzrock R. Dosing targeted and cytotoxic two -drug combinations: 
Lessons learned from analysis of 24,326 patients reported 2010 through 2013. Int J Canc er. 
2016;139(9):2135 -2141.  
Nilsson EE, Larsen G, Skinner MK. Roles of Gremlin 1 and Gremlin 2 in regulating ovarian 
primordial to primary follicle transition. Reproduction. 2014;147(6):865 -74. 
The Cancer  Genome  Atlas  Program,  https://www.cancer.gov/about -nci/organization/ccg/research
/structural -genomics/tcga. Aug 2019.  
Sneddon JB, Zhen HH, Montgomery K, et al. Bone morphogenetic protein antagonist gremlin 1 
is widely expressed by [CONTACT_67380] -associated stromal cells and can promote tumor cell proliferation. 
Proc Natl Acad Sci [LOCATION_003]. 2006;103(40):[ZIP_CODE] –7. 
Sun, Z., S. Cai, C. Liu, et al. Increased Expression of Gremlin1 Promotes Proliferation and 
Epi[INVESTIGATOR_313552]. Cancer Genomics Proteomics. 2020;17(1):[ADDRESS_386093] this 
clinical study as outlined in this protocol and according to current Good Clinical Practice.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
Approval Signatures
Name: [CONTACT_165342]001-Protocol-amend-6-26Jun2023
Version: 1 . 0
Document Number: CLIN-000225639
Title: ONC001 Protocol Amendment 6-26Jun2023
Approved Date: [ADDRESS_386094]: ApprovedName: 
[CONTACT_18469]: Subject Matter Expert
Date of Signature: 27-Jun-2023 16:17:53 GMT[PHONE_006]
Approval
Verdict: ApprovedName: 
[CONTACT_18469]: Medical
Date of Signature: 27-Jun-2023 16:19:43 GMT[PHONE_006]
Approval
Verdict: ApprovedName: 
[CONTACT_18469]: Clinical
Date of Signature: 27-Jun-2023 16:21:41 GMT[PHONE_006]
Approval
Verdict: ApprovedName: 
[CONTACT_18469]: Clinical
Date of Signature: 27-Jun-2023 17:08:50 GMT[PHONE_006]
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.